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Chapter 1 – Introduction  
1.1 Overview of immunity  
We live in a world predominated by microorganisms. Some of these microbes can cause disease. 
In order to maintain a healthy constitution, we have evolved an immune system to prevent or 
counteract the onset of infection. In higher vertebrates, including humans, this system is comprised 
of a complex network of cells, tissues, and biological processes aimed at fighting pathogenic 
invaders. It can be broadly divided into to two branches: the innate immune system, which relies 
on germline encoded mechanisms of pathogen detection, and the adaptive immune system, which 
develops somatically and is specific toward individual pathogens.  
 
1.2 The innate immune response  
1.2.1 Non-cellular constituents of innate immunity  
The innate immune response is rapid and hard-coded within the genome, responding broadly to 
almost all classes of pathogenic invaders and microorganism. At its most basic, epithelial cells in 
the skin, gastrointestinal tract, urogenital tract and respiratory system form tight intercellular 
junctions sealing the body from the external environment. Epithelial barriers within the body are 
mucosal membranes. Cells along these surfaces secrete antimicrobial compounds such as lysozyme 
or phospholipase A2, which non-specifically kill microbial cells. Cells along epithelial linings are 
also continually sloughed off, a mechanism particularly important against helminth infection.  It 
has been termed the ‘weep-and-sweep’ mechanism of defence (Anthony et al. 2007).  
 In the event that this barrier is disrupted, as occurs during burning, wounding or 
pathogenic breaching, invading microorganisms are immediately confronted with the body’s 
second line of defence. The complement system is a collection of 30 soluble proteins found in the 
blood and other bodily fluids. The complement system acts as a network of different pathways, 
different combinations of which drive direct cell killing or opsonise targets for destruction by 
innate immune cells (Holers 2014). Many of the components of the complement system are 
proteases or cytolytic factors and thus are secreted as pro-enzymes, zymogens, to avoid off-target 
effects.  
 The complement system can become activated by three main pathways, all three of which 
rely on C3 (Sarma and Ward 2011). The classic complement pathway is triggered when the C1-
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complex binds to either IgM or IgG1 engaged with an antigen. The alternative pathway relies on 
spontaneous hydrolysis of C3. If this occurs on the surface of a pathogen, C3 becomes covalently 
bound to the pathogen, blocking it from H-mediated inactivation (Conrad, Carlos, and Ruddy 
1978). The final pathway of activation is similar to the classic pathway, but relies on binding of 
mannose-binding lectin, opsonin, or ficolins, rather than the C1-complex. As mentioned the 
complement system is tightly regulated and host cells do not accumulate C3 due to the expression 
of cell surface molecules such as cluster of differentiation 35 (CD35), CD46, CD55 and CD59, 
which work to inhibit the complement system (Holers 2014).  
 As well as the complement system, many organism including vertebrates, invertebrates and 
plants secrete small cysteine-rich polypeptides called defensins (Ganz 2003). Defensins target 
bacterial, fungal and viral cells for phagocytosis and embed themselves in the microbial cell 
membrane. Here they form pores in the membrane that cause efflux of the pathogen’s cytosol 
(Ganz 2003).  
 
1.2.2 Innate immune receptors  
Key to the activity of the innate immune system are a number of genetically pre-encoded receptors. 
These receptors are termed pattern recognition receptors (PRRs) as they recognise key chemical 
or structural motifs specific to pathogenic organisms but not host cells. These pathogen associated 
molecular patterns (PAMPs)  are highly conserved molecules necessary for pathogen survival and 
include targets like bacterial lipopolysaccharides (LPS), flagellin, and viral-associated nucleic acids, 
for example double-stranded RNA (dsRNA).  
 One class of innate immune receptors is the toll-like receptors (TLRs). TLRs derive their 
name from their similarities to the Drosophila developmental receptors (Medzhitov, Preston-
Hurlburt, and Janeway 1997). TLRs recognise a variety of different pathogenic molecules 
summarised in Table 1.1. All TLRs are membrane associated, but TLR3, 7, 8, and 9 are located 
within intracellular compartments (Kollmann et al. 2012).  
All TLRs with the exception of TLR3, and in some situations TLR4, function through the 
MyD88 adaptor protein. MyD88 recruits IRAK kinases that trigger a signalling cascade 
culminating in the translocation of NF-κB to the nucleus and transcriptional activation of genes 
associated with the induction of an inflammatory response (Akira and Takeda 2004). TLR3, and 
TLR4 in a MyD88-independent fashion, function through the adaptor protein TRIF (Akira and 
Takeda 2004).  
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Receptor Target(s) 
TLR1 Bacterial lipoproteins 
TLR2 (heterodimerises with TLR 1 
and TLR6) 
Lipoproteins/lipopeptides 
Reptidoglycan 
Lipopteichonic acid 
Zymosan 
TLR3 Viral dsRNA 
TLR4 Taxal 
LPS 
RS virus F protein 
Tamm-Horsfall glycoproteins 
Damage-associated moledular patterns (DAMPs) 
Allergens 
TLR5 Bacterial Flagellin 
TLR6 Mycoplasma lipopeptides  
Zymosan 
TLR7 ssRNA  
viral RNA  
TLR8 ssRNA 
viral RNA 
TLR9 CpG DNA 
Hemozoin 
Viral DNA 
TLR10 Target unknown  
Table 1.1: Human TLRs and their targets  
 
 Some innate immune receptors are located within the cytosol to detect intracellular 
pathogens. Nucleotide-binding oligomerisation domain (NOD) receptors detect peptidoglycan 
within the cytoplasm of infected cells and signal through NF-κB to induce an inflammatory 
response (Philpott et al. 2013). Also expressed intracellularly, are the retinoic acid-inducible gene 
I (RIG-I)-like receptors. Three of these receptors exist: RIG-I, MDA5, and LGP2. The RIG-I-like 
receptors bind ssRNA and dsRNA and trigger type I interferon production (Yoneyama et al. 2004; 
Yoneyama and Fujita 2007).  
 Another important class of immune receptors is Fc receptors (FcRs). FcRs are found on 
the surface of a number of different immune cell-types including dendritic cells (DCs), 
mononuclear phagocytes, and granulocytes (Table 1.2) (Shi, McIntosh, and Pleass 2006) and are 
so named because they recognise the fragment, crystallisable region of antibodies bound to 
pathogens. Importantly, FcRs can be associated with either immunoreceptor tyrosine-associated 
activation motifs (ITAMs) or immunoreceptor tyrosine-associated inhibitory motifs (ITIMs), and  
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Receptor Signal motif Cell type 
FcgRI ITAM Mast cells 
Basophils 
Monocytes 
Langerhans cells 
Neutrophils 
FcεRII C-type lectin B cells 
T cells 
NK cells 
DCs 
Eosinophils 
Macrophages 
FcRγRI ITAM 
Peiplakin 
Monocytes 
Macrophages 
Neutrophils 
Eosinophils 
FcγRIIa ITAM Monocytes 
Macrophages 
Neutrophils 
Langerhans cells 
Platelets 
FcγRIIb ITIM Monocytes 
Macrophages 
B cells 
FcγRIIc ITAM Monocytes 
Macrophages 
Neutrophils 
B cells 
FcγRIIIa ITAM Macrophages 
NK cells 
γδ T cells 
Monocytes 
FcγRIIIa GPI Neutrophils 
Eosinophils 
FcαRI ITAM (can inhibit) Monocytes 
Macrophages 
NK cells 
Neutrophils 
Eosinophils 
Kupffer cells 
DCs 
FcRH1-6 ITAM/ITIM B cells 
Table 1.2: Human FcR receptors  
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regulate the activation state of the host cell. This can either have a dampening or activatory effect 
on the overall activation state of the target cell. FcR receptors have varying affinities for the Fc 
region of antibodies and compete with each other for ligand binding (Smith and Clatworthy 2010). 
Availability of ligand and concentration of the receptors on the cell surface influences the cellular 
response (Smith and Clatworthy 2010).The final class of innate immune recetpors is the C-type 
lectin receptors. As with FcRs, the C-type lectin receptors are associated with ITAMs, which 
mediate their activation. C-type lectins drive the expression of reactive oxygen species and 
inflammatory cytokines in response to specific carbohydrate motifs. They are well reviewed by 
Osorio and Reis e Sousa (Osorio and Reis e Sousa 2011). 
 
1.2.3 Innate Immune lymphocytes  
Operating at the interface of innate and adaptive immunity are several subsets of lymphocytes. 
Natural killer (NK) cells are cytolytic lymphocytes involved in the immune response to virally 
infected cells and tumour cells. Critical to NK cell function is inhibitory, killer-cell 
immunoglobulin-like receptors (KIRs) that recognise MHC I (Parham 2005). This is important 
because tumour cells are reported to downregulate Major Histocompatibility Complex class I 
(MHC I) as an immune evasion mechanism (Nouroz et al. 2016; Bubeník 2004). In the absence of 
this ‘self’ signal and KIR-derived inhibitory signals (Borrego 2006), NK cells will release cytolytic 
molecules, such as granzyme B, and inflammatory cytokines, like IFN-γ (Mandal and Viswanathan 
2015). NK cells are also activated in response to inflammatory cytokines from other innate 
immune cells acting at the site of infection.  
 Another type of lymphocyte operating between innate and adaptive immunity is the 
Natural Killer T cell (NKT cell). T cells are discussed further in section 1.3.3. NKT cells represent 
only a small fraction of circulating lymphocytes and are characterised by the expression of an 
invariant TCR α chain. NKT cells specifically recognise lipid antigens presented on CD1 rather 
than MHC (Kinjo et al. 2005). NKT cells are important for their rapid release of inflammatory 
cytokines in response to infection (Barral and Brenner 2007). 
 Finally, γδ T cells represent a unique branch of T lymphocytes with innate-like functions. 
Although γδ T cells undergo somatic T cell antigen receptor (TCR) rearrangement during 
development, their TCRs are used as PRRs, much like TLRs. For example, the Vγ9/Vδ2 subset 
responds rapidly to microbial metabolites during acute infections. γδ T cells promote the activation 
of APCs and are proposed to act as APCs themselves (Tyler et al. 2015). Their rapid response to 
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infection and ability to present antigen means that their function straddles the innate response and 
the adaptive response to microbes.  
 
1.2.4 Dendritic cells translate innate immunity to adaptive immunity  
During acute infection pathogenic antigens are deposited at the site of infection. These antigens 
are endocytosed either by phagocytosis or pinocytosis by innate immune cells, processed, and 
presented on MHC II. Although this process can be performed by neutrophils and macrophages, 
DCs are more specialised in the process of antigen processing and presentation. Dendritic cells act 
as the sentinels of the immune system. They are resident both in lymphoid and non-lymphoid 
organs and are usually associated with epithelial cells. Indeed, it was this observation that lead to 
the hypothesis that DCs are important in translating early innate immune responses into adaptive 
immune responses (Bujdoso et al. 1989) (Figure 1.1). Unlike other immune phagocytes, protein 
degradation within dendritic cells is slow under steady-state conditions, i.e. in the absence of 
infection, but switches to become more rapid in the presence of local inflammatory cues 
(Trombetta et al. 2003). Even in steady-state DCs continually traffic cargo, such as debris from 
apoptotic cells, from their sites of residence to the draining lymph nodes for presentation to T 
cells. In the absence of inflammatory signals this process is involved in maintaining peripheral 
tolerance (Mueller 2010). DCs that are naïve to pathogenic antigen are referred to as immature. 
On exposure to pathogenic antigen in the presence of inflammatory signals, dendritic cells undergo 
maturation. During this process antigen uptake is decreased and the DC becomes more migratory, 
upregulating CXCR4, CCR7, and CCL19/CCL21, which brings mature DCs into proximity with 
naïve T cells in the lymph nodes (Sallusto et al. 1999; Barrat-Boyes et al. 2000; Yanagihara et al. 
1998). DCs, on exposure to pathogenic antigen also upregulate expression of TNF-R, which 
enhances the expression of the inflammatory cytokine, IL-12. The production of cytokines such 
as IL-12, IL-6 and type I interferons by DCs is important in driving T cell activation and polarising  
the T helper immune response. DCs also upregulate T cell costimulatory molecules such as CD86, 
which is intracellularly clustered with MHC II and remains clustered on the cell surfaces to prime 
T-cell activation (Turley et al. 2000). These unique features or DCs make them exquisitely 
specialised for priming the adaptive immune response. 
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Site of infection
(periphery)
pathogenic
antigen
immature 
dendritic cell
Migration to lymph node
DC maturation
mature DC
Immunological 
synapse
naïve T cell
activated 
T cell
antigen-primed
B cell
Lymph Node
endocytosis
A
B
C
Figure 1.1 Overview of antigen presentation by dendritic cells (A) During an 
infection antigens are deposited in the periphery by pathogens. Tissue resident dendritic 
cells (DCs) endocytose, process, and present pathogenic antigens. Inflammatory cues 
from the surrounding tissue activate DCs, which undergo maturation and migrate to tissue 
draining lymph node. (B) Antigen-presenting dendritic cells will cease to migrate once 
they reach the lymph node and will begin to interact with circulating naïve T cells. Once 
the cognate TCR is engaged by pMHC on the DC, the T cell will become activated. (C) 
Some subsets of activated T cells will then engage and activate antigen-primed B cells to 
initiate the process of antibody production. Other subsets will egress from the lymph node 
to the cite of infection to mediate their effector function.  
lymph node
egress
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 1.3 The adaptive Immune response  
1.3.1 Overview of adaptive immunity 
Adaptive immunity differs from innate immunity in that it provides a response to infection that is 
narrowly specific to each pathogen, rather than broadly specific toward conserved pathogenic 
motifs. The adaptive arm of the immune response is dependent on B cells and T cells, both of 
which are derived from common lymphoid progenitor cells in the bone marrow. The fate and 
function of B and T cells is highly dependent on non-germline encoded antigen receptors, the B 
cell receptor (BCR) and the TCR, respectively. Both the BCR and TCR are highly diverse in their 
ligand recognition. This diversity is generated during their development through the process of 
somatic recombination. Although the actual number of clonal lymphocytes varies from species to 
species, it is estimated at ~3x1011 in humans (Hataye et al. 2006; Elhanati et al. 2014). Cross-
recognition of antigens allows for recognition of >1015 pMHC variants (Regner 2001). 
 
1.3.2 B cell development  
Unlike the innate immune system, which relies on germline encoded receptors, the BCR and TCR 
are assembled through genetic recombination to generate a high degree of diversity amongst 
different BCRs and TCRs. The BCR is a transmembrane receptor with a unique antigen-binding 
moiety. On the B cell surface, the BCR forms a complex with the transmembrane proteins CD79a 
and CD79b, which contain ITAM motifs that mediate BCR-induced signalling (Chu and Arber 
2001; Otipoby et al. 2015). B cells (and T cells) express recombinase activating gene 1 (RAG1) and 
RAG2 necessary for gene rearrangement, as well as Terminal deoxynucleotidyl transferase (TdT). 
The BCR is assembled through a process called V(D)J somatic recombination. During the first 
step of this process, pro-B cells combine one each of the variable (V), diversity (D), and joining 
(J) gene segments from the immunoglobulin heavy locus (Y. S. Li, Hayakawa, and Hardy 1993; 
Karasuyama et al. 1997). These combine with a surrogate light chain to form pre-BCRs 
(Karasuyama et al. 1997; Reth et al. 1985). Cells that successfully complete this process pass to the 
next stage of development, where they assemble a BCR light-chain via a similar process, but do 
not include a D segment (Reth et al. 1985). The heavy- and light-chain constructs are then 
assembled to form a mature BCR. Each B cell that survives development is a unique clone 
expressing a single variant of the BCR. The error-prone process of non-homologous end joining 
during V(D)J recombination leads to a high degree of B cell diversity, but frequently results in cells 
capable of recognising ‘self’ antigen (Nemazee and Weigert 2000; Wardemann et al. 2003). 
Autoreactive B cells, recognising self-antigen are eliminated in the bone marrow during their 
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development and the number of autoreactive B cells decreases through each stage of B cell 
development.  
 Once primed with antigens, and activated by T cells, B cells will once again go through 
somatic mutation of the immunoglubulin region. B cells in germinal centres (GC) express the 
enzyme AID (Activation Induced Deaminase), which is necessary for further somatic 
hypermutation and class switching recombination. AID mediates the conversion of cytosine to 
deoxyuracil, which mimics thymidine when paired with deoxyguanosine, and is acted upon by the 
DNA repair machinery. Class switching does not change antibody specificity but instead causes a 
change in the constant region of the heavy chain allowing it to interact with different FcRs (Maul 
and Gearhart 2010; Maul et al. 2014).  In GCs, antigen-primed B cells undergo several rounds or 
proliferation and hypermutation of the BCR locus. B cell clonal evolution in GCs is driven by 
affinity-dependent selection in a Darwinian manner to select only B cell clones expressing high 
affinity BCRs (Maul and Gearhart 2010). Survival is dependent on the ability of B cells to collect 
and present antigen to local CXCR5+, CD4+ T-follicular helper cells (TFH) (Figure 1.1) (Kurosaki, 
Kometani, and Ise 2015).   
 
1.3.3 T cell development  
T cells are the second major cell type in the adaptive immune response. Like the BCR, the TCR is 
also generated through V(D)J somatic recombination. Unlike B cells, T cell progenitors migrate to 
the thymus to undergo development. During the first stage of development, thymocytes rearrange 
their TCR β chain, first by D-J rearrangement and then V-DJ joining (Shah and Zuniga-Pflucker 
2014). Thymocytes that successfully rearrange TCRβ begin to express the pre-TCR along with a 
surrogate TCRα chain. The developing thymocytes will then undergo V(D)J rearrangement of the 
TCRα subunit. This process is not allelically exclusive and will use the α subunit from both 
chromosomes, however T cells expressing two variants of the TCR will have only one variant that 
signals strongly enough to undergo positive selection (Klein et al. 2014). Thymocytes at this stage 
of development become double positive for both TCR co-receptors, CD4 and CD8 (Klein et al. 
2014).  
 Once the double-positive thymocyte has successfully rearranged both a TCRβ and α chain, 
it will migrate to the cortex of the thymus for positive selection by MHC I- and MHC II-expressing 
thymic epithelial cells. Unlike the BCR, which can recognise antigenic structural epitopes, the TCR 
is restricted to antigens presented on MHC. Therefore, the TCR must be able to recognise self-
MHC. Thymocytes unable to recognise MHC undergo ‘death by neglect’ during positive selection. 
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Those cells that survive positive selection move to the medulla of the thymus for negative 
selection. Here, thymocytes are presented with self-antigen by specialised epithelial cells expressing 
the transcription factor AIRE (autoimmune regulatory element) (Klein et al. 2014). AIRE allows 
these thymic epithelial cells to express self-antigen from around the body (Anderson 2002). T cells 
that react too strongly to these self-antigens are triggered to undergo apoptosis, though some are 
thought to be driven down the T regulatory (Treg) lineage (M. O. Li et al. 2016; A. G. Levine et al. 
2014; A. E. Moran et al. 2011). These developmental checkpoints help establish a population of 
non-autoreactive naïve T cells capable of recognising MHC-restricted antigenic peptide. These 
immature T cells then exit the thymus into the periphery where they recirculate through secondary 
lymphatic organs. Here, they are presented with antigen by mature DCs (Figure 1.1).  
 
1.3.4 T cell effector subsets  
Optimal T-cell activation through the αβ-TCR, discussed further in Section 1.4 and in Chapter 4, 
is mediated by either the CD4 or CD8 co-receptor. Developing thymocytes express both the CD4 
and CD8 coreceptors, but mature T cells are committed to either a CD4- or CD8-single positive 
linage fate. Co-receptor expression is partially determined by the MHC-specificity of the TCR. 
Thymocytes recognising MHC-II will commit to expression of the CD4 co-receptor and 
thymocytes that recognise MHC-I will commit to expression of CD8. This process is review by 
Germain (Germain 2002).  Mature T cells can thus be subdivided and classified based on their 
expression of either the CD4 or CD8 coreceptor. Futher subclassifications can be made based on 
a T cell’s effector function within the adaptive immune response (Table 1.3).  
 Activated CD8+ T cells mediate killing of cells expressing foreign antigen on MHC-I, this 
includes tumour cells and pathogen-infected host cells. These cytotoxic T lymphocytes (CTLs) 
rapidly proliferate in the presence of IL-2 and mediate target cell killing through the polarised 
secretion of perforin and granzymes, as well as through activation of the Fas signalling pathway in 
target cells.  
 Naïve CD4+ T cells are driven toward particular effector lineages (Table 1.3) through a 
combination of TCR-derived activation signals and environmental cues in the form of cytokines. 
Each subset is defined by a particular cytokine secretion profile. Each lineage helps fulfil a 
particular function during an immune reaction. T helper 1 (TH1) cells, which are characterised by 
the expression of transcription factor Tbet (Kanhere et al. 2012), differentiate following 
stimulation by IFN-γ and IL-12 to secrete pro-inflammatory interferons and TNFs, which facilitate 
immunity against intracellular pathogens. Activated T cells expressing IL-4, IL-5 and IL-13 belong 
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to the TH2 subset and mediate immunity against extracellular parasites (Kanhere et al. 2012). Also 
involved in the host response to parasites is the TH9 subset, which is characterised by the 
expression of IL-9 and the anti-inflammatory cytokine, IL-10 (Kaplan 2013). T helper cells 
expressing IL-17, IL-21, IL-22, and IL-26 are involved in host defences against extracellular 
bacterial infections and fungal pathogens. These T cells belong to the TH17 lineage (Tesmer et al. 
2008). The TH22 lineage is particularly associated with mucosal immunity, secreting IL-22 (Eyerich 
et al. 2009). Follicular helper T cells (TFH) are characterised by expression of the transcription 
factor Bcl-6 and the surface receptor CXCR5, which allows them to home to the B cell follicles of 
secondary lymphoid organs. They secrete the cytokine IL-21 and are intrinsically tied to the 
survival and selection of germinal centre B cells (Fazilleau et al. 2009). TFH cells may display a 
cytokine profile similar to that of the previously mentioned T helper cell subsets. 
 CD4+ T cells can also be directed toward a regulatory lineage (Treg). Regulatory T cells are 
characterised by the expression of the FoxP3 transcription factor and secrete the anti-
inflammatory cytokines IL-10 and TGF-β (Hori et al. 2009). It is thought that developing 
thymocytes are driven toward a regulatory phenotype by strong recognition of self-MHC (M. O. 
Li and Rudensky 2016). Tregs are involved in the suppression of other effector T cell subsets.  
 
T cell subset Activating cytokines Cytokine Expression profile 
CD8+ cytotoxic T cell IL-2 - 
CD4+ TH1 IL-12, IFN-γ INF-γ, TNF, IL-2 
CD4+ TH2 IL-4, IL-33 IL-4, IL-5, IL-13, IL-10 
CD4+ TH9 IL-4, TGF-β IL-9, IL-10 
CD4+ TH17 IL-1, IL-6, IL-21, IL-23, 
TGF-β 
IL-17, IL-21, IL-22, IL-25, IL-26 
CD4+ TH22 IL-6, TNF IL-22 
CD4+ TFH IL-6, IL-21 IL-21 
CD4+ Treg IL-2, TGF-β IL-10, IL-33, TGF-β 
Table 1.3: T cell effector subsets 
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1.3.5 Immunological memory response  
The general paradigm in immunology is that the adaptive immune response is responsible for the 
generation of immunological memory. This is perhaps somewhat simplistic as recent findings have 
suggested that epigenetic changes to innate immune cells may allow for a different type of 
immunological memory (Netea et al. 2015). However, classic immunological memory is restricted 
to B and T lymphocytes. The T cell immune response is characterised by three phases: expansion, 
contraction, and maintenance. Following activation by an APC (Figure 1.1), both CD4+ T helper 
cells and CD8+ cytotoxic T cells undergo a phase of rapid proliferation. This proliferative phase 
lasts approximately 2 weeks and allows the T cells to exert their effector function. This is followed 
by a phase of decline during which most activated T cells undergo apoptosis. However, some T 
cells are selected to undergo memory lineage commitment through a process that is not fully 
understood (W. Huang et al. 2017). CD8+ memory T cells are retained almost indefinitely and 
CD4+ memory T cells have a half-life or ~15 years (Hammarlund et al. 2003). Memory T cells are 
found in both lymphoid and non-lymphoid organs, known as T central memory (TCM) and T 
effector memory (TEM), respectively. Tissue specific signals derived from DCs drive the homing 
capacity of TEM cells (Shin and Iwasaki 2013; Bouneaud et al. 2005; X. Zhou et al. 2010; Speiser et 
al. 2014). On re-infection, pathogen-specific memory T cells are able to rapidly mount an 
inflammatory response against the invader. Memory T cells are sustained through a process termed 
homeostatic proliferation, where the population occasionally turns over (Boyman et al. 2009).  This 
is in contrast to naïve T cells, which are maintained in interphase (Surh and Sprent 2000).  
 B cells can also undergo commitment to a memory lineage. Once activated, T cells will 
migrate to the B cell-zone of the secondary lymphoid organs where they interact with B cells that 
have internalised, processed, and presented the cognate antigen on MHC II (Figure 1.1) (De Silva 
and Klein 2015). Following activation in the presence of TFH cells, B cells undergo proliferation in 
the germinal centre. Most clones will become antibody-producing plasma cells, but some are 
directed down a memory B cell lineage. B cells that undergo memory formation tend to be those 
that have undergone somatic hypermutation and have been affinity selected to produce high-
affinity BCRs (De Silva and Klein 2015). Like the T cell memory response, B cell memory allows 
for the rapid onset of antibody-mediated immunity on re-infection by a previously encountered 
pathogen.   
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1.4 The T cell antigen receptor and signalling complex  
Decades of research has provided us with a good working understanding of the classic TCR 
complex. The TCR is comprised of an α and a β subunit, which have the variable regions 
responsible for the recognition of pMHC (Sancho et al. 1989; Geisler, Kuhlmann, and Rubin 
1989). These subunits do not contain any intrinsic signalling capacity themselves but form an 
obligate multimeric complex with six CD3 subunits – two ζ subunits, two ε subunits, and one each 
of γ and δ (Figure 1.2). Collectively these CD3 subunits have ten ITAMs, which are defined as a 
pair of YxxI/L amino acid sequences. Although the TCR itself does not have any intrinsic 
enzymatic activity, the CD3 ITAMs are phosphorylated by the src-family kinase Lck and serve as 
a docking site for the SH2-domain of the zeta-associated protein-kinase of 70 KDa (ZAP70) 
(Wange et al. 1993). The immediate downstream substrates of ZAP70 phosphorylation are Linker 
for Activation of T cells (LAT) and SH2 domain containing leucocyte protein of 76 KDa (SLP76). 
LAT and SLP76 serve to nucleate other TCR signalling molecules involved in calcium fluxing and 
downstream kinase signalling cascades (Balagopalan et al. 2010) (Figure 1.2). The TCR signalling 
machinery and activation process are well reviewed by Smith-Garvin (Smith-Garvin et al. 2009).  
Although our knowledge of the underlying TCR signalling machinery is reasonably 
comprehensive, precisely how varying signals through the TCR and costimulatory receptors are 
internalised and translated into an appropriate output response is still poorly understood. 
However, new techniques for the manipulation of cell signalling pathways are beginning to yield 
fresh insights into signalling dynamics. In this thesis I discuss the development of an optogenetic 
approach to T cell signalling. Mechanisms of TCR signal transduction are discussed further in 
Chapter 4.  
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Figure 1.2 Overview of the T cell antigen receptor  The TCR complex is comprised 
of an an α and a β subunit, as well as six CD3 subunits. The α and β subunits are assem-
bled through V(D)J recombination and bear the variable region responsible for antigen 
recognition. The TCR forms an obligate heterodimer with six CD3 subunits; two ε 
subunits, two ζ subunits, one δ subunit, and one γ subunit.These CD3 subunits each have 
ITAM motifs (yellow), which once phosphorylated by Lck (not show), serve as a docking 
site for ZAP70. Immediately downstream of ZAP70 is the scaffolding protein LAT (pink). 
LAT has 9 phosphorylatable tyrosine motifs (red), which serve as the docking site for 
several TCR-associated signalling proteins. Shown in this figure are a limited selection of 
signalling proteins including, SLP76, the SLP76-adapter protein GADS, PLC-γ1, PKC, 
RASGRP, Sos1, the Sos1 adapter protein Grb2, Nck, Vav, and WASp. Shown as well is the 
secondary messenger DAG. Together these proteins, among others, serve to regulate 
downstream T cell activation events including Calcium fluxing, Transcription factor activa-
tion, kinase signalling, and cytoskeletal reorganisation. 
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1.5 Chemical and optical manipulations of cellular signalling pathways  
1.5.1 Chemically-inducible dimerization  
Cells are dynamic entities, continually responding to spatially- and temporally-encoded 
environmental signals. A multitude of different cellular receptors act as sensors for these cues and 
transmit signals accordingly through networks of signalling proteins. Proteins within these 
signalling networks need to be tightly controlled and many fulfil their function only at specific 
cellular locations or in complex with other proteins. Although genetic knockout or overexpression 
studies have traditionally been used to study cell biology, the chronic nature of such manipulations 
does not reflect the dynamicity of cell biology. Chemically-inducible dimerization (CID), provides 
a mechanism to more acutely interrogate cellular signalling pathways. Over the past few years a 
number of different CID systems have been developed (Table 1.3). 
 
Domain Partner Dimeriser Reference 
FKBP12 FKBP12 FK1012  (Spencer et al. 1993) 
FKBP12 Calcineurin A FKCsA (Belshaw et al. 1996) 
FKBP12 FRB Rapalog (Liberles et al. 1997) 
ABICS PYLCS ABA (Liang, Ho, and Crabtree 2011) 
GAI GID1 GA3-AM (Miyamoto et al. 2012) 
SNAP-tag HaloTag MeNV-HaXS (Erhart et al. 2013) 
Table 1.4: Chemically-Inducible dimerization systems  
 
 In CID systems, protein-protein interactions can be acutely induced on the addition of a 
small molecule, most commonly a rapamycin analogue (Bayle et al. 2006; Putyrski and Schultz 
2012). CID dimerization has been particularly important in interrogating lipid signalling pathways 
(DeRose, Miyamoto, and Inoue 2013). In these studies, one CID domain is localised to the plasma 
membrane, whilst its interaction partner is fused to a protein of interest (POI). Addition of the 
dimerising drug results in the recruitment of the interaction partner to the plasma membrane 
typically within seconds to minutes. Here, the POI exerts its effector function. For example, in a 
study by Varnai et al. (Varnai et al. 2006) the type IV 5-phosphatase domain was fused to the 
FKBP domain. On the addition of a rapamycin analogue, the FKBP fusion protein was recruited 
to a membrane-anchored FRB domain. This process resulted in the rapid dephosphorylation of 
PI(4,5)P2 at the plasma membrane, ATP-induced calcium influx, and decreased activity of TRPM8 
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channels (Varnai et al. 2006). In this way CID was used to rapidly trigger a physiological response 
in the cell.    
 Among the earlier CID studies is Graef et al.’s (Graef et al. 1997) interrogation of ZAP70’s 
orientation during T cell activation. As mentioned before, ZAP70 is recruited to the TCR complex 
on phosphorylation, where it exerts its kinase activity. Again, the FKBP-FRB CID system was 
employed. Using rapamycin analogues that allowed for differing degrees of rotational freedom of 
a fused ZAP70 kinase, Graef et al. (Graef et al. 1997) determined that simply recruiting ZAP70 to 
the plasma membrane was not enough to mediate its function. Instead, ZAP70 conformational 
freedom was necessary to drive downstream signalling, as rapamycin analogues that restricted the 
movement of ZAP70 did not result in T cell activation (Graef et al. 1997). 
 Studies such as the two outlined above highlight the utility of CID as a method to 
interrogate cell signalling. However, they also bring to the fore a major weakness of CID as a 
technique. Even with the advent of microfluidics technology, it is still currently difficult to precisely 
spatially administer drugs. It is now becoming clear that cells must respond to highly localised 
cellular signals, such as Cytotoxic CD8+ T cells polarizing their release of cytolytic granules toward 
an APC (Stinchcombe et al. 2006). New techniques in cell biology are emerging that bypass this 
limitation. As well as this, CID systems are difficult to reverse and in some cases the dimerisation 
is irreversible. 
 
1.5.2 Overview of optogenetics  
Over time, diverse groups of organism across all phylogenetic kingdoms have evolved mechanisms 
to sense and respond to various wavelengths of light (380-790nm; UV-Infrared).  These light-
inducible sensors allow organisms to detect continually varying environmental light conditions and 
respond appropriately. Molecular cloning and genetic manipulation of the proteins underlying 
these light response mechanisms has given rise to a new set of techniques in the field of molecular 
biology known as ‘optogenetics’ (Häusser 2014). Optogenetics is so named because it relies on 
genetically-encoded, light-responsive proteins, which distinguishes it from chemical photocaging 
methods. The fundamental modularity of cell biology has allowed for the rapid expansion of a 
suite of light-controllable protein tools for the modulation of diverse cell signalling pathways (Lim 
2010; Tischer and Weiner 2014). Some of the more commonly used systems are outlined in Table 
1.4, adapted from (Repina et al. 2017).  
 
Page 34
System Td1/2 λON (nm) λOFF (nm) Size (aa) Reference 
ChR2 15 ms ~470   737 (Boyden et al. 2005; 
Nagel et al. 2002) 
AsLOV2 ~50 s ~450  143 (Wu et al. 2009) 
Phy/PIF 4 s 650  ~760 908/100 (Levskaya et al. 2009) 
BphP1/PpsR2 15 min ~760  ~650 732/465 (Kaberniuk, Shemetov, 
and Verkhusha 2016) 
CRY2/CIBN ~12 min ~450  498/170 (Kennedy et al. 2010) 
FKF1/Gigantea h ~450  619/1173 (Yazawa et al. 2009) 
EL222 ~50 s ~450   222 (Motta-Mena et al. 
2014) 
UVR8/COP1 Irreversible ~300  440/675 (Favory et al. 2009) 
Table 1.5: Commonly used optogenetic systems  
 
 Optogenetics first emerged in the early 2000s for use in neuroscience. Structural and 
functional similarities between endogenously expressed ion channels in mammalian neurons and 
bacterial (Boyden et al. 2005) and algal light-gated ion channels (Nagel et al. 2002; Nagel et al. 
2003) meant that when these foreign proteins were expressed in mammalian neurons, light could 
be used to regulate neuronal polarisation. This finding revolutionised the field of neuroscience, 
heralding the beginning of more precise and regulated neuronal modulation (Fenno, Yizhar, and 
Deisseroth 2011). Individual neurons or brain regions in free moving mice could be precisely 
activated or inactivated. As many neuronal signals are temporally encoded by time-varying signals 
(Gao and Wehr 2015), the ability to precisely modulate individual cells and cell networks has 
yielding new molecular and behavioural insights in neurobiology.    
 Following the success of optogenetics in neuroscience, the technique has been adopted 
more widely in cell biology. The most common systems are outlined in Table 1.4 (Repina et al. 
2017). Advances in our understanding of fundamental cell biology over recent decades has 
underscored that fact that cells are not merely a random assortment of proteins, salts and lipids, 
but rather are complex and dynamic, anisotropic structures; constantly changing in both space and 
time in response to varying environmental stimuli. When viewed in this context, the utility of 
optogenetics becomes immediately apparent. Existing techniques include the genetic manipulation 
and pharmaceutical obstruction of cellular signalling pathways and individual proteins. Gene 
knockout and overexpression studies have yielded important insights into cell biology, and new 
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technologies such as CRISPR-Cas9 (Sander and Joung 2014) and TALENs (Joung and Sander 
2012) have made genetic manipulation considerably easier, but ultimately these techniques are a 
blunt instrument. Genetic manipulations are temporally imprecise and can have broad, unintended 
consequences beyond the pathway in question; destroying, rather than modulating, the cellular 
circuitry (Fenno, Yizhar, and Deisseroth 2011). Though there is no doubt that these kinds of 
consequences can be interesting, this sort of genetic perturbation does not reflect the intrinsic 
spatial and temporal nuances of cell biology.  Pharmaceutical interventions have also been 
implemented for the interrogation of cellular signalling pathways. Normally, these molecules 
function as inhibitors rather than activators of signalling pathways. A key feature of pharmaceutical 
perturbation is that it can be employed on a relatively rapid timescale, compared to genetic 
manipulations. However, the slow rate of reversibility means that any degree of spatial resolution 
is lost. Moreover, identifying protein-specific inhibitors can require laborious efforts in chemical 
engineering (Repina et al. 2017).   
 Optogenetics holds promise in addressing some of the issues seen with common genetic 
engineering techniques and pharmaceutical interventions. First, optogenetic tools can be 
implemented in parallel with the endogenous signalling machinery. This circumvents the problem 
of pathway subversion or normalisation seen with long-term genetic knockout or knock-in 
systems. As the effect of the optogenetic system is tightly regulated by exposure to a specific 
wavelength of light, the effects of modulation are acute and in most cases reversible. Likewise, the 
kinetic tunability and responsiveness of optogenetic tools mean that they can be engineered for 
spatial precision. When combined with stearable laser systems and live cell imagining, optogenetics 
can be administered with a high degree of spatial precision (Repina et al. 2017; Tischer and Weiner 
2014). The tunability and intrinsic variety of optogenetic tools making them an intriguing option 
for the interrogation of cellular dynamics.   
 
1.5.3 The mechanistic underpinnings of cellular optogenetics    
Although optogenetic tools in cell biology have so far been implemented in a number of different 
settings, from cell migration (Kato et al. 2014) and organelle positioning (van Bergeijk et al. 2015; 
Duan et al. 2015) to protein localisation (Strickland et al. 2012) and developmental signalling 
(Johnson et al. 2017), they all fundamentally rely on two basic mechanisms (Toettcher et al. 2011): 
1) allosteric caging of protein function or 2) the formation (or dissociation) of  protein-protein 
interactions (Figure 1.3). The first method was used by Wu et al. (Wu et al. 2009) to control the 
activity of Rac1. Photoisomerisation of a Rac1-fused optogenetic domain relieved inhibition of  
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A)
B)
Figure 1.3 Mechanistic overview of optogenetic systems Optogenetic systems can 
be broadly classed into two main mechanisms of action: (A) photocaging and (B) light 
inducible protein interactions. The optogenetic domains are shown here in blue. (A) In 
the first method, the activity of the protein of interest (POI) is caged by the optogenetic 
domain in the dark state. Treatment with light results in a conformation change in the 
fused optogenetic domain, allowing the POI to fulfil its function. (B) In the second 
method, the the POI(s) are separate in the dark. On exposure to light the POI(s) are 
brought into proximity allowing them to fulfil their stated function. Of note, optogenetic 
systems also allow for the light-inducible dissociation of protein complexes. The symbol in 
the top, right-hand corner of denotes light and will be used throughout the rest of this 
thesis. 
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the constitutively active Rac1 protein allowing it to exert its function within the cell. A similar 
approach was used to allosterically cage a nuclear localisation sequence (Niopek et al. 2014) and a 
nuclear export sequence (Niopek et al. 2016), which allowed for light-inducible control of protein 
recruitment to or from the nucleus. More commonly, optogenetic domains have been used to 
induce protein-protein interactions, either through heterodimeric interactions (Strickland et al. 
2012; Kennedy et al. 2010) or intrinsic homo-oligomerisation (Che et al. 2015; Park et al. 2017). 
Such techniques have proven successful because proteins often rely on specific interaction partners 
or specific cellular localisation to exert their function. By precisely controlling these properties, 
one can exert an effect on the underlying signalling circuitry. 
 
1.5.4 Multiplexing optogenetics with the molecular biology toolkit  
 In engineering, complex electrical systems can be interrogated by modulating the 
amplitude and frequency of incoming signals and measuring the output response. Optogenetics 
now provides researchers with a similar means of interrogating complex cellular signalling 
modules. By multiplexing optogenetic tools with existing techniques in molecular biology, such as 
fluorescent protein tags, fluorescent and luminescent gene reporters, immunoblots, and RNAseq 
(Wilson et al. 2017) among many others; researchers can combine input modulation with 
quantitative readouts of cellular activity. This type of precise examination can allow researchers to 
delineate the effect of specific signalling axes from within complex multi-facetted responses. For 
example Toettcher, Weiner & Lim (Toettcher, Weiner, and Lim 2013) recently used such an 
approach to investigate the Ras/Erk signalling pathway. By modulating the pulses of Ras signalling 
activity, they were able to show how modulation of a single signalling pathway can lead to divergent 
output responses. In this way, it was shown that the Ras-Erk signalling module behaved as a 
bandpass filter, with signals >1 hr activating STAT3. High-frequency, short duration signals did 
not activate STAT3. This highlights the fact that cells are able to integrate temporally encoded 
signals. Chemically-inducible and traditional genetic knockout and knock-in approaches do not 
provide the spatiotemporal resolution or reversibility to answer these sorts of questions.  
 
1.6 Scientific Aims  
Chemical and optical methods of cell manipulation are providing previously unprecedented 
control over cellular signalling dynamics. I began the work presented in this thesis with the goal of 
leveraging these newly described tools for the interrogation of immune cell signalling pathways, 
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with particular focus on signalling downstream of the TCR. I began this project by designing and 
testing an optogenetic switch based on the T cell scaffolding protein, LAT. In doing this I had 
hoped to define the duration of membrane proximal signalling necessary for T cells activation. 
One outstanding question in the field of T cell biology, and indeed this is true for other systems 
as well, is whether or not sustained signalling is necessary for a specific output response and how 
a cell is able to interpret the duration of membrane proximal stimulation once a signal has been 
internalised. Optogenetics provides a precise means for defining time-limited signal pulses.  
It is now becoming apparent that cells are able to sense and interpret gradients and 
directionality of environmental cues. How such signals are interpreted by the cells remains a 
relative unknown. The formation of an immunological synapse provides T cells with a defined 
directionailty toward a target antigen presenting cell. However, it is not known whether signalling 
complexes nucleated by the LAT scaffolding protein must remain membrane localised to retain 
their signalling capacity. I sought to test this hypothesis through the optogenetic relocalisation of 
the LAT protein.  
Actin cytoskeletal remodelling is an integral process in T cell activation. LAT is known to 
interact indirectly with the actin remodelling protein WASp, but the temporal association of these 
two proteins remains unknown. Through the use of optogenetics I sought to precisely define the 
location and temporal intiation of microcluster formation. Although microcluster formation is 
known to be important in T cell activation, the dynamics of microcluster formation have proven 
difficult to define with existing tools.  
Finally, as I developed the project further, I shifted focus slightly to interrogate the ability 
of T cells to integrate signals over time. In the periphery, naïve T cells interact with multiple 
different dendritic cells on their transit through the lymph node, the significance of these sub-
threshold activation events in the overall state of T cell activation remains unknown. Furthermore, 
computer modelling of T cell activation has given the suggestion that sub-threshold activation 
events may result in the accumulation of unstable signalling intermediates that reduce the duration 
of signalling necessary for a future activation event. To test this hypothesis I used a LOV2-based 
chimeric antigen receptor to precisely modulate the duration of incoming activation signals to a 
Jurkat T cell lines expressing a fluorescent gene reporter system.  
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1.7 Overview of results 
In this thesis, I will discuss the development of an optogenetic toolkit for the interrogation 
of T cell signalling dynamics. I begin with a chapter focused on tool development, outlining the 
kinetics and design of the systems used in the subsequent chapters. In Chapter 4, I identify the 
limitations of a LAT-based optogenetic system for the interrogation of TCR microcluster 
formation and early T cell signalling. In Chapter 5, I discuss the development of a light-controllable 
chimeric antigen receptor. Here, I multiplex the FRB-FKBP CID system with the light controllable 
LOVTRAP system. This was used to investigate T cell signal integration and illustrate the rapid 
rate of signal decay in the proximal TCR signalling pathway following disengagement of the 
receptor. This work illustrates that TCR proximal signalling functions under tight negative 
feedback. I was also able to show that an increase in signal duration caused a decrease in the rate 
of signal decay. This finding will allow us to build a timeline of TCR-induced signalling events and 
understand how T cells integrate sub-threshold activation signals over time. Finally, in chapter 6, 
I illustrate the biophysical mechanism of T-cell triggering by bispecific antibodies.  
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Chapter 2: General Methods & Materials   
2.1 Stock solutions and buffers  
A number of common stocks and buffers were used throughout the course of this project. A list 
of these buffers can be found in Table 2.1.  
 Stock Solution/Buffer Protocol 
2.1.1 TE buffer (1X) 10 mM Tris-HCl, 1 mM EDTA. Bring to 
pH 8.0 with HCl  
2.1.2 Orange G loading dye (6X) 10 mM Tris-HCl (pH 7.6), 0.15% Orange 
G, 60% glycerol, 60 mM EDTA 
2.1.3 FACS Wash 0.1% Sodium Azide, 2% FCS in 10 mM 
PBS pH 7.4  
2.1.4 FACS Fix 0.1% Sodium Azide, 2% Glucose, 1.6% 
PFA in 10 mM PBS pH 7.4  
2.1.5 ELISA Wash 0.05% Tween 20 in 10 mM PBS pH 7.4  
2.1.6 ELISA Stop Solution 1M P3PO4  
2.1.7 NP40 Lysis buffer 250 μl 10X TBS, 25 μl NP40, 100 μM 
NaVi 25 μl, 200 μM PMSF (Thermo 
Fisher Scientific) 13 μl, 10X CI tablet 
(Roche) 250 μl, ddH2O 1937 μl  
2.1.8 TBS (10X) – 1 L 24g Tris base, 88g NaCl, 900mL ddH2O, 
pH to 7.6 with HCl (adjust to 1 L with 
ddH2O)  
2.1.9 TBS-T TBS, 0.1% Tween 20 
2.1.10 TBE buffer (10X) – 1 L 108g Tris base, 55 g Boric acid in 900 ml 
ddH2O, 40 ml of 0.5 M Na2EDTA pH 8.0 
(adjust to 1 L with ddH2O) 
2.1.11 Filtered (0.22 µm syringe) TSS buffer 
(1X) 
10 % PEG-3350 (or PEG-8000) 
5 % DMSO 
50mM MgCl2 
Prepare in LB broth, pH 6.5  
Table 2.1: Stock buffers  
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2.2 Mammalian Cell Culture  
2.2.1 Suspension cell lines  
Jurkat E6-1 human T lymphocytes (Weiss et al. 1984), Jurkat-derived JCaM2.5, and Raji human B 
lymphocytes (Pulvertart 1964; Epstein et al. 1965) cell lines were grown in suspension in RPMI-
1640 media (Life Technologies), supplemented with HEPES (1 mM Final concentration), 10% 
Heat Inactivated Foetal Calf Serum (HI-FCS[Gibco]) and a Penicillin-Streptomycin-Glutamine 
cocktail (PSG [Gibco]); final concentration 2 mM L-glutamine. Stock cell lines were passaged in 
T-12.5 flasks (Falcon™) and expanded into larger cultures as necessary. Cell cultures were 
incubated at 37°C in 5% CO2. Jurkat cell lines were maintained at a density of 0.2-1.0 x 10
6 cells/ml 
and passaged every 2-3 days. The Raji cell line was maintained at a density of 0.4-1.2 x 106 cells/ml 
and passaged every 2-3 days as necessary.  
 
2.2.2 Adherent cell lines  
HEK293T human embryonic kidney cells (DuBridge et al. 1987) and NIH3T3 mouse embryonic 
fibroblast cells (Green and Meuth 1974) were maintained in a T-75 flask in Dulbecco’s Modified 
Eagle’s Medium (DMEM [Life Technologies]) supplemented with 10% HI-FCS and PSG. Cells 
were incubated at 37°C in 5% CO2. Cultures were established by seeding ~2 x 10
6 cells into a fresh 
T-75 flask in 13 ml of Complete DMEM. Cells were grown to 90% confluency prior to next split 
(3-4 days).  
 To split, spent media was removed and discarded and cells were washed once in tissue 
culture-grade, sterile calcium-free PBS (prepared in house at the LMB). 3 ml of 0.25% Trypsin, 
phenol red (Gibco) for HEK293T cells or 0.25% Trypsin-EDTA, phenol red (Gibco) for NIH3T3 
cells was added and cells were returned to 37°C tissue culture incubator for 5 minutes to allow for 
dissociation. Trypsin was inactivated by adding 7 ml of complete DMEM and mixing gently to 
ensure that cells were in single-cell suspension. Cells were counted by eye using a haemocytometer 
by mixing the suspended cells 1:1 in Trypan Blue (Gibco). 2 x 106 cells were seeded into a fresh T-
75 flask and volume was brought to 13 ml with fresh complete DMEM. Cells were split every 3-4 
days as necessary.   
 
2.2.3 Cell line cold storage 
To maintain consistency between experiments, cell lines were expanded, stored, and periodically 
thawed and re-expanded. Cells were stored in freezing media, either complete RPMI or complete 
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DMEM supplemented with 10% DMSO, depending on the cell line. Suspension cells were grown 
to a density of ~0.8 x 106 cells/ml and then centrifuged at 1200 rpm for 3 minutes and media 
discarded. Cell pellet was resuspended in the residual volume of media and brought to a density 
of 2 x 106 cells/ml in freezing media. Cell suspension was divided into 1 ml aliquots into 1.8 ml 
CryoTube Vials® (Thermo Fisher Scientific), which were placed in a Mr. Frosty™ (Nalgene) 
container with 100% isopropyl alcohol and allowed to cool overnight to -70°C. Once frozen, cells 
were transferred from the -70°C freezer to vapour-phase liquid Nitrogen storage at -180°C. 
Similarly, adherent cells were prepared for storage via the same protocol, but were first washed in 
PBS and dissociated into single cell suspension using the trypsinisation protocol described in 2.2.2.     
 
2.2.4 Mycoplasma testing  
Mycoplasma testing was performed using a MycoAlert™ Mycoplasma Detection Kit (Lonza). 
Positive and negative controls were kindly provided by Yvonne Vallis.  
 
 
2.3 Polymerase Chain Reaction Conditions & DNA purification  
2.3.1 Primer design and in silico PCR  
Prior to in vitro DNA replication, restriction cloning or In-Fusion cloning, reactions were designed 
and tested in silico using SnapGene® Version 4.0.1. SnapGene® software was used to predict 
expected band sizes following PCR reactions and annealing temperatures for all primers (Appendix 
A).  Where necessary, RevComp was used to identify reverse-complement from DNA FASTA 
sequence for reverse primer design. The IDT® OligoAnalyzer 3.1 Tool1 was used to test the 
propensity of primers to form hairpins and homo- or hetero-dimers. All subsequent Polymerase 
Chain Reactions were performed using a G-Storm (GS-1) Thermocycler. 
 
2.3.2 KOD HotStart Polymerase Conditions  
KOD Master Mix, containing MgCl2 and dNTPs (71086-3, Millipore) was prepared according to 
manufacturer’s protocol and distributed into 150 μl aliquots in 500 μl microcentrifuge tubes 
(Eppendorf). Aliquots were stored at -20°C and thawed to room temperature prior to use. 
                                                 
1 http://www.idtdna.com/calc/analyzer   
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Lyophilized primers were diluted in TE buffer to a stock concentration of 100 mM. Prior to 
reaction, primers were diluted 1:10 in MilliQ water to prepare 10 mM stocks. Standard PCR 
reaction mixture is as follows: 
Reagent Volume (µl) 
Template DNA (100 ng) 0.5 
Forward primer (10 mM) 2.0 
Reverse primer (10 mM) 2.0 
KOD polymerase 0.5 
KOD master mix 13.0 
(DMSO*) (2.5) 
dH2O Adjust to 50 
* DMSO was added to a final concentration of 5% when template GC >65%.  
 
In the case of overlap extension PCR (‘stitch PCR’) reactions were prepared as follows:   
Reagent Volume (µl) 
Template DNA 1 (50 ng) 5.0 
Template DNA 2 (50 ng) 5.0 
Forward primer (10 mM) 2.0 
Reverse primer (10 mM) 2.0 
KOD polymerase 0.5 
KOD master mix 13.0 
(DMSO) (2.5) 
dH2O Adjust to 50 
 
 
DNA fragments were amplified under the following thermocycler conditions:  
  32 cycles    
95°C for 2 
min 
95°C for 
20 s 
Lowest Primer 
Tm°C 10s 
70°C for 
15s/kb 
70°C for 2 
min 
hold at 
10°C 
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2.3.3 Q5 Polymerase Conditions  
Q5 PCR conditions were established according to manufacturer’s protocol (M0491S, NEB). 
Standard reaction mix is as follows:  
Reagent Volume (µl) 
Template DNA 1 (100 ng) 5.0 
Forward primer (10 mM) 1.25 
Reverse primer (10 mM) 1.25 
Q5 polymerase 0.25 
Q5 Reaction Buffer (5x) 5.0 
(Q5 high GC enhancer*) (5.0) 
dNTPs (10 mM) 0.5 
dH2O Adjust to 25.0 
* GC Enhancer was added to a final concentration of 5% when template GC >65%.  
 
Thermocycler conditions for the above reaction are as follows: 
  32 cycles    
98°C for 30 s 98°C for 
10 s 
Lowest Primer 
Tm°C 15 s 
72°C for 
30s/kb 
72°C for 2 
min 
hold at 
10°C 
 
2.3.4 MyTaq Colony Screen Polymerase Chain Reaction  
In order to check success of bacterial cloning (outlined Section 3.4), colony screen PCR was 
performed using MyTaq (Bioline) colony screen PCR reagent according to manufacturer’s 
protocol. A master mix was prepared for each set of reaction conditions – primer pairs were 
determined by the vector being screened and confirmed in silico using SnapGene® – with 15 
colonies screened per condition. Reaction mixture was divided into 15 µl aliquots in individual 
PCR tubes. Each colony was gently sampled using a fresh, sterile p10 tip, leaving that majority of 
the colony still intact. Each sample was then transferred to a PCR tube and immersed in pre-
prepared reaction mix containing primers. The tip was gently spun in the mixture to dissociate the 
bacterial cells. The reaction mixture is outlined as follows:   
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Reagent Volume (µl) 
Forward primer (10 mM) 0.6 
Reverse primer (10 mM) 0.6 
MyTaq Mix 7.5 
dH2O 6.3 
 
Thermocycler conditions for the MyTaq reactions were as follows:  
  32 cycles   
95°C for 1min 95°C for 
15 s 
Lowest Primer 
Tm°C 15 s 
72°C for 
30s/kb 
hold at 
10°C 
 
 
2.3.5 Gel electrophoresis  
Agarose gel was prepared by dissolving agarose powder (Eurogentec) in TBE buffer to a final 
concentration of 1%, for DNA fragments of an expected size of >500bp. For DNA fragments of 
an expected size of <500bp but >250bp, a final concentration of 1.5% was used. For DNA 
fragments of an expected size <250bp, a final concentration of 2% was used. Gels were run in TE 
buffer in electrophoresis unit (Geneflow) at 130V for 25 minutes. Run time and voltage were 
adjusted where necessary to improve band separation. Samples were prepared by adding 6X 
Orange G loading dye at a dilution of 1:6.  
 
2.3.6 Gel Extraction  
DNA fragments were isolated from agarose gel post-electrophoresis by cutting out desired bands. 
Agarose gel fragments were transferred to a 1.5 ml microcentrifuge tube (Eppendorf) and DNA 
was extracted using Gel Purification Kit as per manufacturer’s protocol (Qiagen). Samples were 
eluted into 50 μl of elution buffer. Once eluted, samples were screened for DNA concentration 
using Nano-photometer (Geneflow).  
 
2.3.7 PCR purification  
For non-restriction digested DNA fragments, PCR products were purified directly from PCR 
reaction using a PCR purification kit (Qiagen). DNA concentration was screened using a Nano-
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photometer. Band size was confirmed by performing gel electrophoresis using 4 μl of eluted 
sample.  
 
2.4 Bacterial Cloning  
2.4.1 Preparation of Competent Bacteria  
Competent bacterial cells were prepared in house. A starter culture was established by thawing a 
50 μl aliquot of DH5α E. coli and adding it to 4 ml of sterile LB buffer (prepared in house at the 
MRC-LMB). Starter culture was incubated overnight in shaking incubator at 37°C. Overnight 
culture was used to inoculate 20 ml of fresh LB buffer in a non-vented T75 bacterial culture flask 
(Falcon). Flask was returned to shaker and incubated at 37°C until OD600 reached 0.4-0.6. OD600 
measurement was acquired using a spectrophotometer (Eppendorf). Once the specified optical 
density was achieved, cells were centrifuged at 3000 rpm for 10 minutes in a benchtop centrifuge 
(Thermo Fisher Scientific). Media was discarded and pellet was resuspended in residual volume by 
gentle flicking.  Cells were resuspended in 2.5 ml of chilled TSS buffer and mixture was incubated 
on ice for 30 minutes. Following incubation cells were gently mixed and distributed into 50 μl 
aliquots in 500 μl microcentrifuge tubes. Aliquots were frozen at -70°C and stored until use.  
 
2.4.2 Cloning by Restriction Digest  
Restriction digestions were prepared and performed according to manufacturer’s protocol (NEB). 
Digest buffers were determined using the NEB Double Digest Finder Tools2. A schematic of the 
standard vector is shown in Figure 2.1. Digestions were performed at 37°C in water bath for 1 
hour. The reaction mixture is as follows:  
Reagent Volume (µl) 
DNA vector (300 ng) 15.0 
Restriction Enzyme 1 2.5 
(Restriction Enzyme 2*) 2.5 
Digest Buffer** 5.0 
dH2O Adjust to 50 
*Second restriction was used in double digest reactions, **Digest buffers were selected according to NEB Double 
Digest Finder 
                                                 
2 https://www.neb.com/tools-and-resources/interactive-tools/double-digest-finder 
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cpPDZ LATint mRuby2 IRES LAT-TM LOVpep
MluI SpeI BamHI NotI EagI
WPRE
3’ - LTR
pBR322
SFFV promoter
cPPT
11,609bpHIV genes
Psi
5’ LTR SV40 Promoter/Enhancergpt
SV40 ployA + Intron
pHR: cpPDZ-LATINT-Ruby
IRES-LATTM-LOVpep
Figure 2.1 Example pHR IRES plasmid Plasmids were designed to be easily inter-
changable by restriction cloning. Shown here is the low affinity TULIPs construct. The 
PDZ binding domain is intercahngable by MluI/SpeI subcloning from non-IRES vectors. 
The LOVTRAP constructs were designed in the same way. Both components of the system 
were expressed on the same vector.
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To improve the efficiency at which fragments were inserted in the correct orientation during 
NotI single digest and EagI cloning reactions, 6 μl of AP buffer and 2 μl of Antarctic phosphatase 
(NEB) were added directly to completed digestion mixture. Total volume was brought to 60 μl 
with dH2O. Sample was transferred to thermocycler and incubated at 37°C for 30 minutes and 
then brought to 80°C for 2 minutes to heat inactive. Linearised vector was then used directly in 
ligation reactions. 
 
2.4.3 DNA Ligation  
DNA ligation was performed using T4 ligation buffer and T4 ligase (NEB) at room 
temperature for 2 hours (or overnight at 16˚C). Serial dilution reactions were performed as follows:  
Reagent Volume (µl) 
Purified vector 5.0 
Purified insert 0.0, 1.0, 10.0 
T4 Ligase buffer 2.0 
T4 DNA ligase 1.0 
dH2O Adjust to 20 
 
 
2.4.4 Heat-shock Transformation of Competent Bacteria  
DH5α competent cells were thawed on ice for 15 minutes and 5 μl of ligation mixture was added 
to cells. Cells were gently flicked to mix. Transformation mixture was incubated on ice for 1 hour 
and then heat shocked at 37°C for 5 minutes and returned to ice for 2 minutes. 200 μl of pre-
warmed, 37°C SOB media was added to the tubes and samples were returned to water bath to 
recover for 1 hour at 37°C.  
 Following 37°C incubation, samples were spread on an Agar plate for overnight incubation 
on plate with appropriate antibiotic resistance. Agar plates were prepared in house at the MRC-
LMB. As the pHR vector uses Ampicillin resistance, I predominantly used Agar plates with 
Ampicillin (100 μg/ml). Plates were allowed to dry briefly at room temperature for 15 minutes 
before transferring to 37°C bacterial incubator (SciQuip) for overnight incubation.  
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2.4.5 Plasmid Purification  
Following overnight incubation, DH5α colonies were screened using the MyTaq Colony Screen 
PCR protocol (Section 2.2.4). Positive colonies were harvested using a clean, sterile p10 Tip and 
transferred to a 15 ml Falcon tube containing 4 ml of LB broth supplemented with 100 μg/ml 
Ampicillin. Cultures were incubated overnight at 37°C in shaking incubator.  
 Once the DH5α cultures were expanded, p10 tips were removed from 15 ml falcon tubes 
and cells were harvested by centrifugation at 3000 rpm for 10 minutes at 4°C. Media was decanted 
from the samples and plasmids were purified according to Plasmid Purification Mini-prep Kit 
protocol (Qiagen). Purified plasmids were eluted into 80 μl of TE elution buffer and DNA 
concentration was determined using Nano-photometer. Samples were adjusted to 200 ng/μl with 
TE buffer. Plasmids were stored at -20°C until use.  
 
2.5 DNA transfection and Transduction  
2.5.1 Transient transfection  
HEK293T cells were seeded at a density of 0.2 x 106 cells per well in a single well Cell View™ 35 
mm glass bottom, Advanced Tissue culture, No. 1.5 dishes. Cells were allowed to settle and expand 
overnight at 37°C and 5% CO2. The following day, cells were transfected with 1-1.5 μg of DNA 
and GeneJuice reagent (Millipore). 3 μl of GeneJuice reagent were used per 1 μg of DNA. A master 
mix of transfection reagent was made by adding 3 μl of gene juice to 100 μl of serum free DMEM 
(SFM) and incubating the mixture for 5 minutes at room temperature prior to adding the DNA. 
After adding DNA, tubes were flicked gently to mix and left to incubate at room temperature for 
25 minutes. Following incubation, DNA mixture was added dropwise to the imaging dishes and 
the plates were gently rocked and swirled to evening distribute the transfection reagent across the 
dish. Plates were incubated overnight again and then processed for imaging or flow cytometry. 
   
2.5.2 Lentiviral Transduction  
HEK293T cells were seeded at a density of 1 x 106 cells per well in a 6-well plate (Greiner bio-one) 
and allowed to settle and expand overnight at 37°C and 5% CO2. The following day, HEK293T 
cells were at a confluency of ~60-80% and transfection reagent was prepared by adding 4.5 μl of 
GeneJuice to 100 μl of SFM. Mixture was incubated for 5 minutes prior to adding DNA. DNA 
lentiviral transduction mixture was prepared using 3 μl of pMD2.G expressing the VSV-G 
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envelope at 100 ng/μl stock concentration; 3 μl of p8.91, expressing the HIV-1 packaging genes 
Gag, pol, rev, and tat, at 200 ng/μl stock concentration; and 3 μl of the vector to be transduced, 
also at a stock concentration of 200 ng/μl. The total amount of DNA in each transduction reaction 
was 1.5 μg. DNA mixture was added to the pre-prepared SFM with GeneJuice reagent and allowed 
to incubate for 25 minutes at room temperature. Following the incubation, DNA transduction 
mixture was added dropwise to HEK293T cells and incubated for 48 hours at 37°C and 5% CO2.  
 After 48 hours, viral media was harvested by carefully removing media from HEK239T 
cells and transferring to a 2 ml screw-top tube (StarLab) and centrifuging at 8K rpm in benchtop 
microcentrifuge for 3 minutes. The viral media was then stored a 4°C for up to one week prior to 
use or used immediately for transductions. In transducing suspension cells, such as Jurkat E6-1 
cells, 500 μl of cells at a density of ~0.8 x 106 were transferred to each well of a 6-well plate. Viral 
media was carefully removed from the 2 ml tube so as not to disrupt the pellet and added directly 
to the suspension cells in the 6-well plate. Cells were then incubated in viral media at 37˚C and 5% 
CO2. After 24 hours, a further 2 ml of fresh, complete RPMI was added to the transduced cells. 
In transducing adherent cells, the cells were plated at a density of 0.5 x 106 cells per well in a 6-well 
plate the night before. The media was then removed and replaced with viral media. After 24 hours, 
the viral media was removed and replaced with fresh, complete DMEM. Two days after viral 
transduction, cell were passaged again as normal using 0.25% trypsin or trypsin-EDTA.  
 
2.5.3 Lentiviral concentration   
In cases where construct expression was low, we increased the viral titre using Lenti-X 
concentrator (Takara). This was done according to the manufacturer’s protocol. Following the 
overnight incubation at 4˚C and subsequent centrifugation, the Lenti-X concentrated virus was 
resuspended in 250 μl of fresh complete RPMI. This was added 1:1 to 250 μl of Jurkats at 1 x 106 
cells/ml in a 24-well dish and incubated overnight at 37°C in 5% CO2. The following day, the 
transduced cells were transferred to 1.5 ml of fresh RPMI in a 6-well plate. Two days after lentiviral 
transduction the transduced cells were passaged again as normal.  
 
2.6 Confocal Microscopy 
2.6.1 Sample preparation and image acquisition  
Optogenetic relocalisation assays were performed using live cell, multi-channel confocal 
microscopy. Imaging was carried out on an Eclipse Ti Spinning Disk confocal microscope (Nikon) 
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equipped with an Okolab incubation chamber. Chamber was equipped to provide 5% CO2 and 
37°C. Blue light illumination was supplied via an overhead condenser fitted with a white light LED 
source and 450nm condenser filter. To ensure that our blue light illumination protocols were 
directed at a small subset of cell for any given time course, the condenser was narrowly focused 
using the field aperture in the correct plane at 10X magnification prior to running microscopy 
imaging protocols. Fluorophore excitation was provided by a set of Andor lasers: 405 nm, 488 nm, 
561 nm, and 640 nm. Images were acquired at 60X or 100X magnification.  
HEK293T cells were prepared for imaging through the transient transfection protocol 
outline in section 2.5.1. Just before imaging, spent DMEM was removed from cells and replaced 
with DPBS with Ca2+ and Mg
2+ (Gibco).  
 To standardise and automate our imaging protocol we wrote a script using the BeanShell 
programming language, which was executed using the MicroManager 1.4 software package 
(ImageJ). This script allowed for standardisation of the channel settings across multiple images 
with regards to laser colour, filter, and exposure time. When conducting time course images the 
duration of the time course and the blue LED exposure time were programmed using our script.  
LED intensity and laser intensity were controlled manually and adjusted where necessary on a cell-
cell basis. The annotated BeanShell imaging script can be found in Appendix C.  
 
2.6.2 Image Processing  
All image processing was carried out using Fiji (ImageJ) open source image analysis software. To 
avoid inconsistencies in analysis between samples I generated a standardised image analysis 
workflow (Figure 2.2). Briefly, multichannel images were separated into single channel images and 
then Look Up Tables (LUTs) were converted to greyscale. Time series images were corrected for 
photo-bleaching using the exponential fit method. Background was subtracted in each channel 
using a 100 pixel rolling ball background subtraction method.  A 100 pixel radius was selected to 
avoid loss of signal in time course images where cytoplasmic fluorophore intensity was low. 
Contrast was then enhanced by histogram normalisation so that images were comparable between 
channels. RGB colour images were prepared by merging the channels and single colour images 
were saved in grayscale.  
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Raw microscopy 
image (tiff)
Split channel
Channel 1 
Image
Channel 2 
Image
Convert LUT to grayscale Convert LUT to grayscale
Bleach correct, subtract 
background, 100 pixel radius 
Bleach correct, subtract 
background, 100 pixel radius 
Enhance Contrast, normalize 
histogram
Enhance Contrast, normalize 
histogram
Merge Channels
RGB composite8-bit grayscale 8-bit grayscale
Figure 2.2 Overview of ImageJ workflow All images were processed using a stan-
dardized image analysis protocol. Multichannel images were split into single channel 
image stacks. Single channel images were converted to grayscale, photobleach corrected 
using the exponential fitting method and background was subtracted using the rolling 
ball subtraction method. Contrast was enhanced by normalizing the histogram and then 
channels were merged and converted to RGB composite images for colour images, or to 
8-bit grayscale images as single channel images. 
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2.7 Flow Cytometry  
2.7.1 Sample preparation and surface staining  
In preparing samples for flow cytometry, ~0.75 x 106 cells were centrifuged at 1.2K rpm for 3 
minutes in a FACS tube (Falcon™). Media was discarded and samples were resuspended by gentle 
aggitation in the residual media. For each sample antibodies were prepared in 100 μl FACS wash 
buffer (Table 2.1, 2.1.3) 10 µg/ml final concentration.  Complete list of antibodies can be found 
in Table 2.2. Cells were transferred to 4°C fridge and incubated for 25 minutes with occasional 
agitation. Cells were then washed once in 3 ml of FACS wash buffer by centrifugation at 1.2K rpm 
for 3 minutes. Wash buffer was discarded and cells were resuspended by flicking in the residual 
volume. In cases where secondary antibodies were used, 100 μl of FACS wash buffer containing 
secondary conjugated antibody at a final concentration of 2.5 µg/ml was added to the cells and 
incubated at 4°C for a further 25 minutes and washed once more. Cells were fixed in FACS fix 
buffer and either analysed immediately by flow cytometry or stored at 4°C until analysis could be 
performed.   
 When staining for co-receptors CD80 and CD86 on Raji cells Fc Receptor Blocking 
Solution (Human TruStain FcX, Biolegend) was used prior to staining with antibodies. 5 μl of FcX 
was added directly to cells and incubated at room temperature for 10 minutes. Cells were then 
stained as normal.  
 All data were collected using an LSRII Flow cytometer (Becton Dickinson [BD]) or a 
Fortessa flow cytometer (BD). All machines were installed with FACSDiva acquisition software 
(BD). Data were stored and imported as .fcs files.   
 
Antigen Isotype Species Fluorophore Clone Notes 
CD54 IgG1, κ Mouse Alexa Fluor 488 HCD54 ICAM-1  
CD11a IgG1, κ Mouse Unconjugated HI111 αChain subunit of 
LFA-1 
LAT IgG1 Mouse Unconjugated 1111 Used to check 
intracellular expression 
of LAT 
TCR α/β 
(human) 
IgG1, κ Mouse Alexa Fluor 647 IP26 Used to check T cell 
receptor expression 
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CD3ε (human) IgG2a, 
κ 
Mouse Alexa Fluor 647 Hit3a Used to check T cell 
receptor expression 
CD3ε (human) IgG2a, 
κ 
Mouse Unconjugated Hit3a Calcium Flux assay, 
primary unconjugated 
antibody 
CD3ε (human) IgG2a, 
κ 
Mouse Unconjugated OKT3 Primary unconjugated 
and plate bound 
activation assays 
CD6 IgG1, κ Mouse PE BL-CD6 Screen co-receptor 
expression in T cells 
CD28 
(human) 
IgG1, κ Mouse Unconjugated CD28.2 Primary unconjugated 
and soluble antibody in 
plate-bound activation 
assays. Used to check 
co-receptor expression 
in T cells 
CD69 
(human) 
IgG1, κ Mouse Alexa Fluor 647 FN50 Early activation marker 
of T cells 
CD80 
(human) 
IgG1, κ Mouse Alexa Fluor 647 2D10 Co-receptor expressed 
on B cells 
CD86 
(human) 
IgG2b, 
κ 
Mouse Alexa Fluor 647 
Brilliant violet 421 
Brilliant violet 605 
IT2.2 Used to check Synthetic 
Antigen receptor 
Expression and B-cell 
CD86 expression 
IgG1 (mouse) IgG Goat Alexa Fluor 647 Polyclonal Secondary Antibody 
Isotype 
control 
IgG1, κ Mouse Alexa Fluor 647 MOPC-21  
 
ZAP70 IgG Rabbit Unconjugated 3165 T cell immunoblot 
input control  
  Table 2.2: List of Antibodies  
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2.7.2 Intracellular FACS staining  
When assaying for the ablation of LAT in the knockout cell lines it was necessary to perform 
intracellular FACS staining. Staining was performed according to manufacturer’s protocol using 
Nuclear Factor Fixation and Permeabilisation buffer set (BioLegend). Briefly, Approximately 
1x106 cells were centrifuged at 1200 rpm for 3 minutes, media was decanted and cells were 
resuspended by vortex in the residual volume. Cells were fixed for 20 minutes at room temperature 
using nuclear factor fixation buffer (BioLegend) and washed in permeabilisation buffer 
(BioLegend). Cells were immune-labelled in 100 μl permeabilisation buffer with αLAT (1111) at a 
final concentration of 2.5 μg/ml. Cells were washed again in permeabilisation buffer and stained 
with 5 μg/ml of αIgG1-AF647 antibody. Cells were then washed once more in permeabilisation 
buffer to remove excess unbound antibody, then in standard FACS wash buffer, and finally 
resuspended in FACS fix solution.  
 
2.7.3 Ratiometric calcium flux assay 
Indo-1 AM leak resistant (Grynkiewicz, Poenie, and Tsien 1985) (TEFlabs) stock solution was 
prepared by resuspending 50 μg of lyophilized Indo-1 with 50 μl of DMSO, final concentration 
of 1 mg/ml. 500 μl of indo-1 staining solution was prepared per calcium flux sample in SFM to a 
final concentration of 5 μg/ml. 30% pluronic acid was also added to the SFM in a 1:1 ratio with 
the volume of Indo-1 stock solution added. Jurkat E6.1 T cells (~0.5 x 106/sample) were 
centrifuged at 1200 rpm for 3 minutes in FACS tubes, media was discarded and cells were 
resuspended in residual volume by flicking. Cells were resuspended in 500 µl of SFM with Indo-1 
and pluronic, lids were sealed, and samples were incubated in 37°C water bath for 30 minutes with 
occasional agitation.  
 Cells were washed by centrifugation in 3 ml of DPBS with Ca2+ and Mg2+ to remove any 
excess Indo-1. Media was discarded and cells were resuspended by gentle agitation in the residual 
volume. In the meantime, a stock solution of αCD3, clone Hit3a (BioLegend) antibody was 
prepared at 1 μg/ml in Complete RPMI. 500 μl of antibody-containing RPMI was added to the 
resuspended cells and samples were incubated at room temperature for 15 minutes. All further 
steps were performed at room temperature. Following incubation, cells were washed in 3 ml of 
complete RPMI, media was discarded and cells were resuspended in 500 μl of Complete RPMI 
for calcium flux analysis. Cells were rested at room temperature for 15 minutes prior to the start 
of the experiment.  
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 The Indo-1 calcium indicator dye has an excitation of 375 nm and undergoes a peak shift 
in emission from 475 nm in calcium-free state to 400 nm in the presence of calcium. Calcium flux 
can be measured ratiometrically on a cell-cell basis using a flow cytometer equipped with an 
ultraviolet laser (355 nm). Calcium flux was calculated as the calcium-bound signal divided by the 
calcium un-bound signal. Our Assay was performed on a Becton Dickinson (BD) Biosciences 
Fortessa Flow Cytometer. Cells were run for 30 seconds to establish baseline reading and 10 μl of 
anti-IgG polyclonal antibody was added to activate Jurkat E6.1 T cells.  Samples were run for an 
addition 5 minutes and Indo-1 ratiometric data were collected.  
 
2.7.4 FlowJo v10.1r5 
 All initial data analysis of flow cytometry samples was performed using the FlowJo v10.1r5 
software. This software provides a robust tool for data analysis and allows for sample gating and 
limited statistical processing. Processed data were exported as .csv files and opened with Microsoft 
Excel 2013 or Matlab 2016b for further statistical analysis and graphing.   
 
2.7.5 Fluorophore panel selection 
When performing flow cytometry analysis, we attempted to minimise spectral overlap between our 
fluorophores. Fluorophore panels were selected using the SearchLight Spectra Viewer (Semrock) 
and Spectrum Viewer (BD).   
 
2.8 Immunoblot Assay 
We conducted Immunoblot assays to confirm expression or ablation of LAT. Jurkat LAT 
Knockout or Jurkat wildtype cells (2 x 106) were lysed for each sample.  Lysis was performed on 
ice in NP-40-based lysis buffer for 1 hour with occasional agitation. Once lysed samples were 
centrifuged at max speed for 10 minutes at 4°C to remove cell debris. NuPAGE-LDS loading dye 
(15 μl; Thermo Fisher Scientific) supplemented with 100 μM DTT was added per 50 μl of sample 
and samples were boiled in thermocycler at 90°C for 5 minutes to denature proteins. Samples were 
cooled and frozen at -20°C until use or cooled and run on 4-12% Bis-Tris NuPAGE, 1.5 mm 
Protein Gel (Thermo Fisher Scientific). Per lane, 10 μl of each sample was run at 200V for 1 hour. 
Run duration was adjusted where necessary according to protein size.  
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Blot was transferred using iBlot (Thermo Fisher Scientific) P0 – 20 V for 1 minute, 23 V 
for 4 minutes, 25 V for 2 minutes – onto a PVDF membrane and blocked for 30 minutes in 2.5% 
Milk TBS. Membrane was carefully cut in half with the lower half blotted with 5 μl of αLAT (1111) 
antibody was diluted in 10 ml of 2.5% Milk TBS-T to a final concentration of 250 ng/ml and the 
upper half blotted with αZAP70 (D1C10E, Cell Signalling) as input control. PVDF Membrane 
was incubated overnight at 4°C with rocking.  
 The following day, membrane was washed 3 x 5 minutes in 2.5% TBS-T. DyLight 800 
(Thermo Fisher Scientific) secondary antibody was diluted 1:20,000 in 2.5% Milk TBS-T and 
incubated with membranes for 15 minutes at room temperature. Membranes were washed 3 x 5 
minutes in TBS-T and imaged using Licor Odyssey. Western Blot Images were prepared using Fiji 
ImageJ.  
 
2.9 Enzyme-linked immunosorbent assays (ELISA) 
For long term activation assays, IL-2 expression was used as a late-stage marker of T-cell activation. 
This was assayed in spent media from 24-hour time course experiments (details in chapter 5). 
ELISAs were performed using Life Tech kit according to manufacturer’s protocol. Media was 
harvested in 24-well plates following time course assays and stored at -70°C until use. Samples 
were diluted 1:5 in ELISA dilution buffer and run in triplicate. Plate was read using ELISTAR 
plate reader and data were exported as .txt files for analysis in Excel 2013 (Microsoft) and Matlab 
2016b. 
 
2.10 Analysis Software  
2.10.1 Microsoft Excel 2013  
Raw data were compiled and analysed using Microsoft Excel 2013; including data from FlowJo, 
ELISTAR, and ImageJ.  
 
2.10.2 Matlab R2016b  
Matlab was used for statistical analysis of data compiled using Excel. Annotated Matlab Analysis 
scripts are included in Appendices D & E. Details on Matlab analysis can be found in specific 
chapter methods sections. 
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Chapter 3 – Development of  an optogenetic toolkit  
3.1 Introduction  
3.1.1 Optogenetic tool development  
Individual cells are highly ordered and dynamic structures, constantly changing in both 
space and time in response to varying stimuli. Genetic manipulations of signalling networks can 
have broad off-target effects and are temporally imprecise. Pharmaceutical perturbations, although 
much more temporally precise, lack spatial resolution and are also susceptible to off-target effects. 
Although both types of approach have been extremely important in shaping our understanding of 
basic cell biology, neither truly reflects the underlying complexity of cellular signalling dynamics. 
Optogenetics provides a means for spatially and temporally interrogating the underlying circuitry 
of the cell.  
In this chapter, I outline the development of an optogenetic toolkit for the interrogation 
of immune cell signalling. Although our understanding of the cellular machinery underlying the 
TCR signalling network is comprehensive (Smith-Garvin, 2009; Malissen & Bongrand, 2015), the 
spatiotemporal dynamics of T cell activation remains to be fully explained, particularly those events 
in early activation. It is also not understood how small variations in early signalling are internalised 
by the T cell and translated into an appropriate downstream response (Mayya and Dustin 2016). 
It was reasoned, that by developing a system to precisely regulate T cell activation, we would be 
able to investigate both early activation events and signal integration. Although a number of 
optogenetics systems exist – reviewed by Tischer & Weiner (Tischer and Weiner 2014) and 
Schmidt & Cho (Schmidt and Cho 2015) – I focused primarily on the development of several 
Light-Oxygen-Voltage 2 (LOV2) domain-based systems. The most commonly implemented 
optogenetic LOV2 domain is derived from Avena sativa, the common oat (Peter, Dick, and Baeurle 
2010; Lungu et al. 2012).   
 
3.1.2 Mechanistic overview of the LOV2 domain  
Plants, although sessile, must still respond to changes in environmental conditions. They are 
particularly responsive to changes in temperature and light exposure, which influence such 
processes as leaf movement, flowering time, stomatal opening and hypocotyl elongation (C. Lin 
2002). Several families of photoreceptor are involved in regulating these responses, in higher 
plants: phototropins, cryptochromes, and phytochromes. The LOV2 domain is derived from 
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phototropin 1. Phototropins are blue light-activated serine/threonine kinases and were identified 
in screens for Arabidopsis thaliana mutants lacking the chloroplast avoidance response (Christie et 
al. 1999; Harper, Neil, and Gardner 2003). LOV2 forms part of a tandem domain structure with 
LOV1, which is located at the N-terminus of the phototropin protein (Briggs and Christie 2002). 
This tandem LOV domain structure is unique among the 5 subsets of LOV-domain containing 
proteins, as all of the other groups contain only a single LOV domain. Although structurally and 
mechanistically related, LOV1 and LOV2 display quantitatively different photocycle kinetics 
(Christie et al. 1999; Crosson, Rajagopal, and Moffat 2003; Kawano et al. 2013). Studies of LOV 
domain proteins from different species have shown that LOV1 and LOV2 are quantitatively more 
different when derived from phototropin 1 than from phototropin 2, with LOV2 displaying a 
marked slower rate of dark recovery than LOV1 (Christie et al. 1999; Briggs and Christie 2002).  
 Work published by Crosson & Moffat (Crosson and Moffat 2001) has given us insight into 
the structure and mechanism of light-mediated signal transduction in the LOV2 domain (Peter, 
Dick, and Baeurle 2010; Crosson and Moffat 2001; Salomon et al. 2001). LOV domains belong to 
the PER-ARNT-SIM (PAS) superfamily of protein domains. PAS domain-containing proteins 
have been described in plants, animals, and prokaryotes with roles in sensing and responding to 
environmental and developmental signals (McIntosh, Hogenesch, and Bradfield 2010; Vogt and 
Schippers 2015). The LOV2 domain has several structural motifs that help mediate the domain’s 
function in phototropin 1. Two mobile helical motifs exist in the LOV2 domain, a short α′A helix 
at the N-terminus and a longer Jα-helix at the C-terminus. The second feature has been utilised in 
the design of several optogenetics tools. Key to the function of the LOV2 domain is a single 
cysteine residue located approximately 4Å from the Flavin mononucleotide (FMN) atom C (4a). 
FMN is the natural chromophore necessary for LOV2 domain function (Zayner and Sosnick 2014; 
Crosson, Rajagopal, and Moffat 2003; Peter, Dick, and Baeurle 2010). In the dark-state, the FMN 
is non-covalently associated with the LOV2 domain. However, on blue light irradiation, a covalent 
cysteinyl-C(4a) adduct is formed with the FMN, resulting in a conformational change to the 
cysteine residue that is transmitted through the core of the protein. This structural change results 
in unwinding and undocking of the two helix motifs from the PAS core of the domain (Peter, 
Dick, and Baeurle 2010). Mutation of the FMN-proximal cysteine residue renders the domain 
photo-nonresponsive (Zayner, Antoniou, and Sosnick 2012; Zayner et al. 2013; Zayner and 
Sosnick 2014). 
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3.1.3 Designing LOV2-based optogenetic switches  
As was discussed in chapter 1, optogenetic tools rely primarily on two mechanisms: 1) allosteric 
caging and 2) inducible protein-protein association (or dissociation). In terms of the LOV2 
domain, all existing optogenetic systems rely on conformational changes to the Jα-helix to drive 
the photo-switchability of the system. Discussed in this subsection are a few prominent examples.  
 Work by Di Ventura and colleagues has shown that the LOV2 domain can be used to 
allosterically cage a protein localisation sequence. Niopek et al., (Niopek et al. 2014) sterically caged 
a nuclear localisation sequence (NLS) within the Jα-helix. On exposure to blue light and undocking 
of the helical domains, the NLS became exposed allowing for recruitment of the protein of interest 
to the nucleus. The same principle was applied again by Niopek et al. (Niopek et al. 2016) with a 
nuclear export sequence. These experiments highlight how optogenetics can be used to precisely 
control the relocalisation of particular proteins. It should be noted that as optogenetics is still 
relatively in its infancy, some degree of optimisation is still required in the implementation of these 
tools. Lungu et al. (2012) report that in engineering caged peptide sequences, a high degree of 
sequence homology is necessary between the sequence of interest and the Jα-helix, at least until 
peptide I539. Peptide sequences caged within the N-terminus or middle of the Jα-helix are reported 
to function only weakly (Lungu et al. 2012).  
 Less commonly, the LOV2 domain has been used to allosterically inhibit entire proteins. 
Some examples featuring LOV2 fusion proteins are Baarlink et al.’s (2013) photoactivatable RAC1 
(PA-RAC) and Wu et al.’s (2009) LOV-DAD. PA-RAC features the LOV2 fused to a constitutively 
active mutant of the small GTPase Rac1. Photoisomerisation of the LOV2 domain sterically 
uncages the constitutively active Rac1 mutant allowing it to exert its downstream effect (Baarlink, 
Wang, and Grosse 2013).  LOV-DAD is comprised of a LOV2 fusion to the autoinhibitory DAD 
domain of the actin nucleation and elongation factor formin mDia2 (Wu et al. 2009). 
Photoisomerisation of the LOV2 domain has also been used to inhibit protein activity. Dagliyan 
et al. (2017) engineered a light-inactivated Src kinase (PI-Src) by replacing a non-conserved loop 
in a constitutively active Src kinase (Y535F) with the LOV2 domain. In the ground state the kinase 
was active, but on irradiation by blue light conformational changes to the LOV2 domain were 
transmitted through the kinase, sterically disrupting the active site (Dagliyan et al. 2016).  
 Although the methods described above could be implemented in interesting ways with 
regards to the T cell signalling pathway, particularly with regards to kinase activation or inactivation 
in proximal signalling, our tools rely instead on light inducible protein-protein association and 
dissociation. We have repurposed two LOV2-based systems for use in T cells. The first, ‘tunable, 
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light-controlled interacting protein tags for cell biology (TULIPs)’ method described by Strickland 
et al. (2012), relies on the blue light-inducible interaction between an engineered LOV2 domain 
and an engineered PDZ domain (Ferrer et al. 2005; Strickland et al. 2012). The second variant is 
based on the LOV2 trap and release of protein (LOVTRAP) system. In the LOVTRAP system an 
engineered binding partner interacts specifically with the dark state of LOV2, but conformation 
changes result in a greatly reduced binding affinity and dissociation of the engineered interaction 
partner from the LOV2 domain (H. Wang et al. 2016).  
 
3.1.4 Repurposing the TULIPs system for T cell signalling  
Strickland et al. (2012) originally designed the TULIPs system for the interrogation of MAPK 
signalling downstream of the peptide hormone G-protein Couple Receptor in yeast. By inducing 
light-specific recruitment of the Ste5N scaffolding protein Strickland et al. were able to define the 
polarised secretion of yeast mating hormone.  The role of Ste5N can be considered analogous to 
that of LAT in T cells. LAT acts as a scaffolding protein to nucleate signalling molecules 
downstream of the TCR (Figure 1.1). Thus, it was reasoned that a similar approach to signal 
interrogation might provide useful insight to T cell activation. This is discussed in detail in Chapter 
4.  
 The TULIPs system itself is comprised of two components: an engineer Erbin PDZ 
domain (J. Huang et al. 2008; Reina et al. 2002) and its binding target an engineered LOV2 domain, 
‘LOVpep’ (Strickland et al. 2012; Möglich and Moffat 2010). LOVpep features a truncation of the 
Jα-helix and a fusion of the –SSADTWV-COOH peptide sequence, which shares some amino 
acid sequence homology to the wildtype domain but is bound by the engineered PDZ (ePDZ) 
domain, whereas the wildtype LOV2 sequence is not (Strickland et al. 2012). Strickland et al., 
(2012) tested three variants of the PDZ domain, which display binding affinities of >10 μM (Kd) 
to ~0.5 nM (Kd). The lowest affinity variant, cpPDZ (Low), features a single PDZ domain. The 
higher affinity variants, ePDZb (Mid) and ePDZb1 (High), have been engineered into clamp-like 
protein structures featuring a FN3 domain fused to the PDZ domain (Jin Huang, Makabe, et al. 
2009; Jin Huang, Nagy, et al. 2009).  In the dark the LOVpep binding sequence is caged within the 
core of the LOV2 domain but on blue light irradiation, unwinding of the Jα-helix exposes the 
peptide sequence for binding by the PDZ domains.  
 In establishing a TULIPs-based system for use in T cells I focused my initial efforts on the 
membrane scaffolding protein LAT (Sommers, Samelson, and Love 2004). The role of LAT in T 
cell activation is discussed in more detail in chapter 4. LAT has no intrinsic enzymatic activity and 
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relies on its binding partners and membrane positioning to exert its function (Balagopalan et al. 
2010). Following Strickland et al.’s suggested workflow, I created a membrane anchored LOVpep 
domain and a cytosolic truncation of LAT fused to the C terminal of the ePDZ domains. The 
truncated LAT still had all of its signalling motifs intact. The LOVpep domain was localised at the 
plasma membrane by fusion to the C-terminal of the transmembrane domain of LAT.  
 
3.1.5 Repurposing the LOVTRAP system for T cell signalling  
Using a similar approach to the TULIPs system I developed a LOVTRAP version of the LAT-
based optogenetic tool. This system was adapted further in Chapter 5 for use with CD3ζ to 
interrogate TCR signal integration. The LOVTRAP system provides an interesting alternative to 
the TULIPs system as it provides a mechanism for light-inducible dissociation of LAT from the 
plasma membrane. The LOVTRAP system was established by a large scale mutation screen of the 
Z subunit of the Staphylococcal immunoglobulin binding protein A (H. Wang et al. 2016). The Z 
protein variants were screened for binding of the dark state of LOV2 and domains with a high 
affinity for the dark state, but low affinity for the light state were selected for further screening. I 
used the highest binding affinity variant, Zdk1, which shows 26.2 nM (Kd) affinity in the dark but 
>4 μM (Kd) affinity for the light-state of LOV2. Two other variants of the Zdk domain have also 
been described with different binding site and affinities (H. Wang et al. 2016). The Zdk1 binding 
site is located at the C-terminus of the LOV2 domain, overlapping the Jα-helix (H. Wang et al. 
2016). The kinetics of this interaction are tunable via mutations to the LOV2 domain. Faster or 
slower cycling variants affect the rate at which the Zdk domain can re-associate with LOV2 
following the cessation of blue light irradiation. I also tested the fast cycling V416T variant and 
slow cycling V416L variant, which have been shown to have t1/2 of 5 seconds and 496 seconds
3, 
respectively (H. Wang et al. 2016; Zayner and Sosnick 2014; Zayner, Antoniou, and Sosnick 2012). 
As our LOVTRAP system used only the Zdk1 variant, it will herein be referred to a Zdk for the 
sake of simplicity.  
 
3.1.6 Development of CRY2-based signalling systems 
Given the unpredictability of optogenetic engineering, I did not limit my approach solely to the 
development of LOV2-based tools. An alternative optogenetic system that has been widely used 
in cell biology is the Arabidopsis thaliana-derived CRY2 (Crytptochrome 2) domain. CRY2 is one 
                                                 
3 Half-life time taken for the LOV2 domain to thermally revert from the lit state to the ground state 
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of five cryptochrome proteins found in Arabadopsis. These proteins are involved in blue-light 
entrainment of the circadian central oscillator (Devlin and Kay 2000; X. Yu et al. 2010). CRY2 
operates endogenously via two main mechanisms. First, CRY2 has the capacity to interact with 
transcription factors and direct gene expression indirectly. Second, CRY2 can bind chromatin 
independently of other proteins to directly modulate transcription (Liu et al. 2008; Pedmale et al. 
2016). On blue light exposure, the CRY2 domain undergoes a conformational change allowing it 
to interact with its binding partner CIB1 (Liu et al. 2008). Mechanistic details of the conformational 
change and protein-protein interaction remain to be fully described. Like the LOV2 domain, the 
CRY2 domain is similarly dependent on an mammalian cell endogenously expressed Flavin 
cofactor, Flavin adenine dinucleotide (FAD) (C. Lin and Todo 2005), thus preventing the need for 
exogenous supplementation of the tissue culture media or further genetic alteration of the host 
cell line. However, at 593 residues in length, the (At)CRY24 domain is structurally much larger 
than the (As)LOV25 domain (Pathak et al. 2014). Likewise, the CIB1 binding partner is also a large 
domain, at 191 residues. Work done by Taslimi et al. (2014) has provided the optogenetics 
community with a set of second generation truncated CRY2 variants with altered binding kinetics; 
as well as truncated variants of the CIB1 binding partner, CIBN (residues 1-170) and CIB81 
(residues 1-81). Although CIB81 showed light-dependent recruitment of CRY2, the interaction 
was reportedly substantially weaker than when combined with CIBN or CIB1 (Taslimi et al. 2016; 
Taslimi et al. 2014). For this reason, I elected to conduct my experiments using the CIBN variant.  
 As with the LOV2 domain, the CRY2 domain is also tunable by point mutations. Taslimi 
et al. (2016) reported the development of both a fast cycling and slow cycling variant, bearing the 
point mutations W349R and L348F, respectively. The fast cycling mutant was stated to have a t1/2 
of 2.5 minutes, whereas the slow cycling mutant was reported to interact with CIBN with a t1/2 of 
24 minutes. The tunability of these optogenetic domains can allow for signal interrogation at 
varying time scales with minimal light exposure. Light toward the UV end of the spectrum in 
particular can be toxic to cells (Stockley et al. 2017).  
 
3.1.8 Aims  
In this chapter I will outline the steps taken to develop the LAT-based optogenetic tools employed 
in chapter 4. The approaches described herein were performed in HEK293T cells for the purposes 
                                                 
4 Specifically the CRY2 domain from Arabidopsis thaliana  
5 Specifically the LOV2 domain from Avena sativa as LOV domains from other organisms have also been appied to 
optogenetics  
Page 64
of system optimisation and visualisation. The limited cytoplasmic volume of T cells meant that 
Jurkat T cells did not provide an adequate system for investigating LOV2 and CRY2 variants with 
regards to LAT recruitment. Once a functional set of optogenetic tools was developed, these were 
then transduced into T cells for the interrogation of T cell activation.   
 
3.2 Materials & Methods  
3.2.1 Microscopy  
To measure recruitment and dissociation of the optogenetic LAT constructs to and from the 
plasma membrane and other intracellular locations I developed a time course imaging script 
written in the BeanShell programming language and executed on Micromanager 1.4. As described 
in the general methods section, this script allowed us to automate and standardize the imaging 
procedure across different optogenetic systems.  
 In testing the individual LOVTRAP and TULIPs constructs I wanted to measure 
localisation and dissociation in the light and dark states. I adapted the imaging script to take images 
in two channels ever second for 1 minute. For the first 5 seconds images were taken in the dark 
state to establish a baseline of localisation. Constructs were designed with yellow-green- (561 nm) 
and red-excited (640 nm) fluorophores, mRuby2 and IFP2, to avoid unintended activation of the 
LOV2 domains (<475 nm). After 5 seconds, the script was programmed to illuminate the cells 
with 450 nm light using the overhead condenser for 20 seconds, while still taking images in the 
561 Ex/607 Em and 640 Ex/708 Em channels once per second. After 20 seconds of blue light 
irradiation, the script was programmed to switch off the condenser and continue imaging in both 
channels every second for a further 35 seconds, so that the rate of return to the dark state could 
be observed. The BeanShell Script can be found in Appendix C.   
 Similarly, I tested the two-component (TULIPs-LOVTRAP multiplexed) optogenetic 
“knock-sideways” (Robinson, Sahlender, and Foster 2010; Haruki, Nishikawa, and Laemmli 2008) 
system using a time course protocol programmed in Beanshell for Micromanager. However, my 
imaging script was adapted to image over 80 seconds. Cells were illuminated from 5-35 seconds 
during the time course and then allowed to recover to the dark state.  
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3.3 Results  
3.3.1 Design of two opposing LAT-based optogenetic systems  
The main T cell membrane scaffolding protein LAT, is reported to be intrinsically disordered (van 
der Lee et al. 2014). This lack of 3D structure and LAT’s relatively small size (36 KDa) means that 
phosphorylation events have a large impact on LAT’s binding properties, promoting high avidity 
interactions between multiple binding partners (Balagopalan et al. 2010; Flock et al. 2014). Post-
translational modifications drive contortions of LAT resulting in overlapping binding moieties 
allowing for the rapid exchange of binding partners and the nucleation of multiple competing 
signalling molecules (Van Roey and Davey 2015). The first ~30 amino acids of LAT are predicted 
to be comprised of a short extracellular domain and transmembrane (TM) domain (Figure 3.1). 
Experimental evidence has shown that a CxxC motif at the C-terminal end of the TM domain is a 
palmitoylation site (W Zhang et al. 1999), which facilitates LAT’s insertion into the plasma 
membrane. We designed our optogenetic constructs with the LOV2 domain anchored at the 
plasma membrane via the TM domain of LAT (Figure 3.2 & Figure 3.3). The C-terminal Jα-helix 
is thus exposed to the cytoplasm on blue light irradiation. The second half of the TULIPs- and 
LOVTRAP-LAT systems is comprised of the LOV2 domain interaction partner fused to the 
intracellular domain of LAT; that is, either ePDZ or Zdk, respectively. Thus the TULIPs system 
allows for light-inducible recruitment of LAT to the plasma membrane and the LOVTRAP system 
allows for light-inducible dissociation from the plasma membrane (Figure 3.2 & Figure 3.3).  
 In chapter 5, the LOVTRAP system was redesigned for use with CD3ζ. In this system the 
LOV2 domain was still bound at the plasma membrane, but we used a myristoylated variant of 
Zdk fused to the ITAM motifs of CD3ζ. The kinetics of the interaction between Zdk and mutants 
of the LOV2 domain itself are assumed to be comparable between the systems. The second system 
is discussed in detail in chapter 5.  
 
3.3.2 Point mutation-based tuning of the LOV2 domain  
A number of mutations have been reported to alter the photocycle kinetics of the LOV2 domain 
(Figure 3.4). The mutations affect the rate at which the LOV2 domain decays back to the dark 
state, but do not alter the rate at which it structurally changes to the light state (Harper, Neil, and 
Gardner 2003; Christie et al. 1999). In accordance with Strickland et al.’s development workflow 
we tested a number of different variants of the LOV2 domain including constitutively active and 
inactive variants (Table 3.1).  
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Figure 3.1 LAT-TM-LOV2 constructs engineered according to structural prop-
erties of LAT The DTU Bioinformatics SignalP 1.4 Server was used to predict the trans-
membrane motif of LAT. The single amino acid sequence was entered into the predicive 
software and the results shown here give the probability that a particular amino acid falls 
within the intracellular, extracellular, or transmembrane region of LAT. It is known that LAT 
has a short extracellular domain and thus it can be inferred that the N-terminal amino 
acids to the left of the graph represent the extracellular domain of the protein. 
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Figure 3.2 Schematic overview of the TULIPs-based system (A) In the dark 
state, the peptide binding sequence (red) of the engineered LOVpep domain is caged 
within the Jα-helix and ePDZ-LATint-Ruby is localised to the cytoplasm. (B) Under 
450nm illumination, the Jα-helix  of LOVpep unwinds and undocks from the PAS domain 
core, uncaging the peptide for binding by the PDZ domain. The intracellular domain of 
LAT is then localised to the plasma membrane. On Cessastion of blue light stimulation 
LOVpep reverts to its dark-state conformation causing dissociation of PDZ-LATint-Ruby 
back to the cytoplasm. 
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Figure 3.3 Schematic overview of the LOVTRAP-based system (A) In the dark 
state, Zdk-LATint-Ruby is anchored at the plasma membrane by its interaction partner, 
LAT-TM-LOV2. (B) Under ~475 nm illumination, the Jα-helix  of the LOV2 domain unwinds 
and undocks from the PAS domain core resulting in the passive dissociation of 
Zdk-LATint-Ruby into the cytoplasm. On cessation of blue light stimulation, the LOV2 
domain reverts to the dark state allowing Zdk-LATint-Ruby to return to the plasma mem-
brane. This process is repeatable. 
Dark Light
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Figure 3.4 LOV2 domain photocycle kinetics are tunable via point mutations 
mutable residues Val-416, Cys-450, and Ile-539 are shown here in red. The FMN co-fac-
tor is shown in magenta. The Jα-helix is shown in cyan.  The following point mutations 
were generated via overlap extension PCR: V416T (fast cycling), V416L (slow cycling), 
I539E (constiutively active), C450G (constitutively inactive), and C450S (constiutively 
inactive).  
Jα-helix
Ile-539
Val-416
Cys-450
FMN
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Mutation t1/2 (s) Reference 
Wildtype 80 (Zayner and Sosnick 2014) 
C450G Constitutively 
Inactive 
(Zayner and Sosnick 2014) 
V416T 2.6 (Kawano et al. 2013) 
V416L 495 (H. Wang et al. 2016) 
I539E Constitutively Active (Zayner, Antoniou, and Sosnick 2012) 
‘LOVpepCA’ Constitutively Active (Strickland et al. 2012) 
Table 3.1: AsLOV2 mutant photocycle kinetics  
 
I performed site directed mutagenesis PCR to generate the mutants outline in Table 3.1. The 
products were confirmed by sequencing. The complete list of constructs and primers can be found 
in the Appendices A & B.  
 
3.3.3 Light-inducible recruitment of LAT using the TULIPs system.  
LAT’s lack of significant tertiary structure makes it a good candidate for our optogenetic systems, 
as it is unlikely to sterically hinder the interaction of the ePDZ (or Zdk) domain with the LOV2 
domain. To test the functionality of the TULIP-LAT system, I transiently expressed the LAT-TM-
LOVpep domain and ePDZ-LATint fusion proteins in HEK293T cells. The LATint constructs 
were tagged with a C-terminal mRuby2 fluorophore (Kredel et al. 2009) for real-time visualisation 
of LAT recruitment and dissociation from the plasma membrane. By first expressing the 
constitutively-active variant of LOVpep (Strickland et al. 2012)  I was able to confirm that the 
LATint fusion protein was indeed able to bind the lit-state of LOV2. The pattern of localisation 
was identical to that of full length, Ruby-tagged LAT (Figure 3.5). The same pattern of expression 
was observed in Jurkat cell lines (Appendix F).  HEK293T cells expressing the the LATint-Ruby 
constructs in the absence of their LOV2 binding partners show distinct cytoplasmic localisation 
(Appendix O). 
 Having confirmed that the LATint fusion protein was capable of binding the LOVpep 
domain I next sought to confirm light-inducible localisation of LAT. I focused my analysis on the 
high (ePDZb1) and low (cpPDZ) affinity variants of the ePDZ domain. By measuring depletion 
of the LATint construct from the cytoplasm we were able to infer plasma membrane recruitment  
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Figure 3.5 Constitutively active LOVpep shows membrane recruitment of 
PDZ-LATint construct (A) HEK293T cells expressing Full length LAT tagged with an 
mRuby2 fluorophore and IFP2 anchored at the membrane via a CaaX motif. Both markers 
show clear colocalisation at the plasma membrane. Cells were transiently transfected with 
the pHR-full-length LAT and pHR-IFP2-CaaX (B) The constitutively active LOVpep variant 
recruits the high affinity (ePDZb1) variant of the TULIPs system to the plasma membrane. 
Images are taken at 100X magnification, scale bar 5 μm. Cells were transfected with 
pHR-ePDZb1-LATint-Ruby, pHR-LOVpep(CA), and pHR-IFP2-CaaX
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Figure 3.6 Light-inducible recruitment of the TULIPs-LAT constructs Pre-illumi-
nation images are taken a 1 s, illumination images are taken at 7 s, and post-illumination 
images are taken at 50 s. Images were taken at 100X magnification. Scale bar 5 μm. (A, 
C) The low affinity PDZ (cpPDZ) variant (magenta) of the TULIPs system shows no quan-
tifiable recruitment to the plasma membrane-bound LOVpep binding partner under blue 
light illumination (1 mW/cm2). Cells were transfected with pHR-cpPDZ-LATint-Ruby and 
pHR-LAT-TM-LOVpep. (B, C) The high affinity PDZ variant of that LATint construct 
(ePDZb1) shows rapid membrane recruitment on blue light irradiation. Cells were trans-
fected with pHR-ePDZb1-LATint-Ruby and pHR-LAT-TM-LOVpep (C) Cytoplasmic mRuby2 
intesity shows depletion kinetics of TULIPs constructs. Line colours are given by the back-
ground colours (A-B). Blue area denotes illumination. Error given as SD, n=3 (Biological 
replicates). Samples were normalised to the baseline cytoplasmic intensity (t= 1-5 
seconds) after correcting for photobleaching.
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(Figure 3.6). Under the conditions tested, I was unable to detect recruitment of the low affinity 
variant to the plasma membrane (Figure 3.6A, C), however I was able detect membrane 
recruitment of the high affinity variant (Figure 3.6B, C). There was no observable return of the 
high affinity variant to the cytoplasm on the time scale measured (Figure 3.6B, C). This finding is 
in agreement with previously published work (Strickland et al., 2012).  
 
3.3.4 Light-inducible dissociation of LAT using LOVTRAP system  
In parallel with the TULIPs system I also designed and tested different variants of the LOVTRAP 
construct (H. Wang et al. 2016). In accordance with the recommended workflow, I first tested the 
constitutively active and photo-nonresponsive variants of the LOV2 domain to establish whether 
the Zdk-LAT fusion protein was able to interact with the LOV2 domain and would correctly 
dissociate under illumination. As expected, the LOV2(C450G) photo-nonresponsive mutant 
resulted in recruitment of the Zdk-LATint fusion protein to the plasma membrane (Figure 3.7A). 
In the presence of the LOV2(I539E) constitutively open variant, no recruitment was observed and 
the Zdk-LATint fusion protein was permanently localised to the cytoplasm (Figure 3.7B). As 
expected localisation of LAT with both the photo-nonresponsive LOV2 mutant and the 
constitutively active LOV2 mutant was unaffected by blue light irradiation (Figure 3.7).  
 Once it had been confirmed that the Zdk-LATint fusion protein was capable of interacting 
with the dark state of the LOV2 domain and incapable of interacting with the lit state of the LOV2 
domain, I tested LATint dissociation and recruitment with three variants of the LOV2 domain 
showing different photocycle kinetics (Figure 3.8A-C) (Table 3.1) (Zayner and Sosnick 2014; H. 
Wang et al. 2016). With all three variants there was a sharp increase in cytoplasmic mRuby2 
intensity following blue light irradiation (Figure 3.8D). This reflects the fact that the rate at which 
the LOV2 domain photoisomerises from the dark state to the lit state is unaffected by photocycle-
altering point mutations. There was little measureable difference in the rate of return to the plasma 
membrane between the fast-cycling and wildtype variants, however, on the timescale measured, 
there was no observable change in cytoplasmic Ruby intensity following cessation of blue light 
irradiation when using slow-cycling variant of the system (Figure 3.8D). These results are in 
accordance with previously published work (Wang et al., 2016). With regards to the fast-cycling 
variant and the wildtype variant, these results suggest that the rate of return of the LATint 
construct to the plasma membrane is at least partially limited by its rate of diffusion in the 
cytoplasm. Given the smaller cytoplasmic volume of Jurkats when compared to HEK293T cells it  
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Figure 3.7 Control variants of the Zdk system (A) The photo non-responsive 
(C450G) mutant of the LOV2 domain allows for constitutive recruitment of Zdk-LATint-Ru-
by to the plasma membrane. HEK293T cells were transfected with pHR-Zdk-LATint-Ruby 
and pHR-LAT-TM-LOV2(C450G). (B) The constitutively active (I539E) mutant of the LOV2 
domain prevents the LOV2-Zdk interaction. HEK293T cells were transfected with 
pHR-Zdk-LATint-Ruby and pHR-LAT-TM-LOV2(I539E). Images taken at 100X magnifica-
tion, scale bar 5 μm.
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Figure 3.8 Light-inducible dissociation of Zdk-LATint-Ruby Pre-illumination 
images are taken at 1 s, illumination images are taken at 7 s, and post illumination images 
are taken at 50 s. (A,D) In the dark, Zdk-LATint-Ruby is anchored at the plasma mem-
brane via the Zdk-LOV2 interaction (magenta). Low intensity (~1mW/cm2) 450 nm illumi-
nation results in the rapid dissocaition of the LATint construct to the cytosol. On cessartion 
of blue light irradiation the Zdk-LOV2 interaction can re-initiate. (B) The fast cycling LOV2 
(V416T) variant (cyan) shows kinetics kinetics comaparable to the wildtype (A) version of 
the domain. (C) The Slow cycling LOV2 (V416L) variant shows a slower rate of return to 
the plasma membrane on cessation of blue ligh irradiation (green). (D) Normalised cyto-
plasmic mRuby2 intensity. Colours are given by the background colours (A-C). The blue 
area denotes blue light irradiation. Images taken at 100X magnification in HEK293T cells. 
Scale bar 5 μm. Error given as SD, n=3 (Biological Replicates).  
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would be expected that the rate of return would be somewhat faster with the fast-cycling variant 
when compared with the wildtype variant assuming protein expression levels were comparable. 
 
 3.3.5 Light-inducible recruitment of LAT using CRY2  
In establishing an optogenetic LAT-based system for T cell signalling, I focused primarily on 
LOV2 systems because of its small size, endogenously expressed cofactor, and high degree of 
tunability. However, I also tested the feasibility of a CRY2-based system. Like the TULIPs system, 
CRY2 has also been used to induce protein-protein interactions on blue light irradiation (Taslimi 
et al. 2016; Taslimi et al. 2014; Spiltoir et al. 2016). Recent work by Taslimi et al. (2016) has also 
provided a set of second generation CRY2 constructs with altered photocycle kinetics and smaller 
molecular sizes.  I tested the truncated CRY2PHR variant with the fast- and slow-cycling mutations 
(Taslimi et al. 2016).  
 
Mutation t1/2 (min) Reference 
Wildtype 5.5 (Taslimi et al. 2016) 
L348F 24 (Taslimi et al. 2016) 
W349R 2.5 (Taslimi et al. 2016) 
Table 3.2: AtCRY2PHR mutant photocycle kinetics 
 
As with the previously described LOVTRAP and TULIPs constructs, the CRY2 domain was fused 
at the N-terminus of LATint via a short linker sequence. To test recruitment of CRY2-LATint to 
the plasma membrane under blue light irradiation we used the previously described pmGFP-CIBN 
construct (Tucker, Vrana, and Kennedy 2014), which is anchored at the plasma membrane via a 
prenylation (CaaX) motif and features a GFP marker and the CRY2 interaction partner, CIBN 
(Taslimi et al. 2016; Kennedy et al. 2010) (Figure 3.9). When expressed in HEK293T cells, it was 
found that both the wildtype CRY2PHR construct and the fast-cycling CRY2PHR construct 
(W349R) constructs behaved as expected (Figure 3.10A, B, D). The rate of depletion from the 
cytoplasm was comparable between the two variants, again suggesting that this was limited by 
cytoplasmic diffusion of the construct. A gradual increase in cytoplasmic Ruby intensity was 
observed in the fast-cycling variant ~5 seconds after the cessation of blue light stimulation. This 
was in contrast to the wildtype CRY2PHR variant, where an increase in cytoplasmic ruby intensity 
could not be observe during the 35 second recovery period. The slow-cycling CRY2PHR (L348F)  
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Figure 3.9 Schematic overview of the CRY2-based  optogenetic system 
(A) In the dark state, CRY2-LATint-Ruby is localised to the cytoplasm. (B) 
photoisomerisation of the CRY3 domain allows it to interact with its binding 
partner, CIBN, which is anchored at the plasma membrane via a CaaX motif. CIBN 
is tagged with a GFP marker to visualise protein expression.
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Figure 3.10 CRY2PHR-LAT constructs show light-inducible membrane recruit-
ment HEK293T cells expressing CIBNpm-GFP and variants of the CRY2PHR construct 
were illuminated with 450 nm light (~1 mW/cm2). Pre-illumination images are taken at 1 
s, illumination images were are taken at 7 s, and post illumination images were taken at 
50 s. All images were taken at 100X magnification. (A, D) Wildtype CRY2PHR shows 
rapid, and sustained membrane recruitment on blue light irradiation (magenta). (B,D) 
The fast-cycling (W349R) variant shows cytoplasmic depletion comparable to the wildtype 
variant, but a more rapid return to the cytoplasm (cyan). (C,D) No plasma membrane 
recruitment was detectable with the slow-cycling (L348F) CRY2PHR variant (green). (D) 
The kinetics of cytoplasmic depletion of CRY2PHR-LATint-Ruby presented as normalised 
MFI. The blue area denotes illumination. The line colours are representative of the back-
ground colours (A-C). Images at 100X magnification, scale bar 5 μm. Error given as SD, 
n=3. 
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variant, although expressed, did not behave as expected (Figure 3.10C, D). No recruitment of 
LATint to the plasma membrane was detectable.  
I tested two other truncations of the CRY2 system, CRY2(535) and CRY2(515), described 
in detail by Taslimi et al. (2016). These were found to recruit LAT in a manner identical to the 
CRY2PHR variant (Figure 3.11).  A complete list of the CRY2 constructs can be found in 
Appendix B. Using the Matlab curve fitting function I was able to calculate the rate of cytoplasmic 
depletion for each of the CRY2 variants (Table 3.3). All were found to be comparable suggesting 
that the rate of recruitment is dependent on cytoplasmic diffusion. As with the LOV2-based 
systems, it would therefore be expected that this would occur somewhat faster in Jurkat T cells 
because of their low cytoplasmic volume.  
 
Mutation Rate Constant 
CRY2PHR -7.8x10-2 
CRY2(515) -9.8x10-2 
CRY2(535) -9.5x10-2 
CRY2PHR(W349R) -5.1x10-2 
Table 3.3: Rate of CRY2 construct cytoplasmic depletion  
 
3.4 Discussion  
Here, I have shown the feasibility of several LAT-based optogenetic constructs for the 
interrogation of T cell signalling dynamics. Optimisation of these systems was performed in 
HEK293T cells prior to using them in T cells. HEK293T cells represent a good model system 
because they are an easily-manipulable human cell line and unlike Jurkat T cells they have a large 
cytoplasmic volume relative to the nucleus. This made observing and quantifying LAT recruitment 
considerably easier than in Jurkat T cells.   
 As optogenetics is still a relatively new field, some degree of optimisation is necessary for 
the development of new tools. Here, I adapted the TULIPs system for use with the T cell 
scaffolding protein LAT. As such I was able to show rapid, light-driven association of the LATint 
construct with the plasma membrane. This process occurred immediately on exposure to blue 
light. However, there was no quantifiable recruitment detected with the low affinity (cpPDZ) 
version of the system. This may indicate that the interaction between cpPDZ and LOVpep has a 
short half-life and may simply have a high turnover rate, even when the system is in the lit state.  
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Figure 3.11 Light-inducible recruitment of second generation CRY2 constructs 
Immediately on blue light stimulation (blue area) the CRY2 LATint constructs show deple-
tion from the cytoplasm and recruitment to the plasma membrane. The kinetics of recruit-
ment were identical between the wildtype CRY2 system (black), the CRY2(535) truncated 
variant (magenta), and the CRY2(515) truncated variant (red). Error given as SD, n=3.  
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Although I was not able to detect cytoplasmic depletion using the low affinity version, this 
may still be occurring allowing LAT to mediate downstream signalling functions in T cells. 
Importantly, the addition of the high affinity PDZ (ePDZb1) domain to the C-terminus of the 
intracellular domain of LAT did not seem to sterically hinder the PDZ domain and quantifiable 
recruitment of LATint was detectable. This is significant given that others have reported steric 
hindrance of proteins when fused to the LOV2 domain (Lungu et al. 2012). This TULIPs-LAT 
tool provides a unique mechanism for light-driven T-cell activation. Previous groups have tried 
this with chemically-caged antigens (Huse et al. 2007), but this approach results in irreversible 
activation of the T cell. The TULIPs-LAT system is reversible with tunable kinetics allowing for 
more precise interrogation of the T-cell signalling pathway.  
Similarly, I also adapted the LOVTRAP system for use with LAT. It was shown that while 
using the LOVTRAP system, LAT was anchored at the plasma membrane and dissociated on blue 
light stimulation. Wildtype, full length LAT is normally anchored at the plasma membrane, 
therefore the dark-state of the LOVTRAP system closely mimics the endogenous signalling 
pathway. Previous work has reported that T cells require chronic low level TCR signalling to 
maintain cellular homeostasis (Štefanová et al. 2003). This is process is referred to as ‘tonic 
signalling’. It has been shown that in the absence of tonic signalling through the TCR, T cells 
gradually begin to downregulate TCR expression and eventually apoptose (Polic et al. 2001). By 
closely mirroring the endogenous signalling machinery, it might be expected that T cells expressing 
the LOVTRAP-LAT system would be less susceptible to changes in the downstream signalling 
pathway.  
I also confirmed that the kinetics of LAT recruitment were tunable via point mutations in 
the LOVTRAP system, meaning that this approach may be useful not only for proximal signalling 
events, but also for more distal signalling events. It was noted however that the rate of return to 
the baseline dark-state was at least partially dependent on the rate of LAT diffusion in the 
cytoplasm. It would therefore be expected that the photocycle kinetics of the LOV2 domain may 
have a more pronounced impact when employed in a T cell signalling context because the 
cytoplasmic volume in Jurkat T cells is lower than that of HEK293T cells.  
In this chapter I also optimised an alternative approach to LAT recruitment, by testing 
several variants of the CRY2 system. The CRY2 system provides a good alternative to the TULIPs 
system, because both are blue light responsive and reliant on endogenously expressed Flavin 
cofactors. Thus, there is no need for extensive adaptation of the experimental equipment or 
exogenous supplementation of the culture media, as would be the case with the red-light 
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responsive Phytochrome system. Like the TULIPs version of the LAT system, I was able to show 
light-inducible recruitment of LAT to the plasma membrane using the CRY2 domain and plasma 
membrane-anchored CIBN. The rate of return to the ground state, in which LATint was localised 
to the cytoplasm, was tunable via point mutations. These results indicate that the CRY2 system is 
a good alternative to the LOV2 based systems. 
Other variants of the LOV2 domain have also been reported. Kawano et al. (2015) 
developed a pair of light-switchable proteins from a fungal photoreceptor, Vivid (VVD). These 
domains were engineered in parallel to express complementary electrostatic interaction sites, which 
were caged in the dark state. This system was reported to have low background binding due to the 
engineered electrostatic interactions and was tunable via point mutations to have an interaction t1/2 
of between 25 seconds and ~2 hours (Kawano et al. 2015). Although this system in theory provides 
a good alternative to the TULIPs system, I was unable to express the complementary VVD 
domains in HEK293T cells when combined with the LAT system. This, however, does not appear 
to be unique to LAT, as our collaborator Ralitsa Madsen was also unable to detect expression of 
an optogenetic PI3K system using the same constructs acquired independently (Personal 
Communication).  
 Although other groups have successfully used the red/far red-responsive PhyB domain 
(Stratiievska and Gordon 2016; Toettcher et al. 2011), I did not test this system for use with LAT. 
The PhyB system requires exogenous supplementation of the cofactor and re-engineering of the 
hardware necessary to control light stimulation and so is not a good alternative to the LOV2 
domain.  
 Taken together, the findings presented in this chapter indicate that LOVTRAP, TULIPs 
and CRY2 all provide feasible mechanisms for controlling LAT recruitment and localisation. All 
three systems are tunable and thus provide flexibility to interrogate signalling events across varying 
time scales. 
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Chapter 4 – Investigating early T cell signalling dynamics using 
LAT-based optogenetic switches  
 
4.1 Introduction 
4.1.1 TCR microclusters and immunological synapse maturation  
The Immunological synapse (IS) or Supramolecular Activating Cluster (SMAC) forms at the 
interface between a T cell and an APC and is an important step in the process of T cell activation. 
The classical, Kupfer-type immunological synapse is comprised of a series of concentric rings that 
form a bullseye pattern on the surface of the T cell. Each ring is enriched for different sets of 
signalling molecules associated with the TCR signalling network. At the centre of the structure 
(cSMAC) there is an enrichment for the TCR, Protein Kinase C Theta (PKCθ), and the co-receptor 
CD28 (Sanchez-Lockhart, Graf, and Miller 2008). It has been proposed that these molecules are 
partitioned within the cSMAC and function somewhat independently in signal propagation, 
implying that signalling from the two receptors is integrated downstream from the plasma 
membrane (Saito, Yokosuka, and Hashimoto-Tane 2010; Sanchez-Lockhart and Miller 2006). 
Immediately outside of the cSMAC is the peripheral SMAC (pSMAC). The pSMAC is enriched 
for integrin signalling molecules such as LFA-1 (Lymphocyte function-associated antigen 1) and 
its associated factor Talin. LFA-1 interacts with its APC-expressed counterpart ICAM-1 
(Intercellular Adhesion Molecule 1) to form a tight adhesion between the T cell and the APC 
(Graf, Bushnell, and Miller 2007). The interaction of integrins on the surfaces of the T cell and the 
APC bring their membranes within ~40nm of one another. The pSMAC is also characterised by 
a dense F-actin network, whereas the cSMAC is cleared of actin and is reported to be a site for 
exocytosis of cytokines and cytolytic proteins and endocytosis of the TCR (Bunnell et al. 2001; 
Comrie, Babich, and Burkhardt 2015; Comrie et al. 2015). The cell-cell junctions formed by the 
interactions of pMHC and the TCR (~15nm) and the integrins serve to sterically exclude 
phosphatases; including the main TCR phosphatase, CD45, in a process of T cell triggering 
referred to as kinetic segregation (S. J. Davis and van der Merwe 2006; James and Vale 2012; 
Cordoba et al. 2013). This ring of exclusion around the pSMAC is referred to as the distal SMAC 
(dSMAC). CD45 is passively driven to the dSMAC because of its large, rigid extracellular domain 
(Chang et al. 2016). This structural feature also precludes CD45 from entering smaller 
microclusters (Varma et al. 2006).  Truncations of the CD45 extracellular domain result in 
abrogated TCR activation due to increased dephosphorylation of key signalling molecules such as 
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CD3 and ZAP70 (James and Vale 2012). It should be noted, however, that dephosphorylation by 
CD45 is necessary to relieve the inhibition of the co-receptor associated kinase Lck and trigger the 
downstream signalling cascade.  
 Since the initial description of the immunological synapse by Monks et al. (Monks et al. 
1998) as a site for sustained TCR signalling, our understanding of the precise role of the IS in TCR 
activation has been adapted and improved. As the cSMAC is enriched for TCR signalling 
molecules and the co-receptor CD28, the IS was initially proposed as a site for enhanced T cell 
activation signals. This paradigm has been shifted with the discovery of TCR microclusters, which 
are the smallest detectable unit of TCR-induced signalling (Varma et al. 2006; Saito and Yokosuka 
2006; Yokosuka et al. 2005). Although the precise composition of TCR microclusters is somewhat 
loosely defined, it is generally agreed that these signalling platforms contain the TCR complex, 
including the CD3 chains; LAT; SLP76; ZAP70 and, at least transiently, Lck (Varma et al. 2006; 
Yokosuka et al. 2005; Hashimoto-Tane et al. 2010). These microclusters form continuously in the 
dSMAC during T cell activation and are trafficked to the centre of the IS where the signals are 
terminated and the TCR is endocytosed (Griffiths, Tsun, and Stinchcombe 2010; Čemerski et al. 
2008). Even this view is somewhat simplistic as it has been reported that not all T cell-APC 
interactions result in the formation of an IS. Brossard et al. (2005) report that conjugates between 
splenic DCs and splenic T cells formed multifocal adhesions between the two cell types, but on 
conjugation with macrophages or B cells the same T cells formed a more classic bullseye structure 
(Brossard et al. 2005). As activating signals seem to be driven by microclusters rather than the IS, 
this could provide a mechanism for enhanced T cell activation. Moreover it has been reported that 
in the presence of weak signals – low concentrations of antigenic peptide or low affinity peptide – 
the IS does indeed act as a signal booster, concentrating TCR activating signals within the cSMAC 
(Čemerski et al. 2008). If correct, this means that T cells are able to rapidly gauge signal strength 
and regulate their morphology accordingly to titrate incoming TCR signals. Given that the 
response seems to be at least partly cell type dependent, this also suggests that differences in 
secondary, co-stimulatory or co-inhibitory signals may play a role in shaping IS formation.  
 Reports that microclusters are trafficked toward the cSMAC from the dSMAC have led to 
the conclusion that interactions between the cytoskeleton and TCR microclusters must be 
important for the overall formation of the IS. During the formation of the IS, the TCR, co-
stimulatory receptors, and LAT are swept toward the cSMAC via retrograde actin flow (Yi et al. 
2012; Comrie, Babich, and Burkhardt 2015; Beemiller and Krummel 2010; Beemiller, Jacobelli, 
and Krummel 2012).  Although TCR microclusters are trafficked toward the cSMAC by retrograde 
actin flow they are reported to travel at a slower rate than the flow of actin (DeMond et al. 2008). 
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This was shown by deflection of the TCR’s trajectory of motion by micro-patterned surfaces. The 
TCR would move parallel to the micro-patterning, whereas the underlying retrograde actin flow 
remained unchanged. Work performed by C. Yu et al. (2010) in Jurkat T cells confirms this 
‘slippage model’ of actin association. It is therefore assumed that interactions between the actin 
cytoskeleton and TCR microclusters are transient and dynamic, with microclusters being shunted 
along F-actin tracks at a slower rate than the flow of actin. This occurs in a frictional manner (Y. 
Yu, Smoligovets, and Groves 2013). Furthermore, it has been shown that the actin motor protein, 
myosin IIA, is important in the formation of the IS and trafficking of the microclusters toward the 
cSMAC (Kumari et al. 2012). This finding lends further credence to the involvement of the actin 
cytoskeleton in the formation and trafficking of microclusters toward the immunological synapse.  
 Work by Kumari et al., showed that F-actin reorganisation is important in the early 
formation and trafficking of microclusters, but during late synapse formation and trafficking within 
the cSMAC this role seems to be taken over by interactions of microclusters with microtubules. 
Evidence for this comes from work performed by Varma et al. (2006). Inhibition of F-actin 
polymerization with Latrunculin A slowed the trafficking of existing TCR-microclusters toward 
the cSMAC, but did not affect the size of existing microclusters or the stability of the cSMAC 
itself. Blocking F-actin polymerization inhibited the formation of new microclusters resulting in 
the termination of T cell signalling. Signalling, as measured by calcium influx, terminated as the 
existing clusters completed their transit toward the cSMAC. This finding indicates not only the 
involvement of actin polymerization in microcluster formation, but supports the idea that TCR 
signalling is initiated and sustained by the formation of new microclusters and not in the 
concentration of TCR microclusters at the cSMAC (Varma et al. 2006; Yokosuka et al. 2005). 
Conversely, siRNA downregulation or pharmaceutical inhibition of the microtubule motor protein 
dynein also inhibited trafficking of microclusters to the cSMAC but increased T cell activation 
through the stabilization of microclusters in the actin-rich pSMAC (Hashimoto-Tane et al. 2011). 
Dynein-inhibited cells showed increased phosphorylation of LAT and Src family kinases, as well 
as enhanced IL-2 production (Hashimoto-Tane et al. 2011). Taken together these results indicated 
a strong link between TCR signalling microclusters and the T cell cytoskeletal network. Different 
components of the cytoskeleton show temporally distinct roles in the mediation of TCR signalling 
(Billadeau, Nolz, and Gomez 2007).    
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4.1.2 Formation of TCR Microclusters  
 Despite more than a decade of work into the immunological synapse, surprisingly little is 
known about the early events in synapse formation. In particular, the events leading to the 
generation of microclusters have been difficult to observe and quantify.   
 It is well established that a signalling cascade beginning with CD3 ITAM phosphorylation 
by co-receptor-bound Lck is responsible for initiating TCR signal transduction. This signal is 
transmitted along the pathway by phosphorylation and activation of ZAP70 and subsequent 
phosphorylation of the downstream signalling components. However, it is not understood how 
signals transduced through the interaction of the TCR and pMHC induce the formation of TCR 
microclusters. A Recent study by Taylor et al. (2017) indicated that the dwell time of the TCR-
pMHC interaction promotes the formation of clusters. This was shown using DNA-based 
chimeric antigen receptors with different interaction affinities. Those with higher affinities 
promoted more receptor clustering. This research also shows supports the hypothesis that receptor 
clustering plays a role in ligand discrimination (Taylor et al. 2017). Others have reported somewhat 
different mechanisms of cluster formation.  
It has been proposed that pre-existing microclusters containing the molecules necessary 
for downstream signalling are already present on naïve T cells (Crites et al. 2014). These pre-
existing clusters were described in both naïve and activated murine T cells and were shown to 
contain the signalling machinery necessary for T cell activation. The formation of such clusters 
was not dependent on ligand binding as T cells stimulated with non-activating pMHC or MHC-
negative surfaces still had pre-existing microclusters on their cell surfaces. This is consistent with 
work by Schamel et al. (W. W. A. Schamel 2007; W. W. A. Schamel and Alarcón 2013), which 
suggests that the TCR exists in pre-clustered oligomers on the cell surface. Work done by Pageon 
et al. (2016) also confirmed the existence of these nanoscale TCR-complex structures, but further 
advocated for a functional role for these clusters in signal transduction. Pre-clustering of the TCR 
into functional oligomers on the cell surface with the signal transduction proteins LAT, Lck, and 
ZAP70 could provide a mechanism for the transduction of signals from rare antigenic peptides on 
the surface of APCs (Castro et al. 2014). This hypothesis fits nicely with the experimental data 
shown by Taylor et al. (2017), but does not provide mechanistic insight into nanocluster or 
microcluster formation. Small platforms of pre-clustered TCR and downstream signalling 
molecules would increase the probability of a productive re-binding event with low frequency 
pMHCs. The density of clusters was higher in activated cells suggesting the recruitment of more 
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molecules and larger complexes were also more likely to include phosphorylated molecules. These 
nanoclusters aggregate on activation to form signal-transducing microclusters (Pageon et al. 2016).  
 Pre-existing microclusters containing the scaffolding protein LAT were also shown by 
Williamson et al. (Williamson et al. 2011), but in their analysis, it was determined that these pre-
existing microclusters did not fulfil a role in signal transduction. Instead, they proposed that the 
supply of LAT on the plasma membrane was instead supplemented by a vesicular supply of LAT 
that was responsible for signal transduction. This hypothesis is somewhat difficult to explain, and 
would need to involve an as-yet-undetermined membrane anchor for the recruitment of vesicular 
LAT.  CD6 may be able to fulfil this role but that remains to be determined (Malissen and Marguet 
2011; Bounab et al. 2013). In 2013, the claim that LAT clusters on the plasma membrane did not 
participate in signalling was directly refuted by Balagopalan et al. Using a chimeric version of LAT 
that could be tracked from the cell surface, Balagopalan et al. (Balagopalan et al. 2013) were able 
to show that LAT on the plasma membrane does indeed play a role in TCR-induced signalling and 
particularly in early signalling. It may be that recruitment of vesicular LAT is instead important in 
sustaining TCR signalling.  
 Work by Lillemeier et al. seems to indicate a different mechanism of microcluster 
formation, with the partitioning of different signalling components into separate and non-
interacting membrane protein islands. Again, their work suggested the formation of pre-existing 
protein clusters on the surface of T cells with enhanced clustering on activation. What was striking 
was that electron microscopy of activated T cells seemed to suggest that LAT and the TCR exist 
on separate protein islands and that even during activation the interaction of these separate protein 
islands was only transient (Lillemeier et al. 2010). This work does not seem to agree well with the 
more recent studies discussed earlier, which suggest a more prolonged interaction between LAT 
and other microcluster signalling components. It is possible that the dissociation of LAT from the 
TCR is a mechanisms of attenuating input signals and regulating the downstream signalling 
response. Although there is some contention among groups regarding the exact mechanism of T 
cell activation these findings point to the key involvement of LAT in microcluster formation and 
TCR signalling. Cytoskeletal involvement also appears to be critical for complete T cell activation. 
  
4.1.3 LAT is essential for T cell development, function, and immune homeostasis   
 Membrane bound scaffolding proteins play an integral role in a number of cell surface 
receptor signalling pathways in a variety of different cell types (Horejsí et al. 2004). They serve as 
docking hubs for the nucleation and propagation of downstream signalling responses. The role of 
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LAT as a scaffolding protein in the TCR-induced signalling pathway has been well studied since 
its initial discovery in 1998 by Zhang et al. and by Weber et al. (W. Zhang et al. 1998; Weber et al. 
1998). 
 Evidence for LAT as critical in both the positive and negative regulation of T cell signalling 
can be seen from studies of LAT knockout mice and the recent identification of two highly 
consanguineous families with allelic variations in LAT resulting in partial or complete loss of 
protein expression. Studies of LAT knockout mice by Zhang et al. (1999) showed that LAT is 
important for linking the pre-TCR to the intracellular signalling network. Although these mice 
appeared relatively healthy – in contrast to other mouse lines deficient in another T cell scaffolding 
protein SLP76 or the tyrosine kinase Syk, which are characterised by bleeding disorders and platelet 
deficiencies (Judd et al. 2002; Cornall et al. 2000) – it was show that the loss of LAT affected 
primarily T cell development. Specifically both αβ- and γδ-T cells were observed to be absent and 
thymic T cell development was arrested in the CD4/CD8 double negative stage (W Zhang et al. 
1999). This phenotype is comparable to mouse TCR knockout lines, which fail to undergo the 
process of RAG recombination and mature T cell development (Mombaerts et al. 1992). 
Ultimately, the loss of LAT in early development was responsible for serve immunodeficiency.  
 Several studies in the early 2000s determined that the role for LAT in maintaining T cell-
mediated immune homeostasis was not clear-cut and that LAT is essential for both positive and 
negative regulation of T cell signalling and activation, as well as differentiation toward particular 
effector lineages. In 2002, a set of back-to-back studies by Aguado et al. (2002) and Sommers et 
al. (2002) looked at a mutant variant of LAT in which tyrosine residue 136, which is the binding 
site for PLCγ1, was mutated to phenylalanine (Y136F). Using knock-in mouse models bearing the 
mutant tyrosine motif both groups observed that T cell development was severely inhibited, but 
not completely blocked. Of note, the negative regulator of T cell activation, CD5, was down 
regulated during thymic development and upregulated in the periphery (Sommers et al. 2002). This 
points to the tunability of T cell signalling and the dynamic nature of cell biology. Similar findings 
have been reported using a mutant of the T cell kinase ZAP70, in which the SKG mutation resulted 
in a reduced T cell activation threshold and the development of an autoreactive immune response 
(Sakaguchi et al. 2003; Siggs et al. 2007). Moreover, it was observed that the Y136F mutation 
resulted in increased T cell infiltration to the liver and spleen as well as lymphopenia, eosinophilia, 
and an enhanced B cell response (Sommers et al. 2002; Aguado et al. 2002). These results are 
somewhat surprising and are accounted for by the enhanced TH2 profile seen in the homozygous 
mutant mice. These results indicate that LAT is involved in both the positive and negative 
regulation of the T cell activation process. These findings were later confirmed using a Cre-
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inducible LAT knockout system (Shen et al. 2009). In these experiments mice heterozygous for 
LAT Y136F and a wildtype LAT flanked by loxP were treated with a Cre-recombinase via lentiviral 
transduction resulting in normal thymic T cell development, but mature T cells in which signalling 
competent LAT had been ablated. When transferred back into T cell deficient mice the LAT 
Y136F cells caused splenomegaly and lymphadenopathy, and where characterised by a potent TH2 
effector profile. Again, these results suggest that LAT also mediates an important negative 
regulatory role in T cell activation.  
 Work by Nuñez-cruz et al., (2003) looked at the role of the 3 C-terminal tyrosine residues 
in T cell development. Mutation of tyrosines 175, 195, and 235 in mice resulted in the complete 
block of αβ T cell development and a partial block in γδ T cell development. Interestingly the γδ 
T cells that did develop had a phenotype skewed toward TH2, which resulted in increased IgG1 
and IgE production with splenomegaly and enlarged lymph nodes (Nuñez-Cruz et al. 2003). These 
results further validate the role of LAT in immune regulation and homeostasis.  
 The significance of LAT as important in T cell activation is further confirmed by the 
identification of two consanguineous families with separate LAT frameshift mutations. The first 
case presented with three siblings homozygous for a 2-bp deletion in LAT resulting in a truncated 
version of the protein, but with intact extracellular and transmembrane domain. The mutation 
resulted in the loss of Y132, Y171, Y191, and Y226, but seemed to retain enough signalling capacity 
through the other tyrosines to induce T cell development. The three siblings presented with 
chronic infection and autoimmunity characterised by hepatosplenomegaly, lymphadenopathy and 
red oedematous nodules on the forearms (Keller et al. 2016). These findings were not unlike those 
seen in the mouse models of LAT. The second mutation was caused by a 1bp insertion in exon 1 
of the LAT gene. The 5 members of the consanguineous family homozygous for this mutation 
presented with complete loss of LAT and severe immunodeficiency. The patients had extremely 
low T cell numbers, but B cell and NK cell development was apparently unaffected (Bacchelli et 
al. 2017) highlighting the role of LAT specifically in the development of T cells.  
 Conversely, upregulation of LAT expression has also been linked to severe pathologies. 
Patients with Severe Aplastic Anaemia (SAA) have been reported to show increased total LAT and 
phosphorylated LAT, as well as increased ZAP70 activation (Sheng et al. 2014). The upregulation 
of LAT was linked to increased perforin and granzyme B expression in CD8+ T cells. Moreover 
the immune polarization of SAA patients is skewed toward a TH1 response with enhanced IL-2 
and IFN-γ expression.    
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 Taken together, the mouse and human studies of LAT indicate the critical role that this 
scaffolding protein plays in mediating T cell development, function and immune polarisation. 
Although the dynamic nature of cell signalling is able to compensate for mutations in LAT to a 
certain extent, it would appear that the necessity for LAT to fulfil varying roles during T cell 
development and in the periphery mean that mutations resulting in loss of wildtype LAT function 
diminishes the capacity of T cells to fulfil their roles appropriately. Dysregulation of LAT can 
result in both autoimmunity and immunodeficiency.      
 
4.1.4 LAT localisation and function  
LAT is a type III membrane protein, which are similar to Type I membrane proteins in that they 
have a cytosolic c-terminus. However, unlike type I membrane proteins, type III membrane 
proteins lack a signal peptide sequence and instead have a palmitoylation sequence that allows for 
lipidation and anchoring of the protein at the plasma membrane (W Zhang, Trible, and Samelson 
1998). In LAT, this lipidation site is comprised of a pair of N-terminal cysteine residues. 
Substitution of the palmitoylation site for other membrane anchoring motifs has been shown not 
to affect LAT’s function (M. Hundt et al. 2006; Zhu et al. 2005; M. Hundt et al. 2009), but 
preventing LAT from associating with the plasma membrane through mutation of the two cysteine 
residues (C26 and C29) in the palmytolaytion motif results in a complete block of LAT-mediated 
signalling activity (J. Lin et al. 1999). Loss of these palmitoylation sites has also been shown to 
make LAT more susceptible to degradation (Gringhuis et al. 2000). Thus we reasoned that by 
controlling the intracellular position of LAT we would be able to modulate the LAT-mediated 
signalling pathway.       
 
4.1.5 Molecular interaction partners link LAT to downstream effectors  
LAT is a critical component of TCR microclusters and regulates the nucleation of downstream 
TCR signal-associated molecules. LAT-deficient T cell lines were shown to have abrogated 
signalling along the MAPK axis, defective calcium mobilisation and failure to upregulate markers 
of T cell activation (Finco et al. 1998; Pasquet et al. 1999; Bunnell et al. 2002). These processes are 
linked to LAT via a diverse array of signalling cascades and protein-protein interactions. Super-
resolution microscopy of T cells on activating surfaces indicate that LAT is recruited to signalling 
clusters within seconds (Bunnell et al. 2002). 
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At the molecular level LAT has been shown to interact directly or indirectly with an 
expansive network of signalling proteins in T cells. LAT contains 233 amino acids and is predicted 
to have no intrinsic enzymatic function. Its role in T cell activation is mediated by nine 
phosphorylatable tyrosine motifs that allow for interaction with SH2 domain-containing proteins 
(Wonerow and Watson 2001; Roncagalli et al. 2014). LAT is phosphorylated immediately 
downstream of the TCR-associated kinase ZAP70 (Paz et al. 2001). Affinity Purification Mass 
Spectroscopy (AP-MS) analysis of the LAT and SLP76 ‘signalosome’ identified dozens of diverse 
protein interactions in a network formed by protein and lipid kinases, phosphatases, Guanine 
nucleotide Exchange Factors (GEFs), E3 ubiquitin ligases and phospholipases (Salek et al. 2013; 
Roncagalli et al. 2014). The TCR signalling network showed significant enrichment for proteins 
containing SH2, SH3 and pleckstrin-homology domains. Below are described some of the more 
well-characterised LAT signalling partners. 
 One important mediator of T cell activation is the multi-domain protein, phospholipase 
C-γ1 (PLC-γ1). This protein has been shown to interact directly with LAT, but it is thought that 
multivalent interactions with SLP76 and Vav1 are responsible for positioning PLC-γ1 in the 
correct orientation for optimal function (Knyazhitsky et al. 2012). PLC-γ1 hydrolyses 
phosphatidylinositol 4,5-bisphosphate (PIP2) to form 1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG) (Fu et al. 2010). The formation of IP3 is detected by IP3 Receptors (IP3Rs) on the 
endoplasmic reticulum, promoting the release of intracellular calcium stores (Nagaleekar et al. 
2008). Once intracellular stores of calcium are depleted, extracellular calcium influx is triggered 
through the Orai1-STIM pathway (Y. Zhou et al. 2010). This sustained calcium signal is necessary 
for the activation of the NFAT (Nuclear Factor of Activated T Cells) transcription factor, which 
is necessary for regulating the expression of genes associate with T cell activation (Oh-hora 2009).  
 In parallel to the IP3 signals, DAG also serves as a secondary messenger to activate Ras 
guanyl-releasing protein 1 (RasGrp1) and PKCθ signal transduction (J. P. Roose et al. 2005).  
RasGrp1 and SOS1, which associates with LAT via Grb2 (Growth-factor-receptor-bound protein 
2), function together in a positive feedback system to increase Ras activation and subsequent MAP 
kinase pathway signalling (J. P. Roose et al. 2007). Of note, the interaction between SOS1, Grb2, 
and LAT has been proposed as a mechanisms of LAT oligomerization as SOS1 interacts with 2 
Grb2 molecules and thus bridges the interaction of two LAT molecules (Houtman et al. 2006). 
SOS1 and Grb2 constitutively interact with one another and are recruited to LAT simultaneously 
(Buday et al. 1994). Grb2 is also thought to recruit the signal titrating molecule, Themis into the 
LAT signalosome (Paster et al. 2013). 
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 Activation of PKCθ signalling is also indispensable for productive T cell activation. Cellular 
depletion or pharmacological inhibition of PKCθ results in the inhibition of T cell activation 
(Altman and Villalba 2002). It has been shown that PKCθ exerts its function on T cell activation 
through the activation of JNK and subsequent downstream signalling to the AP-1 transcription 
factor (Ohtsuka, Kaziro, and Satoh 1996). AP-1 is involved in the transcription of genes involved 
in T cell activation, for example interaction between AP-1 and NFAT drive IL2 gene expression.  
 LAT also interacts with another member of the Grb2 family, Gads (Grb2-related protein 
downstream of src).  Gads is structurally similar to Grb2, but has a unique glutamine- and proline- 
rich domain (O. Moran et al. 2008). Gads bridges the interaction between LAT and SLP76 
(Harkiolaki et al. 2003), another scaffolding protein whose presence is essential for T cell activation 
(Yoder et al. 2001). SLP76 interacts with Vav1, Nck, and ITK and is involved in mediating and 
regulate further downstream signalling via Rap1 and PLCγ1 (Zeng et al. 2003).   
SLP76 is a particularly important protein in the TCR signalling network because it provides 
a link to the actin cytoskeleton. The interaction between Nck, Vav1, Cdc42 and SLP76 recruits the 
actin reorganising protein WASp (Wiskott Aldrich syndrome Protein) (Zeng et al. 2003; Barda-
Saad et al. 2005). Wiskott Aldrich syndrome (WAS) is an X-linked genetic condition with a strong 
immune phenotype. Loss of WASp results in an increased risk of eczema and inflammatory disease 
as well as susceptibility to infection (Notarangelo, Miao, and Ochs 2008). Mouse knockout models 
seem to accurately recapitulate the WAS phenotype and give rise to T cells with impaired migratory 
capacity that fail to form a polarising immunological synapse (Cotta-de-Almeida et al. 2007). WASp 
activates the Arp2/3 complex via its verprolin homology, central acidic (VCA) domain to facilitate 
actin reorganisation at the immunological synapse a process reviewed in detail by Millard, Sharp, 
and Machesky (2004). More recently, Vav1 was reported to participate in this protein complex in 
a scaffolding capacity, as GEF activity-deficient Vav1 is still recruited to the multiprotein complex 
and still facilitates T cell activation (Miletic et al. 2009). WASp has also been proposed to form de 
novo actin foci that help regulate the activity of PLCγ1 (Kumari et al. 2015) and thus plays an 
important role not only in actin remodelling, but also TCR-induced signalling.  
Finally, in a 12-component cell-free reconstitution system, Su and Ditlev showed that 
induction of CD3 phosphorylation results in the spontaneous formation of downstream signalling 
components into clusters (Su et al. 2016). This finding is interesting as it indicates that the 
formation of clusters within the TCR signalling network appears to be an intrinsic property of the 
system. Although this result indicates that the cytoskeleton and LAT seems to have an important 
role in the formation of TCR signalling microclusters in vitro, it does not fully explain the formation 
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of such signalling platforms in vivo. In this study, multimeric protein complexes were also found to 
exclude CD45.  
 
4.1.6 Negative regulation of LAT  
 Ubiquitination is an important process in cell homeostasis and protein degradation and 
LAT is also subject to this process. Ubiquitination of LAT has been proposed to occur on two 
lysine residues, K52 and K204 (Balagopalan et al. 2011). The ubiquitination of LAT has been 
proposed as a mechanism of TCR internalisation and signal termination (Brignatz et al. 2005). 
Cells in which these residues were mutated showed an enhanced propensity for signalling and 
prolonged activation (Kunii et al. 2012; Balagopalan et al. 2011). The ubiquitination of LAT 
appears to be dependent on its association with c-Cbl, an E3-ubiquitin ligase. Grb2 mediates the 
LAT-c-Cbl, but this complex may be stabilized through interactions with PI3K and Nck 
(Balagopalan et al. 2007).  
  
4.1.7 LAT as the basis for an optogenetic switch  
 In an attempt to explain the early events and signalling dynamics involved in early T cell 
activation I developed and tested a number of LAT based optogenetic tools (Chapter 3). LAT was 
selected as a good candidate for our optogenetic systems because of its lack of intrinsic enzymatic 
activity and requisite membrane proximity to fulfil its scaffolding function. LAT is also 
unstructured and the results presented in Chapter 3 indicate that when combined with the 
LOVTRAP, TULIPs, or CRY2 optogenetics systems it is correctly localised on blue light 
irradiation and can be controlled with tunable interactions kinetics. LAT is also reported to be 
phosphorylated early during TCR-induced signalling and is an important component of signalling 
microclusters, thus controlling the cellular position of LAT provides a means of controlling the 
TCR signalling process early in activation (Huse et al. 2007).  
 
4.2 Materials & Methods  
4.2.1 Cas9-mediated gene knockout  
 Two sets of Cas9 guide RNAs were designed against the transmembrane region of LAT 
using the Zhang lab CRISPR design tool (Cong et al. 2013). The guide sets are as follows:  
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Pair Name Sequence 
1 LAT-CRISPR1_Forward 5ʹ-caccgatcctggtcccctgcgtgct-3ʹ 
1 LAT-CRISPR1_Reverse 5ʹ-aaacagcacgcaggggaccaggatc-3ʹ 
2 LAT-CRISPR2_Forward 5ʹ-caccgatctgaggatgtgctctcgt-3ʹ 
2 LAT-CRISPR2_Reverse 5ʹ-aaacacgacagcacatcctcagatc-3ʹ 
Table 4.1: LAT, CRISPR gRNA oligos  
 
 The pHR-Cas9-GFP vector (Appendix B) was linearised according to the manufacturer’s 
protocol (NEB) using the following reaction:  
Reagent Volume (µl) 
BsmBI (NEB) 1.5 
Buffer 3.1 (NEB) 5.0 
Cas9 Vector (200ng/µl) 15.0 
dH2O 28.5 
 
Plasmid was incubated with BsmBI restriction enzyme at 55˚C for 1 hour and gel purified as 
outline in Chapter 2. Guide oligo pairs were prepared according to the following reaction:  
Reagent Volume (µl) 
Forward oligo (100 µM) 1.0 
Reverse oligo (100 µM) 1.0 
T4 Ligation buffer 1.0 
dH2O 7.0 
 
Guide oligos were annealed in the thermocycler at 37˚C for 30 minutes, followed by 5 minutes at 
95 ˚C. The temperature was then reduced to 25˚C at a rate of 5˚C/min. Annealed primers were 
diluted 1:100 in dH2O for use in cloning reaction. The complete cloning and transformation 
procedure can be found in Chapter 3.1 ‘Bacterial Cloning’. Cas9 plasmids were screened for gRNA 
oligo insertion by sequencing (primer ‘JJ2187’): 
5ʹ-ctcgagcggccggccccttcaccgagggcctatttcccatgattcc-3ʹ 
 Jurkat E6.1 cells were serially transduced through two rounds of lentiviral transduction 
with pHCr-[LAT]-GFP vectors according to the protocol outline in Chapter 2.5 ‘DNA 
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transfection and Transduction’. Transduced Jurkat E6.1 cells were single cell sorted into a 1:1 
mixture of fresh complete RPMI and spent, filtered complete RPMI using a Sony iCyt Synergy 
Dual Channel, High Speed Cell sorter. Spent RPMI was prepared by centrifuging 12.5 ml of 
wildtype Jurkat-containing RPMI two days after split to remove the majority of cells. The cell pellet 
was discarded and media was passed into a fresh 50 ml Falcon tube through a 0.45 µm syringe 
filter to remove any remaining suspension cells. Spent media was then mixed with fresh complete 
RPMI and 50 µl was transferred into each well of two 96-well plates (Gibco). Transduced Jurkats 
were single cell sorted according to GFP expression. The top 15% of GFP-expressing cells were 
sorted and the rest discarded.  Following sorting, 96-well plate was centrifuged at 1200 rpm for 3 
minutes to settle cells.    
 Cas9-mediated LAT knockout Jurkat clone cell lines were selected on their inability to flux 
calcium and on TCR expression. Protocols for these procedures are outline in Chapter 2.7 ‘Flow 
Cytometry’. Cells unable to flux calcium, but with parental levels of TCR expression were again 
single cell sorted and expanded to create a single LAT-specific knockout Jurkat clone line. 
Immediately following expansion, liquid nitrogen stocks of the Jurkat LAT-specific knockout cell 
lines were prepared to preserve their phenotypes.  
 
4.2.2 Design of Specialised DNA fragments  
Signalling incompetent LAT was designed with the flanking primer binding sequences for the 
primer oligos JJ1166 and JJ1167 (Appendix A). The construct was also designed with a 5ʹ SpeI cut 
site and a 3ʹ BamHI cut site as well as point mutations to avoid targeting by Cas9.  
 
4.3 Results  
4.3.1 Chronic LAT depletion prevents phenotypic rescue of JCam2.5 cell line 
In chapter 3 a number of LAT-based optogenetic tools are outlined. These tools were designed 
based on two existing systems, the LOVTRAP system and the TULIPs system.  In both systems 
the LOV domain is anchored to the cytoplasmic side of the plasma membrane via the 
transmembrane domain of LAT. The cytoplasmic domain of LAT, with its nine phosphorylatable 
tyrosines, is fused to the C-terminus of either the Zdk domain or the ePDZ domain. To test the 
capacity for these systems to reconstitute downstream signalling in T cells I initially used the 
previously described JCaM2.5 cell line (W. Zhang et al. 1999).  These cells are derived 
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Figure 4.1 Characterising the TULIPs and LOVTRAP system in JCaM2.5 cells 
(A) JCaM2.5 LAT-deficient Jurkat E6.1 cells were transduced with IRES vectors with 
either the LOVTRAP or TULIPs systems. To validate the system I first tested the consti-
tutively active version of the TULIPs system with the high affinity PDZ domain (CA-Hi). I 
also tested the wildtype version of the construct (LOVpep) with the high affinity PDZ 
domain (Hi). As a positive control I transduced the JCaM2.5 cell line with the wildtype 
full-length version of LAT. Each of the LAT constructs was tagged with an N-terminal 
mRuby2 fluorescent tag. (B) Once transduced with the LAT constructs, calcium flux was 
measused ratiometrically using Indo-1 dye. JCaM2.5 cells were labelled with anti-CD3 
antibodies and a baseline reading was established for 30 seconds. A polyclonal IgG 
crosslinking antibody was added at 30 seconds (red arrow) to trigger the cells. Flux 
profiles are representative of n=3 (technical replicates). 
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from the commonly used model T cell system, Jurkat E6.1, and were generated through random 
chemical mutagenesis. JCaM2.5 cells are LAT-deficient and fail to initiate signalling on TCR 
ligation. 
Reconstitution of JCaM2.5 cells with the optogenetic LAT constructs and full length LAT resulted 
in highly variable LAT expression (Figure 4.1A). Once expression of the constructs had been 
confirmed, I wanted to test if the optogenetic LAT systems could reconstitute downstream 
signalling. The JCaM2.5 cell line was initially characterised by its inability to flux calcium and it has 
been reported that reconstitution of JCaM2.5 cells with LAT rescues this phenotype (W. Zhang et 
al. 1999). This was found not to be the case. Reconstitution of JCaM2.5 cells with full length LAT 
only partially rescued the calcium flux phenotype (Figure 4.1B). Moreover, I was unable to detect 
calcium fluxing in both the high affinity, constitutively active version of the TULIPs system and 
the LOVTRAP system in the dark state.   
It has previously been reported that chronic depletion of LAT results in a drop in TCR 
surface expression (Myers, Zikherman, and Roose 2017). I confirmed this to be the case in our 
JCaM2.5 cell line (Figure 4.2). In an attempt to isolate a population of JCaM2.5 cells with high 
TCR surface expression I sorted cells on their surface CD3ε expression by flow cytometry. The 
TCR α and β subunits form an obligate heterodimer with the CD3 and thus it can be used as a 
direct readout of TCR expression. The top 10% highest expressing cells were isolate. Despite 
gating on those cells expressing relatively high amounts of the TCR complex, I found that by the 
time I had re-expanded the population TCR surface expression had again diminished. To confirm 
that TCR deficiency was cell line-specific, the Acuto lab kindly provided us with a vial of JCaM2.5 
cells from their own stock. The results presented in Figure 4.2 confirm a ~10-fold drop in TCR 
expression in the JCaM2.5 cell line relative to the Jurkat parental cell line. This finding helps explain 
why the JCaM2.5 cells do not signal as expected when expressing the full length LAT construct.  
 
4.3.2 Development of a LAT-specific knockout Jurkat E6.1 cell line  
 Given its obvious problems as a model system, I abandoned the JCaM2.5 cell line and 
returned to the Jurkat parental cell line. Using CRISPR-Cas9 technology I created a LAT-specific 
knockout cell line. Two sets of gRNAs were designed against the first and second exons of LAT, 
which comprise the transmembrane motif of LAT. The Cas9 plasmid jointly expresses the 
selection marker GFP via a viral P2A sequence. Thus, following serial transduction of the Jurkat 
cell line with Cas9 and guides, I was able to single cell sort based on GFP expression to create  
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Figure 4.2 Chronic depletion of LAT results in decreased TCR surface expres-
sion (A) The TCR complex was labelled with anti-CD3, AF647-conjugated antibodies. 
JCaM2.5 cells from two separate lines both showed decreased TCR surface express. 
When sorted on high TCR expression, the JCaM2.5 cells rapidly returned to baseline. 
(B) TCR expression relative to the Jurkat E6.1 cell line shows that the JCaM2.5 cells 
express considerably less TCR on their cell surface. FACS plots are representative of at 
least 3 separate experiments.  
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Figure 4.3 Characterisation of a LAT-specific Knockout Jurkat E6.1 cell line (A) 
CRISPR-Cas9 technology was used to specifically disrupt LAT in the Jurkat E6.1 T cell line. 
TCR surface express remained unchanged relative to the parental cell line as measure 
usinge AF647-conjugated, anti-CD3 antibodies. (B) The Cas9 vector coexpressed GFP as 
a marker. GFP expression was found to be low relative to the parental line. (C) Calcium 
fluxing was measured ratiometrically using Indo-1 dye. Polyclonal crosslinking antibody 
was added at 30 seconds to initiate fluxing (red arrow). The LAT knockout cell line (J-LKO) 
does not flux calcium (red). 
Page 100
a library of LAT knockout CRISPR clones (Appendix G). Given that absence of LAT has 
previously be described to attenuate calcium fluxing, I screened the library of CRISPR LAT 
knockout Jurkat cells ability to flux calcium and on surface TCR expression. After two rounds of 
single cell cloning I was able to identify one clone that was both unable to flux calcium and retained 
wildtype levels of surface TCR expression (Figure 4.3). This cell line will herein be referred to as 
J-LKO (Jurkat E6.1-LAT Knockout).     
 To confirm that the calcium flux phenotype that I observed in the J-LKO clone was caused 
by loss of LAT I performed flow cytometry with intracellular staining for LAT. The results 
presented in Figure 4.4A show that the J-LKO cells overlay with the secondary-only control and 
the previously described LAT knockout cell line, JCaM2.5. I also attempted to confirm ablation of 
LAT by immunoblot assay, but was unable to obtain a signal. This was most likely due to the 
relatively low expression of LAT and use of a monoclonal antibody for immunoblotting (Appendix 
H). Genomic sequencing of the indel sites confirmed with a high degree of certainty (P = 0.968) 
that the Jurkat parental cells are homozygous for LAT, at least within the first two exons, and that 
the J-LKO cell line had a frameshift mutation in each of the LAT alleles, each resulting in a 
premature stop codon and truncation of LAT (Figure 4.4B). Allele 1 was predicted to generate a 
41 amino acid protein fragment and Allele 2, a 45 amino acid protein fragment.  Transmembrane 
prediction software6 further confirmed that the two truncated LAT variants, if expressed, would 
be unlikely to localise to the plasma membrane (Figure 4.5). 
 It is worth noting that while TCR surface expression was initially high in the J-LKO cells 
I did observe a gradual decrease in expression over time (Appendix I). This suggests that chronic 
absence of LAT is responsible for the drop in TCR expression and confirms the phenotype seen 
in the JCaM2.5 cell line. This result also suggests that tonic signals through the TCR are necessary 
to drive TCR surface expression in a positive feedback loop.  
 This result represents the first LAT-specific Knockout Jurkat E6.1 cell line. The original 
JCaM2.5 cell line shows decreased TCR expression due to the loss of LAT. Interestingly, 
transduction of the JCaM2.5 cells with full length LAT only partially rescued their flux phenotype. 
This may suggest that the amplitude of the downstream calcium signal and ability to sustain 
signalling is proportional to TCR expression. The presence of chronic mutations outside of the 
LAT locus process may offer an alternative explanation for the observed phenotype of the 
JCaM2.5 cell line.   
                                                 
6 http://www.cbs.dtu.dk/services/TMHMM/ 
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Figure 4.4 Confirmation of LAT knockout at the protein and genetic level (A) 
To confirm the absence of LAT I used intracellular FACS staining with a primaty, uncon-
jugated anti-LAT antibody and an AF647 conjugated secondary antibody. The known 
LAT-deficient Jurkat cell line, JCaM2.5 was used as a positive control (cyan). (B) 
Sequencing of the CRISPR indel site confirmed that both allele of LAT had a frame shift 
mutation, which disrupts the LAT coding sequence. Shown here are the DNA basepair 
sequences and corresponding single letter amino acid codes.   
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Figure 4.5 LAT frameshift mutations lead to truncated LAT protein The DTU 
Bioinformatics SignalP 1.4 Server software was run on the predicted single amino acid 
sequences of the Cas9-altered LAT alleles. The wildtype LAT sequence is shown above for 
reference. Both Cas9-mediated frameshift mutations resulted in LAT truncations, both of 
which are expeceted to give rise to polypeptides lacking a transmembrane motif. 
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Figure 4.6 Generating a CRISPR-proof LAT variant as the J-LKO cell line constitu-
tively expresses Cas9 I made a series of point mutations to the PAM site and gRNA binding 
site of both of the LAT-CRISPR binding sites. The PAM sites are show in blue, the synony-
mous point mutations are highlighted in red.  
Endogenous:   5′-atcctggtcccctgcgtgctggg-3′
Mutant:  5′-attttggtgccttgtgtcttggg-3′
Endogenous:   5′-tcctacgacagcacatcctcagat-3′
Mutant:  5′-agttacgacagcacatcctcagat-3′
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4.3.3 Optogenetic systems partially rescue LAT knockout phenotype  
 Before the J-LKO cell line could be reconstituted with LAT, I made a series of point 
mutations to prevent the constructs from being targeted by the Cas9 enzyme. Cas9 is restricted in 
its activity by the necessity for a flanking protospacer adjacent motif (PAM), most commonly 5’-
NGG-3’ (Kleinstiver et al. 2015). Mutations that alter the PAM site prevent Cas9 activity. I was 
able to identify a synonymous mutation in the second CRISPR target site which would knock out 
the PAM site, but the first target site could not be modified in this way. Instead, I made 
synonymous point mutations in 7 of the 20 base pairs along the gRNA binding sequence (Figure 
4.6). 
Once the J-LKO cell line had been fully characterised for the absence of LAT, the cells 
were lentivirally transduced with the optogenetic constructs. As discussed in the Chapter 2 
Materials & Methods the two component optogenetic systems were jointly expressed on the same 
vector using an IRES sequence. The LATint components were labelled with a C-terminal mRuby2 
fluorescent tag. Expression of different variants of the TULIPs system yielded comparable levels 
of protein expression, however expression of the LOVTRAP system was considerably lower 
(Figure 4.7).  
 Unlike the JCaM2.5 cell line, reconstitution with the full length wildtype LAT protein was 
sufficient to rescue the LAT knockout phenotype of the J-LKO cells (Figure 4.8). To test the 
capacity for the LOVTRAP system to reconstitute downstream signalling I measured calcium 
fluxing under continuous dark conditions. In this state, it would be expected that the LATint 
construct would be present at the plasma membrane. Engagement of the TCR by antibody 
crosslinking was sufficient to trigger a small but detectable calcium flux. Interestingly, the calcium 
flux profile was improved in cells that had been serially transduced twice with the LOVTRAP-
IRES system (Figure 4.9). However, neither singly nor doubly transduced cells showed a flux 
profile comparable to the parental Jurkat cell line.  
 As described by Strickland et al. (2012), I tested the TULIPs optogenetics system using a 
constitutively active version of LOVpep with the high affinity variant of the ePDZ domain, 
ePDZb1. It was reasoned that this would be most likely to recapitulate TCR-induced signalling. 
As with the LOVTRAP system, a small but detectable calcium flux was detectable using the 
constitutively active TULIPs system. As would be expected, no flux was detected with the light-
inducible variant under the continuous dark conditions tested (Figure 4.10).    
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Figure 4.7 Expression of the LAT IRES constructs in J-LKO cells (A) J-LKO cells 
were transduced with the IRES variants of the TULIPs and LOVTRAP constructs. To first 
evaluate the system, the cells were transduced with the constitutively active version of 
the TULIPs construct and high affinity PDZ domain (CA-Hi). Likewise, I also transduced 
the cells with the LOVpep high affinity version of the system. As expression of the 
LOVTRAP system was low, I serially transduced the J-LKO cells twice with the LOVTRAP 
construct. Expression levels were quantified by expression of the mRuby2, fluorescent 
tag. (B) Here, mRuby2 expression is represented as a bar chart to highlight the differenc-
es in expression between the varios constructs. Full-length LAT was used as a control. 
FACS plots are representative of at least 3 separate experiments. 
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Figure 4.8 Reconstitution with full-length LAT rescues J-LKO phenotype Recon-
stitution of the J-LKO cell line with full-length, CRISPR-proof LAT rescued the calcium flux 
phenotype (red). Calcium flux was measured ratiometrically with indo-1 dye and 
normalised to the Jurkat E6.1 parental control. Calcium fluxing was triggered by antibody 
crosslinking at 30 seconds (red arrow). Flux profiles are representative of n = 5 (biological 
replicates). The LAT-rescued J-LKO cells consistently retained their flux capacity, even 
following cryopreservation and thawing.  
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Figure 4.9 reconstitution of J-LKO cells with LOVTRAP IRES system partially 
rescues calcium flux phenotype J-LKO cells transduced with the CRISPR-proof 
LOVTRAP-LAT system were tested for their ability to flux calcium. Calcium fluxing was 
measured ratiometrically using indo-1 dye and normalised to the Jurkat E6.1 positive 
control. J-LKO cells were transduced either one or twice with the IRES version of the 
LOVTRAP system. Antibody crosslinking was used to trigger calcium fluxing at 30 seconds 
(red arrow). 
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Figure 4.10 LAT-TULIPs IRES system partially rescues J-LKO calcium flux phe-
notype J-LKO cells were transduced with either the LOVpep or the constitutively active 
version of the TULIPs system, both with the high affinity version of the PDZ domain 
(ePDZb1). Calcium fluxing was measured ratiometrically with indo-1 dye and normalised 
to the Jurkat parental control cell line. Polyclonal antibody crosslinking was used to trigger 
caclium fluxing at 30 seconds (red arrow). 
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It was shown that reconstitution with full length LAT was able to reconstitute wildtype 
levels of calcium fluxing in the J-LKO cell line. However, reconstitution with both the LOVTRAP 
and TULIPs optogenetics system was only partially able to restore TCR downstream signalling. 
Given the differences in expression it was reasoned that not enough LAT was present at the plasma 
membrane to produce a robust calcium flux response. The dark state of LOV2 is reported to a 
have peak emission at 498nm and 522nm due to the FMN cofactor (Kawano et al. 2013). This 
signal can be measured by flow cytometry and can be used to approximately gauge LOV2 
expression. No emission could be detected from the IRES expression vector indicating low LOV2 
expression in both the TULIPs- and LOVTRAP-expressing cell lines (Figure 4.11). Wang et al. 
(2016) reported that in the case of the LOVTRAP system, the LOV2 domain should be in excess 
of the Zdk component of the system to maximise viability of the system. I therefore sought to 
quantify the amount of LAT necessary for downstream signalling in the Jurkat E6.1 cell line to see 
if this could explain the lack of activity in my constructs.  
 
4.3.4 Calcium fluxing is invariant to LAT expression above threshold  
 Serially transducing the J-LKO cells twice with the LOVTRAP system improved the ability 
of those cells to flux calcium. It was therefore reasoned that LAT expression levels may influence 
the amplitude and duration of the calcium flux response. I performed a titration assay to investigate 
the level of LAT expression required to drive and sustain downstream signalling. Three variants 
of the full-length LAT vector were established, each with a different promotor to provide varying 
levels of protein expression. The highest expressing variant was under control of the SFFV 
promoter, mid-levels of expression were driven by the ΔSV40 promoter, and low expression levels 
were driven by the inducible mHSP promoter, which is inducible but shows leaky expression (John 
James, personal communication). Although no LAT expression was detectable from the low-level 
expression construct (Figure 4.12A), it was found that endogenous LAT expression in the Jurkat 
E6.1 cell line was still lower than both the SFFV or ΔSV40 promoters (Figure 4.12B).  The calcium 
flux profiles of J-LKO cells transduced with either the high- or mid-level expression systems were 
indistinguishable from the wildtype Jurkat cells (Figure 4.12C). These results suggest that only a 
small amount of LAT is necessary to drive sustained downstream signalling and a robust calcium 
flux response. As we did not detect a shift in 530 nm emission in cells transduced with the 
optogenetic systems as part of an IRES construct, it is conceivable that these cells simply were not 
expressing enough LOV2 at the plasma membrane to recruit a sufficient amount of LAT to 
generate wildtype levels of calcium signalling. With this in mind, I decided to alter my transduction 
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Figure 4.11 IRES constructs yield low expression of LOV2 domain expression of 
the LOV2 domain can be measured by its ground-state emission (530 nm). J-LKO cells 
expressing the IREs verisions of the LOVTRAP and TULIPs constructs show low levels of 
LOV2 expression. 
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Figure 4.12 Jurkat E6.1 Cells show a low level of endogenous LAT expression 
(A) J-LKO cells were transduced with mRuby2-tagged LAT under the control of three 
different promoters: pHR (High), pHRSV (Mid), pHRI (Low). The Low level expression 
construct could not be detected. (B) Staining for intracellular LAT by FACS showed that 
endogenous LAT shows lower expression than the pHRSV construct. (C) Calcium fluxing 
showed that both the pHRSV and pHR versions of the LAT construct were able to rescue 
the J-LKO phenotype, indicating that only a limited amount of LAT is necessary for the 
cells to undergo calcium fluxing. Calcium flux was measured ratiometrically using indo-1 
dye and triggered by the addition of polyclonal crosslinking antibodies at 30 seconds (red 
arrow). The flux profiles (C) are representative of n=2 (biological replicates).
Page 112
100
80
60
40
20
0
100 101 102 103 104 105
N
or
m
al
is
ed
 to
 M
od
e
J-LKO: LOV2
J-LKO: LOVPEP
J-LKO Parental 
530 nm
LOV2
Figure 4.13 Independent transduction of the LAT-TM construct into J-LKO cells 
improves expression By first transducing the J-LKO cells with the LAT-TM-LOVpep and 
LAT-TM-LOV2 membrane anchors, expression of the membrane-anchored optogenetic 
domains was improved. 
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Figure 4.14 Serial transduction of the LATint domain improves expression of 
optogenetic constructs J-LKO cells transduced with the LOV2 domain membrane 
anchors were serially transduced with their complementary LATint-tagged binding 
partners. Transduction first with the LAT-TM-LOV domains and then with the LATint 
domain was able to improve expression of the LOVTRAP and TULIPs system components. 
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strategy by serially transducing the J-LKO cells with each component of the optogenetic systems 
separately.   
 
4.3.5 Serial viral transduction improves TULIPs and LOVTRAP expression in J-LKO cell line  
 To reduce variability between different optogenetic cell lines I first transduced the J-LKO 
cell line with either LAT-TM-LOV2 or LAT-TM-LOVpep. LATint constructs were then 
transduced into cell lines expressing the correct counterpart. This strategy was particularly relevant 
for the ePDZ variants of LATint as it allows for reduced variability between the different versions 
of the TULIPs system.  Using this approach I was able to detect a considerable shift in 530 nm 
emission in cells expressing LAT-TM-LOV2 and a slight shift in 530 nm emission in J-LKO cells 
expressing LAT-TM-LOVpep, relative to a J-LKO parental control. (Figure 4.13).  
 By serially transducing the J-LKO cells first with the membrane-anchored LOV2 domain 
and then with its intracellular interacting partner, I was able to improve expression of the 
optogenetic systems (Figure 4.14). Of note, the Zdk-fused LATint construct in the LOVTRAP 
system still produced lower levels of expression than the equivalent PDZ-tagged construct in the 
TULIPs system, suggesting possible protein misfolding caused by the presence of the Zdk domain.  
 
4.3.6 LOVTRAP-LAT optogenetic system reconstitutes TCR signalling pathway 
Once expression of the LOVTRAP system had been improved, especially with regards to the 
LOV2 membrane ‘sink’, I next sought to test the ability of the LOVTRAP-LAT system to 
reconstitute downstream TCR signalling. Intriguingly, it was found that when triggered under 
continuous dark conditions, the LOVTRAP system now closely mirrored the Jurkat E6.1 cell line. 
However, triggering under continuous light conditions only slightly delayed the onset of calcium 
fluxing and caused only a slight decrease in the peak amplitude of the calcium flux (Figure 4.15). 
This was somewhat surprising, as under blue-light irradiation it would be expected that the 
LOVTRAP-LAT system would not be active. The constitutively active variant of the LOVTRAP 
system also recapitulated TCR signalling, but had a reduced calcium flux capacity (Figure 4.15). 
This can be explained by the reduced level of LATint expression (Figure 4.14). 
 More surprisingly, although I was unable to ablate signalling under continuous light 
exposure, I was able to completely attenuate signalling in LOVTRAP-expressing cells using short 
pulses of light after calcium fluxing had been initiated. This process was repeatable and 
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Figure 4.15 LOVTRAP system rescues calcium flux phenotype J-LKO cells 
expressing the LOVTRAP-LAT optogenetic system were tested for their capacity to flux 
calcium. Calcium fluxing was induced at 30 s following the addition of polyclonal antibody 
crosslinker (red arrow). The wildtype system is shown in magenta, the photo non-respon-
sive control system is shown in blue. Samples were normalised to the Jurkat E6.1 parental 
control line (black). 
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Figure 4.16 light-inducible modulation of calcium fluxing with the LOVTRAP 
system Blue light irradiation is able to rapidly terminate calcium fluxing in the LOVTRAP 
system. This is caused by dissocation of the Zdk-LATint construct innto the cytoplasm. 
(A) J-LKO cells expressing the LOVTRAP system were pre-illuminated for 1 minute prior 
to beginning the experiment. Blue light irradiation was terminated at 150 s and re-initi-
ated at 210 s. Light was pulsed for 1 minute (from 270 s) and then terminated. Light 
was re-initiated at 330 s and pulsed for 1 minute before again terminating. (B) An 
alternative pattern of illumination. Cells were again pre-illuminated for 1 minute prior to 
the start of the experiment. Blue light irradiation was terminated at 180 s and then 
re-initiated for 1 minute at 270 s. Calcium fluxing was initiated at 30 s in both samples 
by the addition of polyclonal crosslinking antibodies (red arrow). Calcium flux was 
normalised to the Jurkat E6.1 control (black). Each condition here is representative of 
n=1 (biological replicates).  
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reversible (Figure 4.16). Signal decay was immediate following blue light irradiation suggesting tight 
negative regulation of the TCR signalling pathway. Calcium fluxing was again initiated following a 
short delay after cessation of blue light irradiation. Wang et al. (2016) report that the LOVTRAP 
system is susceptible to background binding of the Zdk domain. As the early peak in calcium 
fluxing was unaffected by blue light irradiation background binding would imply that only a small 
pool of LAT is necessary to initiate downstream signalling, but that sustained signalling requires 
the recruitment of a larger pool of LAT.  
 
4.3.7 Limited LAT population necessary for TCR signal initiation  
 To test the hypothesis that sustained calcium signalling is dependent on the recruitment of 
a larger LAT pool I sought to delineate extracellular calcium influx from the release of intracellular 
calcium stores. To do this, the calcium flux assay was performed in calcium free media using 
LOVTRAP-expressing J-LKO cells. On antibody engagement of the TCR, it was found that 
calcium fluxing rapidly peaked and then declined as intracellular stores were depleted. Returning 
calcium to the media triggered the re-initiation of calcium fluxing (Figure 4.17). This result 
indicates that T cells rapidly switch from utilising intracellular calcium to utilising extracellular 
calcium. Again, differences in peak amplitude of the flux are likely due to differences in expression 
level between different variants of the LOVTRAP system (Figure 4.14).   
 By controlling both light conditions and calcium concentration in the media, it was 
observed that even under continuous light conditions release of intracellular calcium stores could 
not be ablated by light, only slightly delayed (Figure 4.18). This finding indicates that background 
binding of the LOVTRAP system is responsible for the release of intracellular calcium. It also 
suggests that a limited pool of LAT is necessary to trigger IP3 signalling to IP3Rs on the 
endoplasmic reticulum. However, to sustain calcium signalling a larger pool of LAT is required.  
  
4.3.8 Sustained calcium fluxing requires large pool of LAT  
To try and address the background signalling in the LOVTRAP system I titrated expression of the 
LATint construct. As with the full length LAT construct, Zdk-LATint-Ruby expression was 
controlled using different strength promoters: SFFV (high), ΔSV40 (mid), and mHSP (low) (Figure 
4.19). As the LATint constructs were expressed independently from the LAT-TM-LOV2 
construct, the transmembrane component of the system was expressed equally in all three 
LOVTRAP cell lines. As before, the high expression system showed almost identical flux profiles 
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Figure 4.17 Fluxing in calcium-free media attenuates sustained flux profile To 
delineate the release of intracellular calcium stores from extracellular calcium influx, 
calcium fluxing was performed in a caclium free media (dotted lines). Parental Jurkat 
E6.1 cells (black) were compared to J-LKO cells the wildtype (magenta) and photo-non-
responsive (cyan) variants of the LOVTRAP system. Polyclonal antibodies were added at 
30 s to trigger caclium fluxing (red arrow) Calcium was returned to the media at 180 s 
(black arrow) to a final calcium concentration of 1 mM. 
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Figure 4.18 Depletion of extracellular calcium causes delay but not ablation 
of ER calcium release under light stimulation in LOVTRAP system To overcome 
the background release of intracellular calcium LOVTRAP cells were triggered under blue 
light conditions in the absence of calcium (magenta, dotted). These were compared to 
control cells triggered under continuous dark (magenta, solid). Light pulses are shown 
in blue. Cells were pre-illuminated for 1 minute prior to the start of the experiment. 
Indo-1 values were normalised to the Jurkat E6.1 control (black). Calcium fluxing was 
triggered by the addition of polyclonal crosslinking antibodies at 30 s (red arrow). 
Calcium was returned to the media to a final concentration of 1 mM at 180 s (black 
arrow). 
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Figure 4.19 Titration of Zdk-LATintRuby Expression of the ZDK-LATint-Ruby 
construct under three different promoters SFFV (High, magenta), ΔSV40 (Mid, blue), 
and mHSP (Low, red).  
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under continuous light or continuous dark (Figure 4.20A, D). The mid-level expression system 
showed a pronounced flux in the dark that rapidly diminished over time. However, fluxing under 
continuous light almost completely inhibited calcium fluxing (Figure 4.20B, D). In the low-level 
expression system this was more pronounced. Fluxing rapidly peaked and then diminished even 
under the dark state and fluxing was entirely ablated under continuous light (Figure 4.20C, D). 
This finding is consistent with the results from the calcium-free fluxing assay (Figure 4.17-4.18) 
that only a small population of LAT is necessary to initiate fluxing, but a sustained calcium 
signalling requires the recruitment of a larger pool of LAT.  
 
4.3.9 LOVTRAP-LAT system fails to sustain downstream signalling  
Once it had been established that the LOVTRAP-LAT system was able to rescue early TCR 
signalling events in the J-LKO cell line, I next investigated whether the system could reconstitute 
complete T-cell activation. Surface expression of the C-type lectin protein CD69 is upregulated 
within hours of T cell activation (Llera et al., 2001). J-LKO cells expressing the LOVTRAP-LAT 
system were mixed with dynabeads conjugated to αCD3/αCD28 antibodies. CD69 upregulation 
was measured over a 7 hour time course. As expected Wildtype Jurkats began to express CD69 
within 3 hours of activation. This steadily increased over the next 4 hours (Figure 4.21). Parental 
J-LKO cells showed no upregulation of CD69 (Figure 4.21). Likewise, no upregulation of CD69 
was observed in the LOVTRAP-expressing cells (Figure 4.21). This finding, when taken in the 
context of the Zdk-LATint titration experiment (Figure 4.20) suggests that the interaction between 
LOV2 and Zdk may not occur sufficiently long enough to sustain downstream signalling. This 
effect is mitigated in early signalling in the high expression system (Figure 4.20A), but can be 
observed in the mid- and low-expression systems (Figure 4.20B, C).  
 
4.3.10 TULIPs system partially reconstitutes calcium fluxing  
 In parallel with the LOVTRAP-LAT system, I also sought to improve the TULIPs-LAT 
system. As with the LOVTRAP system, I first transduced the parental J-LKO cell line with LAT-
TM-LOVpep to reduced variability between cell lines (Figure 4.13). The expression of LAT-TM-
LOVpep was somewhat lower than the expression of LOV2 in the LOVTRAP parental cell line. 
J-LKO cells expressing LAT-TM-LOVpep were then transduced with either the high affinity 
(ePDZb1) or low affinity (cpPDZ) variants of the LATint construct. There is almost a two orders 
of magnitude difference in the binding affinity of these two domains for the LOVPEP domain 
(Strickland et al., 2012). Expression of the low affinity version of LATint was considerably higher 
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Figure 4.20 LOVTRAP calcium flux titration Calcium fluxing was triggered by the 
addition of polyclonal crosslinker at 30 s (red arrow) and flux was measured ratiometricall 
with indo-1 dye. Samples are normalised to the Jurkat E6.1 control (black). (A) calcium 
flux profile of the high expression SFFV promoter LOVTRAP system. (B) Calcium flux 
profile of the mid-level expression system, ΔSV40  promoter. (C) Caclium flux profile of 
the Low expression system, mHSP promoter. (D) comparison of all three variants of the 
LOVTRAP system. All three expression verctors were transduced into j-LKO cells express-
ing the LAT-TM-LOV2 construct, thus expression of the membrane recruiter is comparable 
across all samples.  
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Figure 4.21 CD69 upregulation assay (A) J-LKO parental, Jurkat E6.1, and J-LKO 
LOVTRAP (high expression) cells were conjugated with dynabeads linked to CD28 and 
CD3 antibodies to stimulate T-cell activation. The duration of activation is presented 
above each of the FACS blots showing CD69 expression. CD69 was detected using a 
primary conjugated antibody (AF647) (B) The mean fluorescent intensity of CD69 expres-
sion across the population shows a gradual increase in CD69 expression, n=2 (technical 
replicates of each time point). 
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than the high affinity variant (Figure 4.14). To determine if the TULIPs-LAT optogenetic systems 
were able to reconstitute TCR signalling, I conducted calcium fluxing assays under continuous 
blue light or continuous dark conditions (Figure 4.22). It was found that with the high affinity 
domain both light and dark conditions resulted in an early peak in calcium fluxing reminiscent of 
the high expression LOVTRAP system (Figure 4.22). The amplitude of this peak was similar 
between both datasets, but signalling returned to baseline more rapidly in the dark-state cells. Of 
note, even under continuous blue light irradiation there was a gradual decay in calcium flux signal 
in the high affinity variant of the TULIPs system (Figure 4.22). Next, using the low affinity TULIPs 
variant it was observed that calcium fluxing was present under blue light illumination, but almost 
entirely absent when fluxing was performed in the dark (Figure 4.22). Taken together with previous 
results this seems to suggest that there is high background binding particularly in the high affinity 
TULIPs system and that low levels of LAT are needed to initiate intracellular calcium signalling. 
However, the intrinsic Kd of the LOVpep/ePDZ interaction is unable to sustain downstream 
signalling.  
 
4.3.11 Intrinsic dissociation rate of TULIPs interaction inhibits sustained calcium fluxing 
 The interaction between LAT, SLP76 and Vav1 has been proposed to position PLCγ1 in 
an optimal orientation to initiate the calcium signalling cascade (Knyazhitsky et al. 2012). Although 
the LOV2 domain is small relative to other optogenetic domains, it is possible that positioning a 
structured domain between the intracellular signalling domains of LAT and the plasma membrane 
creates a steric inhibitory effect and diminishes signalling capacity. To test this hypothesis I 
generated a truncated version of the LOVpep system, missing the entire LOV2 domain, but 
retaining the PDZ peptide binding sequence, ‘LAT-TM-pep’ (Figure 4.23A). I also generated a 
variant in which the ePDZb1 domain was tagged directly to the C-terminus of the transmembrane 
domain of LAT with a short glycine/serine linker and fused to the binding domain was the 
intracellular domain of LAT, thus creating a single continuous construct (Figure 4.23B). The LAT-
TM-pep construct has no intrinsic marker and thus it was expressed as part of a joint IRES 
expression vector with ePDZb1-LATint-Ruby. Microscopy of HEK293T cells expressing the 
LAT-TM-pep construct (Figure 4.24A) or the constitutively active LOVpep variant (Figure 4.24B), 
LAT-TM-LOVpep(CA), showed identical recruitment of ePDZb1-LATint-Ruby to the plasma 
membrane.  Importantly both of the two component systems showed identical calcium flux 
profiles (Figure 4.25A), whereas the LATTM-ePDZb1-LATINT-Ruby chimeric fusion proteins 
showed a flux profile identical to that of full length LAT (Figure 4.20B). Thus, the inability to 
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Figure 4.22 Light-inducible initiation of signalling using the TULIPs system 
Blue light irradation can be used to induce the interaction of the PDZ domain with the 
LOVpep domain. The low affinity PDZ (cpPDZ) domain shows minimal calcium fluxing in 
the dark (cyan, dotted) and high calcium fluxing in the light (cyan, solid). The high 
affinity PDZ (ePDZb1) shows some fluxing in the dark (blue, dotted) and more sustained 
fluxing in the light (blue, solid). Samples were normalised to the Jurkat E6.1 control 
(black). Calcium fluxing was triggered by the addition of polyclonal crosslinking antibod-
ies at 30 s (red arrow). 
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Figure 4.23 Overview of LAT-TMpep and fused PDZ construct (A) Truncated 
version of the TULIPs system with the pep binding sequence fusted directly to LAT-TM. 
(B) LAT-TM-ePDZb1-LATint-Ruby fusion protein. The high affinity PDZ domain is fused 
within the LAT construct with two short linkers.
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Figure 4.24 Membrane recruitment of the truncated TULIPs system (A) the 
LAT-TM-pep truncated variant shows membrane recruitment identical to (B) the constitu-
tively active varaiant of the LOVpep domain. (A) HEK293T cells were transfected with 
pHR-LAT-TM-pep, pHR-ePDZb1-LATintRuby, and pHR-IFP2-CaaX. (B) HEK293T cells were 
transfected with pHR-LAT-TM-LOVpep(CA), pHR-ePDZb1-LATint-Ruby, and pHR-IF-
P2-CaaX. 
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Figure 4.25 truncated LAT-TMpep variant does not rescue calcium flux pheno-
type, but fusion protein does (A) J-LKO cells expressin the LAT-TM-pep (magenta) 
and LAT-TM-LOVpepCA (blue) constructs with the high affinity PDZ domain show 
identical calcium flux profiles. (B) The LAT-TM-ePDZb1-LATint fusion (cyan) protein 
shows an identical flux profile to full-length LAT (red). Calcium fluxing was triggered at 
30 s with the addition of polyclonal crosslinker and indo-1 ratios were normalised to the 
Jurkat E6.1 parental control. 
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sustain calcium fluxing was due to the intrinsic dissociation rate of the PDZ domain from its 
binding sequence rather than a steric effect caused by the presence of the PDZ domain or 
oscillation of the LOV2 domain between the light and dark state. 
Although I was able to modulate calcium fluxing with light using the TULIPs system, I determined 
that the inability of these J-LKO TULIPs cells to sustain proximal signalling and the high degree 
of background in the high affinity versions of the system made TULIPs unsuitable for the analysis 
of proximal TCR signalling events.  
 
4.3.12 CRY2-CIBN optogenetic system fails to rescue LAT knockout phenotype 
 As discussed in chapter 3, I also attempted to establish a CRY2-based version of the LAT 
optogenetic system. CRY2 functions in a manner analogous to the TULIPs system and provides 
a mechanism for light-inducible membrane recruitment of LAT (Figure 3.10-11). CRY2 also 
represents a particularly attractive alternative to the LOV2 systems because it is blue light-inducible 
and relies on an endogenously expressed cofactor, FAD.   
 I constructed a number of CRY2-LATint fusion proteins using the second generation 
CRY2 systems described by Taslimi et al. (2016) (Appendix B). As with the TULIPs and 
LOVTRAP systems, I first transduced the J-LKO cells with the membrane recruiter component 
of the system, in this case the pmGFP-CIBN construct (Figure 4.26). The LATint component of 
the system was virally transduced into the cells once stable expression of the CIBN construct had 
been confirmed (Figure 4.26). Although the J-LKO cells were positive for both the membrane 
CIBN anchor and the LATint constructs, no calcium flux could be detected (Figure 4.27). 
Importantly, we tested the CRY2 W347A mutant, which is reported to be constitutively active (X. 
Li et al. 2011). In this variant of the CRY2 system, LATint is constitutively anchored at the plasma 
membrane by the CIBN interaction partner. It would be expected to behave similarly to the 
constitutively active variant of the TULIPs system, but instead no calcium flux was detectable 
following TCR crosslinking (Figure 4.27). No flux could be detected in the other variants even 
under blue light irradiation. The CRY2 domain is much larger that the LOV2 domain (Pathak et 
al. 2014). It is therefore possible that the complete absence of fluxing is due to steric hindrance of 
LAT-associated proteins.    
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Figure 4.26 Expression of the CRY2PHR constructs in J-LKO cells J-LKO cells 
were first transduced with the pmGFP-CIBN recruiter and then serial transduced with 
the variants of CRY2PHR. The four variants tested show similar levels of 
CRY2PHR-LATint ruby expression.  
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Figure 4.27 Calcium fluxing in LAT-CRY2PHR expressing cells J-LKO cells 
expressing the variants of the CRY2PHR system and CIBN membrane recruiter were 
triggered with the addition of polyclonal crosslinker at 30 s (red arrow) and indo-1 ratio 
was normalised to the Jurkat E6.1 cell line (black). Flux profiles are representative of 
n=2 (biological replicates). 
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4.3.13 J-LKO cells highly express CD6  
 It was noted that although we had knocked out LAT expression by CRISPR-Cas9 the 
Calcium flux profile of the J-LKO cell line did not precisely match that of the JCaM2.5 cell line 
(Figure 4.28A). In the J-LKO cell line, TCR ligation resulted in a small but unsustained peak in 
calcium fluxing. No such peak was observed in the JCaM2.5 cell line. Membrane receptors other 
than LAT have been proposed to anchor the scaffolding protein SLP-76 at the plasma membrane, 
providing an alternative mechanism for the nucleation of downstream signalling molecules 
(Roncagalli et al. 2014; Malissen et al. 2014). I screened the J-LKO cell line and three other LAT 
knockout clones for surface CD6 expression and found there to be an increase in CD6 expression 
in three of the four clones tested when compared to the Jurkat parental cell line. No CD6 
expression was detectable on the JCaM2.5 cell line (Figure 4.28B). This finding warrants further 
consideration as the JCaM2.5 cells, which show no calcium flux on TCR ligation and low 
expression of the TCR complex (Figure 4.1), are negative for CD6 expression (Figure 4.28). The 
upregulation of CD6 could provide a mechanism for sustained tonic signalling in the absence of 
LAT (Myers, Zikherman, and Roose 2017). 
  
4.4 Discussion  
In this chapter I created and tested three different LAT-based optogenetic tools for the 
interrogation of T cell signalling. The T cell scaffolding protein LAT has no secondary structural 
motifs or enzymatic activity, minimising the need for detailed structural analysis in the design and 
implementation of a LAT-based optogenetic system. Using both the TULIPs and LOVTRAP 
systems I was able to show real-time modulation of TCR-induced signalling outputs and modulate 
early T cell activation dynamics.  
Huse et al. (2007) implemented a light-based approach to T-cell activation using a 
photoactivatable TCR agonist in the past. This approach allowed for precise temporal and spatial 
activation of signalling, but could not be used to modulate the downstream signalling pathway. 
Our results using the LOVTRAP system indicate that T cell signalling is under tight negative 
regulation. Although I was unable to ablate intracellular calcium fluxing due to background binding 
of the Zdk domain, I was able to show almost immediate cessation of extracellular calcium fluxing 
on blue light irradiation. This indicates that membrane-proximal signals via LAT are required for 
sustained calcium fluxing on TCR stimulation. Once this membrane-proximal signal is terminated, 
signalling along the entire downstream pathway ceases. Unfortunately, the LOVTRAP-LAT  
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Figure 4.28 J-LKO cells show limited fluxing and increased CD6 expression 
(A) scatter plot of calcium flux for the J-LKO cell line and the JCaM2.5 cell line. 
Polyclonal crosslinker was added at 30 s to trigger calcium fluxing (red arrow). (B) CD6 
expression and TCR expression in 4 J-LKO clone lines and the JCaM2.5 cell line
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system did not completely reconstitute T cell activation, so it was not possible to infer how long 
these membrane proximal signals were needed to commit T cells to activation. This finding has 
interesting implications for the physiology of the T cell response. As aberrant T-cell activation can 
result in autoimmune disease, allergies, or asthma, it follows that T cell activation must be tightly 
regulated. Here, I have shown that within seconds of signal termination, downstream TCR 
signalling is completely halted. The delay in signal re-initiation indicates that downstream signalling 
‘memory’ is rapidly lost. This signalling memory is proposed to occur in the form of unstable 
signalling intermediates, and may include post-translational modifications, like phosphorylation 
(Lever et al. 2014). The rapid clearance of T cell signalling memory likely provides a mechanism 
for T cell antigen discrimination. T cells are able to recognise antigens with a high degree of 
selectivity and specificity, the precise mechanism of this remains to be fully described.  
The experiments outlined above have also identified some of the limitations of 
optogenetics in T cell signalling. Neither the high affinity nor the low affinity variants of the 
TULIPs system were able to sustain proximal signalling downstream of the TCR. Of note, the rate 
of signal decay under continuous light conditions in the low affinity variant was more rapid than 
the rate of signal decay seen under the same conditions for the high affinity TULIPs system. This 
strongly implicated involvement of the ePDZ domain as the concentration of LOVpep membrane 
binding partner would be invariant in these systems. Both cell lines were derived from the same 
parental J-LKO cell line expressing LAT-TM-LOVpep. The same should be true for the intrinsic 
photocycle kinetics of the LOV2 domain which would be expected to affect both the high affinity 
and low affinity TULIPs systems identically. Thus, the increased rate of signal decay seen with the 
low affinity variant is likely due to the increased Koff of the interaction between the LOVpep 
binding sequence and the cpPDZ domain.  
We found that the LOVTRAP-LAT system, like the TULIPs-LAT system, had a high 
degree of background binding in the ‘off’ state. Although it was found that LOVTRAP was able 
to reconstitute near wildtype levels of calcium fluxing, this signal was not ablated under continuous 
light treatment. Downstream analysis of other T cell activation events also suggested limited 
feasibility of the LOVTRAP-LAT system for investigating T cell signalling dynamics at later time 
points. It was found that J-LKO cells reconstituted with the LOVTRAP system failed to 
upregulate CD69 on dynabead stimulation. Again this finding is similar to that in the TULIPs cells 
in that sustained signalling is necessary to drive T cell activation and that a split LAT construct it 
unable to sustain these signals. Physiologically this points to the tight regulation of the LAT 
signalosome during TCR-induced signalling.  
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These results taken together, suggest that a split LAT system becomes dependent on two 
equilibrium states of the domains involved in mediating the binding interaction. First, productive 
signalling is dependent on the photocycle kinetics of the LOV2 domain, which displays equilibrium 
light state and ground state conformations. Illumination skews the equilibrium toward the light-
state and cessation of blue light stimulation skews the equilibrium toward the dark state, however 
under each condition a proportion of the LOV2 domain is still in either state (Strickland et al. 
2010). Intensity of the blue light stimulation also affects this equilibrium. Second, productive 
signalling is also dependent on the interaction between either the Zdk domain and the LOV2 
domain in the LOVTRAP system or the ePDZ domain and the LOVpep domain in the TULIPs 
system. These effects present themselves at different points in proximal TCR signalling output. 
The equilibrium state of the LOV domain appears to be dominant immediately following TCR 
ligation as both LOVTRAP-LAT and TULIPs-LAT. The high affinity variant of the TULIPs 
system in particular displayed a high degree of background signalling in the “off” state. The binding 
kinetics of the interaction partners appear to have the dominant effect in sustained signalling. Each 
protein has an intrinsic off rate and because LAT activation is tightly regulated, once the interaction 
between the optogenetic binding partners is terminated the TCR downstream signal is rapidly 
attenuated.  These findings confirm those seen by Strickland et al. (2012), that under continuous 
illumination in a slow cycling mutant of LOVpep the downstream activity and growth cycle arrest 
corresponded to the affinity of the LOVpep domain. In the future, computational analysis of the 
point mutations on LOV2 stability may allow for the rational design of a construct with minimal 
background bind in the off state, but high affinity protein-protein interactions in the on state 
(Strickland et al. 2010; Lungu et al. 2012; Stein and Alexandrov 2014). This represents a major 
challenge in the field of optogenetics research and will be critical in adapting these approaches for 
future uses in cell biology.  
I noted as well that on interruption of the LAT gene by CRISPR-Cas9 and loss of LAT 
protein expression there was an apparent increase in the expression of the T cell surface receptor 
CD6, which appears to have low expression levels on the parental Jurkat E6.1 cell line. CD6 has 
3 scavenger receptor cysteine-rich domains and interacts with CD166 on the surface of APCs. 
Tandem Affinity Mass Spectroscopy has indicated that SLP76 is able to interact with CD6 and 
thus CD6 may be able to nucleate some of the LAT-associated TCR signalling network molecules 
(Roncagalli et al. 2014; Breuning and Brown 2017). Upregulation of CD6 may provide a 
compensatory mechanism to maintain tonic signalling in the absence of the LAT signalosome and 
could indicate a role for CD6 in the titration of T cell signalling inputs. GWAS analysis of 
autoimmune diseases such as multiple sclerosis have implicated a role for CD6 in disease aetiology 
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(Y. Li et al. 2017).  Of note, our J-LKO line maintained a minor peak in calcium fluxing on 
induction by TCR-crosslinking antibodies. This was consistent across other Cas9-mediated LAT 
knockout cell lines, but not in the JCam2.5 cells, which show no expression of CD6. This finding 
is interesting and warrants further investigation.  
The LAT-specific knockout Jurkat cell line could provide interesting insights into T cell 
homeostasis and tonic signalling. Furthermore, the CRISPR Cas9 process resulted in the creation 
of several different T cell lines with varying calcium flux profiles (Appendix G). Future work may 
provide insights into the mechanisms of signal maintenance by LAT. It should be noted that some 
of the Cas9 clones displayed a calcium flux phenotype strikingly similar to the TULIPs and 
LOVTRAP reconstituted cells in which there was an early peak in TCR signalling followed by 
rapid signal decay. Analysis of the genetic nature of these mutants could provide further insight 
into the results described below. It is possible that this phenotype in LAT-deficient Jurkat E6.1 
cells is caused by haploinsufficiency.  
In conclusion, although the LOVTRAP- and TULIPs-based LAT optogenetics systems 
were not viable for the interrogation of microcluster formation, they did provide valuable insight 
into the nature of TCR signalling. The results provided in this chapter indicate that the TCR 
signalling network is tightly regulated. Even signals downstream from the plasma membrane are 
rapidly attenuated on cessation of TCR signalling. Such tight regulation may provide T cells with 
a mechanism to discriminate between even closely related antigens.  
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Chapter 5 – Investigating T-cell signal integration with a light-
controllable chimeric antigen receptor 
 
5.1 Introduction 
5.1.1 The immune system and collective decision making  
All living organisms must sense and respond to a diverse array of environmental stimuli. Any given 
stimulus must be internalised, translated, and interpreted so that the output response is 
proportional to, and in accordance with the stimulus input. In multicellular organisms, responses 
to environmental stimuli are highly coordinated, but reflect the collective decision making of 
individual cells. The immune system represents an important paradigm of this concept. The 
collective action of a diverse array of cell types is important in regulating steady-state immune 
homeostasis and the systemic response to pathogens. T cells are important mediators of the overall 
immune response (B Zheng, Han, and Kelsoe 1996; B Zheng et al. 1996; Qi et al. 2014). Once 
activated, certain subsets are involved in direct target cell killing, while others release varying arrays 
of cytokines which serve to activate other immune cell types.  Inappropriate T-cell activation, 
however, can result in autoimmune conditions, asthma, and allergies (Palomares et al. 2014; 
Chaplin 2010). Furthermore, unchecked T-cell driven inflammation toward an infection can result 
in systemic level collateral damage to tissues and organs (Dudley 2002). Hence, it is imperative to 
maintain a balanced immune response. To do this, individual T cells must sense and interpret 
environmental cues including inflammatory cytokines, signals received through the TCR and co-
receptors, and tissue-specific factors (Saleiro and Platanias 2014; Linterman et al. 2014; Campbell 
and Butcher 2002). Precisely how these signals are integrated on the cellular level has remained an 
outstanding question for immunologists and cell biologists. 
  
5.1.2 T cell-mediated responses to infection   
As mentioned above, the activation state of individual T cells in an immune reaction collectively 
forms a systemic response to infection. Precisely how this response is titrated to the severity of 
infection remains somewhat unclear. That is, during a severe infection, the T cell response must 
be appropriately strong, but if the burden of infection is low then the T cell response should be 
proportionate to the severity of infection to mitigate off-target effects (King et al. 2012). This 
implies that individual T cells are able to sense signal strength and respond accordingly.     
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To measure T cell responses in infection several models have been used over the years, 
but Listeria monocytogenes has been a favoured model system by immunologists. L. monocytogenes is a 
gram-positive bacterium responsible for listeriosis and is capable of infecting a murine host 
(Hamon, Bierne, and Cossart 2006). It is also known that clearance of this infection is T-cell 
mediated (Szalay, Ladel, and Kaufmann 1995; Lara-Tejero and Pamer 2004). Using a L. 
monocytogenes OVA model of infection, van Heijst, et al. (2009) showed that the magnitude of the 
T cell response to infection is primarily driven by clonal expansion of activated naïve T cells. This 
result complements previous findings by Prlic, Hernandez-Hovos & Bevan (2006)  and Badovinac, 
Porter & Harty (2002) suggesting that the magnitude of the T cell response is proportional to the 
burden of infection and that these signals are transduced via the TCR. Such findings have raised 
questions as to the nature of T cell activation. Specifically, how are T cells able to tailor their output 
response to the severity of infection? T cell activation results in T cell proliferation and 
differentiation, yet this response must be titrated so as to mitigate collateral damage. So how are T 
cells able to interpret and scale the immune response to best combat infections?  
A number of studies have shown that during an infection, the majority of antigen specific 
T cells become activated (K. E. Tkach et al. 2014; van Heijst et al. 2009). This speaks to the 
selectivity of the T cell response but also to the efficiency of the overall immune reaction. It also 
indicates that the response to infection must be self-limiting and able to provide a diverse output. 
During activation, T cells undergo proliferation and differentiation. Two processes that are 
synchronous, yet independent (Buchholz, Schumacher, and Busch 2016). Ultimately, the process 
of activation gives rise to a population of effector and memory T cells with diverse functional 
specificities; TH1, TH2, TFH, etc. but with a proliferative capacity proportional to the magnitude of 
infection. Functional diversity is thought to be explained partially by TCR signal strength, but also 
by cell-intrinsic differences in protein expression (Cho et al. 2017; Feinerman et al. 2008; Tubo 
and Jenkins 2014; Tubo et al. 2013). This probabilistic determination of effector cell phenotypes 
ensures a more balanced response to infection. Availability of antigen and TCR signal strength and 
duration are thought to be the key variables affecting the T cell proliferative response, with 
increased antigen availability increasing the amount of contact time between T cells and DCs (C. 
Kim et al. 2013).        
 
5.1.3 Translating primary infection to adaptive immunity  
As discussed in Chapter 1, the immune system can be broadly divided into two major responses, 
innate and adaptive. The innate immune response is non-specific, relying on pathogen-specific 
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molecular motifs that distinguish pathogenic organisms from the host (Table 1.1). A series of 
checkpoints allows the innate immune system to detect and respond to the severity of infection. 
These checkpoints allow cells to determine whether the pathogenic organism is present (Napolitani 
et al. 2005), its viability, and the severity of infection (Blander and Sander 2012). These innate 
immune signals are internalised by DCs (and other cells of the innate immune system), which 
migrate to lymph nodes and translate these responses to adaptive immunity via T cell activation 
(Figure 1.1).  
 The probability of a T cell encountering its cognate pMHC in the periphery is low, thus 
naïve T cells recirculate through the lymphatic organs, where the probability of them encountering 
their cognate pMHC is much higher. The architecture of secondary lymphoid organs, including 
lymph nodes, has evolved in such a way as to maximise the efficiency of adaptive immune response 
activation. Indeed, studies modelling the T cell response to infection have shown that during an 
adaptive immune response, effectively all of the cognate T cells become activated (Zehn, Lee, and 
Bevan 2009). Two-photon microscopy of immune cells within the lymphatics has shown that DCs 
can interact with as many as 5000 T cells an hour. T cells migrate through the lymph nodes at a 
rate of ~10 µm per minute and are likely to encounter multiple DCs during their journey (Cahalan 
and Parker 2008; Qi, Kastenmüller, and Germain 2014). On encountering cognate pMHC, T cells 
down-regulate their cellular migration machinery, such as Rho GTPases, and form stable contacts 
with an APC (Bousso and Robey 2003; Michael L. Dustin 2004; M L Dustin et al. 1996; Negulescu 
et al. 1996). The precise duration of T cell-APC interaction necessary to drive T cell proliferation 
and differentiation is still somewhat contentious and seems to vary between CD8+ and CD4+ T 
cells (Obst 2015), with CD8+ T cells reportedly requiring only hours of contact to drive activation 
(Williams and Bevan 2004) and CD4+ T cells requiring several days (Corbin and Harty 2004). The 
duration of this interaction likely influences the proliferative, but not the differentiation, capacity 
of the T cells and is intrinsically influenced by antigen dose, in a ‘dose-to-duration’ manner 
(Miskov-Zivanov et al. 2013; Obst 2015; Mayya and Dustin 2016; Keck et al. 2014). This seems to 
be true both for proliferation and the cytokine response to infection (van Panhuys, Klauschen, 
and Germain 2014; K. E. Tkach et al. 2014; Tscharke et al. 2015). Furthermore it is clear that the 
manner in which antigen is presented influences the outcome of stimulation, i.e. the presence or 
absence of co-stimulatory/co-inhibitory receptors and tissue-specific signals (Campbell and 
Butcher 2002).   
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5.1.4 T cell activation and temporally encoded signals  
In the past two decades we have seen massive progress in our understanding of the process of T-
cell activation; particularly events in early activation. Although our knowledge of the signal 
transduction apparatus has significantly improve, precisely how activatory signals are transduced, 
translated, and interpreted remains somewhat of a mystery. Advances in microscopy and live cell 
imaging have highlighted the complexities of T cell-APC interactions. In particular, it has been 
shown that T cells seem to interact with multiple dendritic cells on their passage through the lymph 
node (Mempel, Henrickson, and von Andrian 2004; Henrickson et al. 2008). The physiological 
significance of these interactions remains incompletely understood, but it has been proposed that 
transient, non-activatory interactions between T cells and APCs may impart the T cell with ‘short-
term’ memory of this interaction (Mayya and Dustin 2016). This feature of T cell activation is 
separate from immunological memory and occurs during the T cell activation process. The short-
term memory hypothesis of T cell activation states that complete T cell activation occurs due to 
the accumulation of as-yet-undefined signalling intermediates (Locasale 2007). The accumulation 
of signalling intermediates allows the T cell to accumulate discontinuous periods of signalling into 
a cumulative output response. In other words, as the T cell interacts with APCs within the lymph 
node, each transient interaction contributes marginally toward the activation state of that T cell. If 
this hypothesis were correct, such signals would need to be tightly regulated to avoid off-target 
activation toward a potentially non-activatory ligand, yet persist long enough to contribute toward 
a second activatory encounter.   
    The above hypothesis can be reconciled by the fact that a number of modelling and 
experimental studies now seem to point to the fact that several TCR-associated enzymatic 
signalling pathways and transcription factors are controlled in a ‘digital’ manner. That is, they are 
either maintained in a state of low activity or a state of high activity. This characteristic is imparted 
on the TCR signalling network through several feedback and feedforward mechanisms that tightly 
control the activation state of proteins within the network.  
 For example, work by Au-Yeung et al. (2014) using a Nur77 GFP reporter system showed 
that increasing the amount of antigen present within the system did not increase the degree to 
which the cells became activated, but rather increased the fraction of responding cells. This seems 
to confirm work by Huang et al. (2013) showing that as little as a single agonistic pMHC is needed 
to initiate T cell activation. This finding is interesting because it confirms modelling studies 
suggesting that T cell activation is amplified by feed forward mechanisms that digitise the TCR 
signalling input (Altan-Bonnet and Germain 2005). In these studies, the T cell discrimination 
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threshold is set by a negative feedback loop that counteracts the positive one. In accordance with 
these modelling studies, Das et al. (2009) were able to show that the Ras signalling pathway is 
under the control of positive feedback mediated by SOS1 and RASGRP. Moreover the authors 
pointed out that the rapid digitisation of the Ras signalling pathway generates lag between the 
upstream and downstream signalling modules. This hysteresis could be a mechanisms that imparts 
short-term memory into the signalling network, i.e. if a second signal is received through the TCR 
before the first signal has completely dissipated then the T cell may be able to sum those signals 
into a cumulative output response. Other groups have also shown the digital nature of other TCR-
associated signalling modules, such as NF-κB (Kingeter et al. 2010) and NFAT (Podtschaske et al. 
2007). All of these findings point to the temporal summation of discontinuous digital signals in T-
cell activation, but do not explain how the T cell is able to sum such signals. 
 
5.1.5 Immediate early gene expression and signal integration    
 To test the TCR signal integration hypothesis, Faraoudi et al. (2003) used the Src kinase 
inhibitor PP2. In their experiment T cells and B cells were conjugated within a collagen matrix and 
calcium activity, ERK mobilisation and IFN-γ production was observed. After 30 minutes of 
activation, the cells were pulsed for 20 minutes with PP2, which was then washed out and the cell 
were activated for an additional 30 minutes. This pattern was then repeated. It was found that a 
single, 30-minute pulse of continuous signalling was not enough to drive cytokine production, but 
several pulses of signalling could drive cytokine production, showing that these signals were 
cumulative. Computer modelling by Locasale (2007) posited that these signalling events could 
accumulate through the expression and stabilisation of immediate early genes (IEGs). As their 
name suggests, these genes are expressed early in the activation process of multiple signalling 
response pathways and do not require the upregulation of other transcription factors to drive their 
expression. They are expressed using the ubiquitously present cellular transcription machinery 
(Bahrami and Drabløs 2016).    
 Several candidates have been proposed to fulfil the role of signal integrator in T cells, 
including Interferon regulatory factor 4 (IRF4), basic leucine zipper transciption factor, ATF-like 
(BATF), Myc, and Fos, among others. IRF4 is reported to accumulate gradually during the first 
24-48 hours of T cell activation, providing a graded IRF4 signal corresponding to the duration of 
TCR signalling (Man et al. 2013; Nayar et al. 2014). IRF4 has also been shown to act as a ‘read-
write integrator and drive expression of antigen-dependent genes (Man et al. 2013; 
Krishnamoorthy et al. 2017). IRF4 binds specific promoters regions in an affinity-dependent 
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manner, with heightened IRF4 expression increasing the probability of promoter occupancy. The 
resulting altered transcription profile affects T cell fate decision (Krishnamoorthy et al. 2017).  
 BATF may also be involved in integrating discontinuous TCR signals. BATF reportedly 
accumulates within the first 72 hours of T cell activation but is dispensable in the later stages of 
activation (Man et al. 2013; Kurachi et al. 2014). Interestingly, haploinsufficiency of BATF or IRF4 
results in decreased proliferative capacity of the activated T cells (Man et al. 2013; Kurachi et al. 
2014). It could be that these factors accumulate and then are diluted in response to successive 
proliferation events, leading to a cell-intrinsic ‘stop’ signal.  
 Myc is another early response factor and serves to prime cells for activation. Myc is not 
unique to T cells, but functions downstream of multiple different signalling pathways (Dang 2013; 
Guy et al. 2013). Transient engagement of the TCR may activate Myc leading to a change in the 
genetic regulatory landscape of the T cell. These changes may serve to prime the T cell for further 
encounters with APCs.  
 Finally, Fos is another IEG candidate proposed to impart short-term memory on the T 
cell signalling network. Many IEG products are rapidly degraded, but hyperphosphorylation of the 
Fos protein may provide enough stability to allow for its accumulation following intermediate 
pulses of signalling (Locasale 2007). Moreover, Fos forms part of the AP-1 transcription factor, 
which interacts with NFAT to trigger gene transcription following T-cell activation (Macian 2005).  
 
5.1.6 Secondary signals regulate T cell activation  
 Prolonged signalling combined with gene transcription creates an intrinsic lag period in the 
signalling network. In the event of prolonged signalling, as might be expected with T cell activation, 
this feature of cell biology would be expected to maximise the dynamic range of the signalling 
output because small differences in the signalling input would be amplified over the duration of 
the activation signal, with longer signals amplifying these differences more than shorter signals. 
However, this does not appear to be the case in the TCR signalling network. Although, 
heterogeneity in protein expression has been suggested to lead to differences in cell fate (Tubo et 
al. 2013) this process is predictable and remarkably consistent between immune responses in 
different mice or different infection models (Cho et al. 2017). This suggests that extrinsic signalling 
factors normalise the T cell response.  
 It is known that T cell fate outcomes are not completely autonomous, but dependent on 
external cues, such as cytokine signalling or co-stimulatory receptor signalling (N. Zhang and 
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Bevan 2011). Experimentally, IL-2 has been shown to actively regulate TCR signalling within the 
first 12 hours of signal initiation (Voisinne et al. 2015). IL-2 expression has been shown to be self-
limiting as expression of IL-2 accelerates expression of the IL-2 receptor (IL-2R) and blocks 
further IL-2 expression through a feedback mechanism mediated by STAT5 (K. E. Tkach et al. 
2014). Increased receptor expression gradually leads to the internalisation and degradation of the 
extracellular IL-2 supply, thus limiting IL-2 signalling. This time-integrated signal feeds into the T 
cell activation state to limit proliferation in the absence of proliferative signals. Thus, this IL-2 
feedback mechanism serves to dampen the T cell response and reduce heterogeneity in the T cell-
mediated immune reaction. Other mechanisms beyond IL-2 likely play a role in tuning the T cell 
response to infection including IL-12, IL-1β, IL-6 and IFNα (Starbeck-Miller, Xue, and Harty 
2014). Prolonged presence of antigen likely extends the duration of IL-2 expression, delaying the 
feedback loop (K. Tkach and Altan-Bonnet 2013; K. Tkach et al. 2014). 
 It should also be noted that these secondary signals occur in concert with self-limiting TCR 
feedback signals. Prolonged TCR signalling results in TCR internalisation and a reduction in the 
magnitude of signals received through the TCR (Boyer et al. 1991; Martínez-Martín et al. 2011). 
This response, together with cytokine receptor feedback and co-stimulatory or –inhibitory signals, 
serves to regulate the duration of TCR signalling.   
 
5.1.7 An engineering approach to cell biology  
As discussed in Chapter 3, optogenetics and CID are providing new ways of interrogating cell 
signalling dynamics. Indeed, an excellent series of work by Toettcher and colleagues has yielded 
new insights into the mechanisms of signal transduction through the canonical Erk signalling 
pathway (Toettcher, Weiner, and Lim 2013; Toettcher et al. 2011; Johnson et al. 2017). Using a 
light-controllable GEF they were able to exert precise temporal control over MAPK signalling to 
show how temporal modulation of a single signalling pathway can yield phenotypically distinct 
outcomes, they were able to show that the Erk signalling module, downstream of the PDGF 
receptor acts as a bandpass filter to screen out low frequency or short duration signals and allow 
long duration signals through. It follows that T cells may be able to interpret the same sort of 
temporally encoded signals through the TCR; as T cells must be able to interpret MHC-restricted 
signals within a narrow range of affinities it follows that they should be able to distinguish 
temporally between activating signals and non-activating signals. Moreover, the work outlined 
above suggests that T cells are also able to interpret temporally discontinuous signals through an 
incompletely understood mechanism.  
Page 144
 Optogenetics is unique in its ability to provide high spatial resolution and precise temporal 
control to cellular signalling pathways. By coupling input modulation to a quantifiable output 
response one can begin to assess the underlying mechanisms of a system. To an extent this has 
been attempted in T cells with the Nur77-GFP reporter system (A. Moran et al. 2011; Zikherman, 
Parameswaran, and Weiss 2012; Au-Yeung BB et al. 2014) but the limited spatiotemporal 
resolution of the drug and antigen inducible system limits the extent of information that can be 
gained from such an approach.  
 By reducing the system to its minimal components we can begin to understand the basic 
mechanisms behind a biological process (Lim 2010). Here I use the Jurkat T cells as a model for 
T cell activation (Bartelt et al. 2009). To address the challenge of signal integration in T cells I have 
developed a drug-inducible, optogenetic chimeric antigen receptor (CAR), ‘optoCAR’ based on 
the blue light-responsive LOV2 domain and the LOVTRAP optogenetic system (Wang et al., 
2016).  The idea behind CARs is relatively straightforward and was conceived in the 1980s (Gross, 
Waks, and Eshhar 1989). An immunoglobulin domain specific toward a surface-expressed cancer 
biomarker is fused to the intracellular signalling motifs of CD3ζ and the CD28 co-receptor 
(Sadelain, Brentjens, and Rivière 2013). Host T cells are then extracted and genetically modified to 
express the CAR, endowing them with the ability to recognise cells expressing the target epitope. 
This technology has successfully been implemented against CD19-expressing myelomas (Posey et 
al. 2016; B. L. Levine et al. 2017) and HER2-positive breast, lung and ovarian cancers (M. Sun et 
al. 2014; Globerson-Levin, Waks, and Eshhar 2014). Rather than an extracellular immunoglobulin 
domain the optogenetic chimeric antigen receptor features a drug-inducible dimerization domain 
which can be used to engage the complementary binding partner expressed on the surface of a 
surrogate APC. Like other CARs, the optogenetic CAR relies on the signalling domains of CD3ζ. 
Photoisomerisation of the intracellular LOV2 domain leads to dissociation of the CD3 signalling 
domains from the rest of the receptor and signal termination. In this way I was able to precisely 
control periods of TCR-like signalling and signal termination.  
  
5.2 Materials & methods  
5.2.1 Cell-cell conjugate calcium flux  
The conjugate calcium flux procedure was adapted from the calcium flux protocol outlined in 
Chapter 2, section 2.7.3. JNFAT T cells were preloaded with Indo-1 AM leak resistant dye 
(TEFlabs) and washed in DPBS as described previously. OptoCAR-positive, Indo-1-loaded 
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JNFAT cells were mixed 1:1.5 with Raji B-cells expressing the complementary FRB-Ex receptor 
in 100 µl of complete RPMI. The cell mixture was aliquoted into individual PCR tubes, which were 
sealed and transferred to a 37˚C water bath for 30 minutes to allow the cells to sediment and 
conjugate. Following the incubation the cells were gently resuspended by pipetting and transferred 
into FACS tubes (Falcon) containing 500 µl of fresh, room temperature, complete RPMI. The cells 
were then left for 30 minutes to equilibrate at room temperature with occasional, gentle agitation 
to prevent clumping.  
 Calcium flux measurements were acquired using a BD Fortessa flow cytometer equipped 
with a UV (355 nm) laser. Live cells were gated on forward scatter and side scatter. The JNFAT 
cells express the fluorescent protein iRFP as a marker and the Raji B cells express TagBFP. 
Conjugates were determined to be events positive for both iRFP and BFP.  
 Samples were run for 1 minute prior to triggering to establish a baseline Indo-1 reading. 
After acquiring a baseline, the FACS tube was removed and the cytometer was left running. To 
trigger the cells, A/C heterodimeriser (AP21967; Clontech) rapalog was added to a final 
concentration of 1 µM. The FACS tube was then returned to the cytometer and ratiometric shift 
in calcium fluxing was observed as described in chapter 2.  Gating was performed in Flowjo 
v10.1r5. 
 
5.2.2 Light Plate Apparatus  
For long-term cell activation assays I used the 24-well light plate apparatus (LPA). Design and 
implementation are well described by Gerhardt et al. (2016). Our LPA was fitted with forty-eight 
5 mm, 475nm LEDs (TEKCORE) and a frosted acrylic diffuser plate, which was designed in-
house (Appendix K). Gaskets were cut using a Trotec Speedy 300 laser cutter. The LPA adapter 
plate was designed for use with a tissue culture-treated, black, glass-bottomed, 24-well plate 
(4titude). The light conditions in each well were programmed according to protocol described by 
Gerhardt et al. (2016).  
 For the 24-hour time course stimulations and pulse width modulation experiments, cells 
were conjugated together in PCR tubes for 30 minutes in a 37˚C water bath in a total volume of 
100 µl of complete RPMI. Cells were conjugated at a ratio of 1:1.5, JNFAT:Raji. Cell were gently 
resuspended by pipetting and added to each well of a 24-well plate containing 400 µl of RPMI and 
A/C heterodimeriser (AP21967), with a final concentration of 1 µM. The loaded LPA was then 
returned to incubator at 37˚C, 5% CO2 for 24 hours.  
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 After the time course was completed cells were transferred to individual FACS tubes and 
centrifuged for 3 minutes at 800 rpm. Media was harvested and immediately frozen for subsequent 
ELISA analysis of IL-2 secretion as described in chapter 2, section 2.9. ELISA samples were 
diluted 1:5 in ELISA dilution buffer prior to analysis. Cells were prepared for FACS analysis as 
described in chapter 2, section 2.7.1. 
 
5.2.3 Data Analysis  
Sample gating and compensation were performed using Flowjo v10.1r5. Data was exported as a 
CSV file for analysis in Matlab R2016b (Appendix D & E). For calcium flux samples, baseline flux 
was established and percent of activated cells above the baseline were calculated along with the 
median ratiometric Indo-1 value. A second script was developed to calculate peak separation 
between positive and negative cells in the 24-hour time course assay. This script was used to 
calculate the percentage of positive cells for each sample relative to a negative control sample as 
well as the median fluorescent intensity of the positive fraction of cells.  
 For generating signal decay curves samples were normalised to the single pulse controls; 
that is, 6 hours of continuous stimulation as the maximum value or a single pulse stimulus 
corresponding to the increment of dark time for the minimum value. I tested dark increment times 
of 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, and 180 minutes. All 
figures were prepared using Matlab R2016b and Adobe Illustrator.  
  
5.3 Results  
5.3.1 Stable expression of light- and drug-controllable chimeric antigen receptor in Jurkat T cells    
Existing models of T-cell activation traditionally rely on either plate bound or soluble antibodies 
to crosslink the TCR, or on mouse-derived T cells with a known antigen specificity. Although 
these models have been extremely instructive in developing working models of T-cell activation, 
they are ultimately restricted in their capacity for rapid and tunable modulation of T cell signalling 
dynamics. I sought to develop a physiologically-relevant, tunable CAR compatible for use in a cell- 
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Figure 5.1 Optogenetic chimeric antigen receptor (Right) On engagement with 
pMHC the ITAM domains of CD3 (yellow) become phosphorylated by LcK. (Left) To 
mimick this interaction a drug-inducible, optogenetic chimerica antigen receptor was 
designed. Addition of the heterodimerising Rapamycin analog causes the formation of a 
ternary complex between FRB, expressed on a surrogate APC, and Fv, fused to the 
extracellular domain of CD86. The LOV2 domain is fused to the cytoplasmic side of the 
chimeric receptor and allows for light-inducible dissociation of the signalling domain. 
The CD3ζ signalling domains of the chimeric antigen receptor are fused to a myristoylat-
ed Zdk domain and diffuse laterally across the plasma membrane.  
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cell system. This optoCAR is drug-inducible via the FRB-FKBP interaction and light-controllable 
via an intracellular LOV2 domain (Figure 5.1). The receptor was designed around the LOVTRAP 
optogenetic system and the Rapalog-inducible FRB-FKBP12 system. In this case, the Zdk domain 
was anchored at the plasma membrane using an N-terminal myristoylation motif and fused via a 
short linker to the three ITAM motifs of CD3ζ at the C-terminus of the construct (Figure 5.1, 
right). The transmembrane component of the optoCAR is comprised of an N-terminal Fv 
(FKBP12) domain fused with the extracellular and transmembrane domains of CD86. At the C-
terminus of the optoCAR on the cytoplasmic side of the plasma membrane is the LOV2 domain 
(Figure 5.1, right). In the dark, the optoCAR mimics the architecture of the wildtype TCR complex 
(Figure 5.1, left) with the signalling domains anchored to the intracellular domain of the receptor 
via the LOV2-Zdk interaction. Under blue light irradiation, photoisomerisation of LOV2 causes 
the CD3ζ chain to laterally dissociate across the plasma membrane away from the transmembrane 
component of the receptor. The transmembrane receptor component and intracellular signalling 
component would be expected to diffuse at different rates within the plasma membrane, thus 
allowing for their complete dissociation (Vaz, Goodsaid-Zalduondo, and Jacobson 1984). The 
optoCAR is activated in the presence of a Rapamycin-analogue (‘rapalog’), which induces the 
formation of a complex between the extracellular, N-terminally expressed Fv domain and its 
interaction partner, FRB, expressed likewise on the surface of a synthetic APC (Figure 5.1). CID 
between the FRB and Fv domains forms a high affinity ternary complex (Kd = ~12 nM) 
(Banaszynski, Liu, and Wandless 2005) and mimics a high-affinity TCR-pMHC interaction. The 
extracellular interaction of the optoCAR functions orthogonally to the endogenous TCR and is 
thus unlikely to interfere with cellular homeostasis. 
 
Mutation t1/2 Reversion (s) Name 
Wildtype ~81 OptoCAR 
V416T ~2.6 OptoCARFAST 
V146L ~496 OptoCATSLOW 
C450G Photo-nonresponsive (Zdk 
constitutively bound) 
OptoCARCLOSED 
I539E Constitutively active (Zdk 
constitutively unbound) 
OptoCAROPEN 
Table 5.1: Overview of OptoCAR variants 
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Photocycle kinetics of the LOV2 domain are tunable via a series of point mutations (Table 
3.1). These mutations have been well characterised and yield LOV2 variants that revert from the 
active lit-state to the unstimulated ground-state at rates both faster and slower than the wildtype 
domain (Zayner and Sosnick 2014; Zayner et al. 2013; Zimmerman, Kuhlman, and Yumerefendi 
2016). It was reasoned that different variants of the optoCAR system would be useful for 
interrogating signalling at different stages of activation. I developed 5 variants of the optoCAR 
system, which are outlined in Table 5.1. 
The optoCARs were stably transduced into the Jurkat-derived, JNFAT cell line. JNFAT 
cells are a clonal population stably expressing a cytoplasmic iRFP marker as well as GFP under 
control of the NFAT promoter, which provides a reliable readout of T-cell activation (Clipstone 
and Crabtree 1992).  To minimise variation between optoCAR-expressing cells lines, I transduced 
the signalling component of the system, myrZdk-CD3ζ-Ruby, into the JNFAT cells first. As would 
be expected, expression of the iRFP marker was identical between each cell line (Figure 5.2A). 
Although most variants of the receptor showed equivalent levels of myrZDK-CD3ζ-Ruby it was 
noted that the LOV2C450G (OptoCARCLOSED) cell line expressed more than the other cell lines 
(Figure 5.2B). For the case of the C450G mutant which shows constitutive binding with the Zdk 
domain, the constitutive engagement of the two receptor components may serve to stabilise 
myrZDK-CD3ζ-Ruby at the cell surface and prevent its degradation. It was found that the 
transmembrane component of the optoCARs were not well-expressed and thus I used lentiviral 
concentration to increase transduction efficiency. This strategy allowed for approximately 
equivalent levels of expression between all of the receptors (Figure 5.2C). Over a period of weeks, 
it was found that expression of the optoCAR system had a tendency to drop, thus I periodically 
returned to frozen stocks to maintain consistency between experiments (Appendix L). Expression 
of the complementary FRB receptor in a clonal Raji B cell line was observed by concurrent BFP 
expression (Figure 5.3).  
The ‘Two Signal Hypothesis’ states that T-cell activation is directed not only through TCR 
signalling, but also through signals derived from co-stimulatory (or inhibitory) receptors (Chen 
and Flies 2013). One well-characterised co-stimulatory receptor is CD28, which is expressed on 
the surface of T cells (Nunes et al. 1996). We confirmed expression of CD28 on our JNFAT line 
by flow cytometry (Figure 5.4A). CD28 interacts with CD80 and CD86 expressed on the surface 
of APCs (Greene et al. 1996).  We confirmed expression of these receptors on Raji B cells (Figure 
5.4B, i & ii). Previous studies have confirmed that Jurkat T cells also express the integrin receptor 
LFA-1 (CD11a) (Bartelt et al. 2009) and that Raji B cells express its interaction partner ICAM-1  
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Figure 5.2 Expression of the OptoCAR systems in JNFAT cells (A) JNFAT cells 
express a cytoplasmic iRFP marker, which remains unperturbed by the addition (B) 
myZdk-CD3ζ signalling motifs and (C) transmembrane receptor components of the opto-
CAR systems
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Figure 5.3 FRB-ex, BFP expression The FRB receptor was coexpressed on a vector 
with the flourescent marker mTagBFP in Raji B cells
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(CD54) (Y. Kim et al. 2007). These data indicate that the JNFAT OptoCAR cell lines, when 
conjugated with Raji B cells expressing the complementary receptor, represent a physiologically-
relevant model system for the interrogation of T-cell signalling dynamics. 
 
5.3.2 OptoCARs recapitulate early T cell activation  
Having generated five JNFAT cell lines expressing different variants of the optoCAR system 
(Table 5.1), we next sought to investigate the ability of these receptors to recapitulate TCR-induced 
signalling. It is well established that engagement of the TCR by its ligand induces a cascade of 
downstream signalling and phosphorylation. One of the earliest events in T cell activation is the 
release of intracellular calcium stores and the subsequent triggering of extracellular calcium fluxing 
(Huse et al. 2007; Balagopalan et al. 2010). This is commonly induced in T cells using αCD3 
antibodies and a crosslinking agent, or chemically with phorbol esters and calcium ionophores. 
These techniques potently trigger calcium fluxing but are clearly non-physiological. I developed an 
alternative method, whereby real-time signalling outputs can be measured in live-cell conjugates 
(Figure 5.5). JNFAT optoCAR cells were preloaded with Indo-1 (Figure 5.5A, left) and then 
conjugated, in the absence of rapalog, with Raji B Cells expressing the complementary FRB 
receptor and BFP (Figure 5.5A, right). Using standard flow cytometry, conjugated cells can be 
identified as events that are double-positive for iRFP and BFP (Figure 5.5B). Addition of rapalog 
triggers the engagement of the optoCAR and subsequent downstream signalling (Figure 5.5C). 
Using the FACS light box (Appendix J), this conjugate assay allowed for precise triggering of T 
cell activation and real-time visualisation of the effect of signal modulation on calcium fluxing.  
 As with the LAT system, I tested the optoCARs using the photo-nonresponsive version 
of the receptor (optoCARCLOSED) and the constitutively open and unbound version of the receptor 
(OptoCAROPEN). I sought to compare activation throught the optoCAR system with activation 
through the endogenous TCR. The antigen specificity of the Jurkat TCR is unknown, but T cell-
APC conjugates are known to be non-specifically triggered by superantigen (Ohnishi et al. 1995). 
Staphylococcal Enterotoxin E (SEE) simultaneously binds TCR and MHC resulting in potent, 
polyclonal T cell activation (Saline et al. 2010). The data presented herein show both the calcium 
flux signal as measured by the ratio of calcium-bound Indo-1 dye to calcium-unbound Indo-1 dye 
and the fraction of cells undergoing calcium fluxing. On the addition of rapalog, optoCARClosed-
expressing JNFAT cells began to flux calcium following a short delay period of ~60 seconds 
(Figure 5.6 & Figure 5.7). This delay in calcium flux triggering is consistent with previous studies  
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Figure 5.5 Overview of the conjugate flux expreiment (A) JNFAT cells expressing 
the optoCAR receptor are pre-loaded with indo-1 dye, washed and conjugated with Raji 
B cells expressing the complementary FRB receptor. JNFAT cells are labelled with an 
iRFP marker and Raji B cells are labelled with a BFP marker. (B) During calcium fluxing 
conjugates are selected on events double-positive for iRFP and BFP. (C) Calcium fluxing  
is triggered on the addition of a heterodimerising drug, which engages the artificial 
receptors. The FACS light box can then be used to modulate light conditions and the 
effect on fluxing can be monitored in real-time. 
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Figure 5.6 Potent calcium fluxing in optoCAR photo-nonresponsive cells 
Pre-gated conjugates were induced to flux calcium via the addition (red arrow) of rapalog 
(A-B), SEE (C), or vehicle (D).The magnitude of calcium fluxing is presented as the ratio 
of calcium bound to unbound indo-1 dye. For each flux profile n=3, calcium flux is 
presented as median ratio above the baseline, error bars are given as SEM.
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Figure 5.7 Majority of optoCAR photo-nonresponsive cells triggered on addi-
tion of rapalog Pre-gated conjgates were induced to flux calcium via the addition (red 
arrow) of rapalog (A-B), SEE (C), or vehicle (D).The fraction of cells undergoing calcium 
fluxing was measured for each sample as those whose median flux ratio was higher than 
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(Liu 2014) and is comparable between cells triggered with rapalog or SEE (Figure 5.6A, C; Figure 
5.7A, C). As expected, this response was unchanged by blue light irradiation (Figure 5.6B, Figure 
5.7B). Cells treated with vehicle did not flux calcium (Figure 5.6D, Figure 5.7D). Of note, the 
magnitude of calcium fluxing in the SEE-treated cells was double that of the rapalog-treated cells 
(Figure 5.6A, C). This observation is likely due to ligand availability and receptor expression (Au-
Yeung BB et al. 2014; Keck et al. 2014). Furthermore the optoCARs are endowed with only 3 
ITAM motifs, whereas the endogenous TCR contains 10 ITAMs. This large difference in the 
number of ITAMs likely accounts for the differences in flux magnitude between the rapalog-
induced cells and the SEE-induced cells (Mukhopadhyay et al. 2016; Guy et al. 2013). Interestingly, 
the fraction of cells responding was only 10% higher in the SEE sample compared with the rapalog 
cells (Figure 5.7A, C). This is consistent with previous studies (Au-Yeung BB et al. 2014).  
 As a negative control we also tested JNFAT cells with a constitutively active LOV2 
mutation, optoCAROPEN (Figure5.2B, C [red]). In these cells Zdk is unable to bind LOV2 and thus 
the signalling domains remain disassociated from the CAR. Predictably, optoCAROPEN-expressing 
JNFAT cells treated with rapalog did not become activated (Figure 5.8). Taken together these 
findings indicate that the optoCAR system, in the presence of rapalog and the complementary 
FRB receptor, recapitulates proximal TCR signalling events. Disengagement of the CD3ζ 
signalling domain from the transmembrane component of the OptoCAR prevents downstream 
signalling (Figure 5.6, 5.7, 5.8).  
 
5.3.3 T cells exhibit tight negative regulation of early signalling events   
Having shown that the optoCAR functioned in a manner analogous to the endogenous TCR, I 
next sought to show that light could be used to modulate input signals to the system. It should be 
noted that due to the method of quantification, the datasets displaying the fraction of responding 
cells exhibit slightly delayed kinetics relative to the Indo-1 flux datasets. This is because I count 
cells as active if they lie above an Indo-1 ratio value determined by the initial baseline reading in 
the first minute of each sample. Therefore, as the cells begin to decrease calcium influx they are 
still counted as active until they reach the baseline value causing a slight delay relative to the 
ratiometric Indo-1 measurements.  
 I began my analysis by testing the wildtype LOV2 version of the receptor (Table 5.1). On 
engagement of the receptor with rapalog under continuous dark condition, it was found that 
optoCAR-expressing JNFAT cells began to flux calcium following a ~60 second delay (Figure 
5.9A, Figure 5.10A).  This response was effectively identical to optoCARCLOSED-expressing cells, 
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both in terms of flux magnitude and the number of responding cells (Figure 5.6A, Figure 5.7A). 
Strikingly, continuous light treatment, beginning one minute prior to the start of the experiment 
resulted in complete ablation of the calcium flux response (Figure 5.9B, Figure 5.10B). This flux 
profile was identical to rapalog-treated optoCAROPEN-expressing cells (Figure 5.8). This level of 
signal control represents a significant improvement on the LAT-based LOVTRAP system (Figure 
4.15). Interestingly, calcium fluxing could be rapidly attenuated by 1 mW/cm2 blue light irradiation, 
indicating tight negative control of proximal T-cell signalling (Figure 5.9C, D). The response to 
light treatment was synchronous across the entire population of cells. (Figure 5.10C, D). 
Importantly, this attenuation in calcium signalling was reversible. Following a 30 second pulse of 
blue light irradiation there was a rapid drop in calcium fluxing observed across the entire 
population of activated cells (Figure 5.9E, Figure 5.10E). Calcium fluxing continued to drop post 
light treatment (Figure 5.9E), reflecting the rate of reversion of the LOV2 domain to the ground-
state (Table 5.1).  Once the indo-1 value reached baseline, there was an approximately 30 second 
delay before calcium fluxing was reinitiated. The magnitude of the second flux peak was equivalent 
to the initial peak showing a complete return to signalling (Figure 5.9E). As mentioned in 5.3.1 
receptor expression tended to drop over time (Appendix L). This is reflected in the dropping 
magnitude of calcium fluxing between samples, though the response to light was still comparable. 
Pre-treatment with light followed by termination of irradiation was able to delay the signalling 
response (Figure 5.9F, Figure 5.10F).  
 To show that my observations were consistent across different variants of the receptor I 
tested the same light-modulation parameters with optoCARFAST-expressing JNFAT cells, the 
LOV2 domain of which returns to the ground-state ~40x as quickly as the wildtype receptor (Table 
5.1). Again, the calcium flux profile of cells triggered in the dark was comparable to the photo-
nonresponsive mutant (Figure 5.11A, Figure 5.12A & Figure 5.6). Following a 60 second delay 
there was an increase in calcium fluxing. This fluxing response was attenuated by continuous blue 
light treatment, but the optoCARFAST-expressing JNFAT cells did seem to show a gradual increase 
in cytoplasmic calcium over time (Figure 5.11B). This background signal may be attributed to 
photocycle kinetics of the LOV2 domain. The V416T mutation makes it energetically more 
favourable for the domain to be in the dark state. The more rapid return to the ground state 
increases the probability of a rebinding event between Zdk-CD3ζ-Ruby and LOV2. This idea is 
discussed in more detail in Chapter 4. Regardless, the fraction of responding cells in the lit state 
remained low (Figure 5.12B). As with the wildtype receptor, light treatment was able to rapidly 
attenuate calcium signalling (Figure 5.11C, D) and was synchronous across the activated 
population of cells (Figure 5.12C, D). A gradual increase in background calcium signalling was also 
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Figure 5.9 Wildtype OptoCAR cells show light-controllable calcium fluxing The 
median calcium flux ratio above baseline was measured under (A) continuous dark, (B) 
continuous light (with 1 minute pre-treatment), (C) light at 225 s, (D) light at 255 s, 
(E) a 30 s pulse of light at 225 s, or (F) 1 minute pre-treatment with cessation of blue 
light at 225 s. For each expreiment n=3 (biological replicates), error is given as SEM. 
Fluxing was triggered by the addition of rapalog (1 μm) at 1 minute (red arrow).
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Figure 5.10 Wildtype OptoCAR cells show variation in number of responding 
cells The fraction of cells responding, as measured by those cells with a median greater 
than the baseline, were observed under (A) continuous dark, (B) continuous light (with 
1 minute pre-treatment), (C) light at 225 s, (D) light at 255 s, (E) a 30 s pulse of light at 
225 s, or (F) 1 minute pre-treatment with cessation of blue light at 225 s. For each experi-
ment n=3 (biological replicates), error is given as SEM. Fluxing was triggered by the addi-
tion of rapalog (1 μm) at 1 minute (red arrow).
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observed in Figure 5.12C. It was noted that although the rate of signal termination was the same 
between optoCAR and optoCARFAST, reflecting the rate at which the LOV2 domain switches from 
the ground state to the active state, the optoCARFAST-expressing cells returned to calcium signalling 
more quickly than the wildtype receptor-expressing cells (Figure 5.9E, Figure 5.11E). This is most 
apparent when looking at the fraction of activated cells, which dips following light exposure, but 
does not return to baseline in the optoCARFAST system (Figure 5.12E). This finding lends support 
to the kinetic proofreading with limited signalling model of T cell activation, whereby activated 
receptors retain signalling capacity for a limited duration following disengagement from pMHC, 
increasing the probability of a productive re-binding event (Lever M et al. 2014). Further evidence 
for background signalling in the fast-cycling system is presented in Figure 5.11F. Unlike the 
wildtype system, pre-treatment with light followed by termination of irradiation results in the rapid 
initiation of calcium signalling in the optoCARFAST-expressing cells (Figure 5.11F, Figure 5.9F). 
This response was reflected on the population level (Figure 5.12F). With the optoCARFAST system, 
mild dark-state phosphorylation of the receptor ITAMs may prime the JNFAT cells for rapid 
activation. This idea is somewhat akin to the concept of tonic signalling.   
   Finally, I looked at calcium fluxing in the slow-cycling variant of the optoCAR system 
(Table 5.1). The rate of return of the LOV2(V416L) mutant is ~12x slower than the wildtype 
domain. Although the trends I observed were the same, the fraction of responding cells was 
somewhat lower with optoCARSLOW-expressing cells than either the wildtype or the fast-cycling 
variants (Figure 5.14). On engagement of the receptor in the dark, the delay to activation (~90 s) 
was slightly longer than either of the other two variants (Figure 5.13A, Figure 5.11A & Figure 
5.9A). Light treatment resulted in ablation of calcium fluxing (Figure 5.13B, Figure 5.14B). 
Although Figure 5.13C shows an uptick in intracellular calcium following blue light irradiation, 
this is likely a result of a skewed median calculation from the small fraction of activated cells 
(Figure 5.14C). As would be expected, on the timescale examined, optoCARSLOW-expressing 
JNFAT cells did no return to signalling following a 30 second pulse of blue light irradiation (Figure 
5.13D, Figure 5.14D). A delay in signalling following light pre-treatment was not observed with 
the optoCARSLOW system (Figure 5.13E, Figure 5.14E). However, the increase in cytoplasmic 
calcium observed was shallow and gradual (Figure 5.13E) and thus is likely to represent ambient 
noise within the small fraction of activated cells (Figure 5.14E) in the system rather than a bona 
fide activation signal.   
 The receptor variants presented above represent a set of tools for the analysis of T-cell 
signalling dynamics at different stages of the activation pathway. The fast-cycling and wildtype 
variants provide a unique approach to interrogating early signalling events, whereas the prolonged  
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Figure 5.11 OptoCARFAST cells (V416T) show light-controllable calcium fluxing, 
but some background signalling The median calcium flux ratio above baseline was 
measured under (A) continuou,s dark, (B) continuous light (with 1 minute pre-treat-
ment), (C) light at 225 s, (D) light at 255 s, (E) a 30 s pulse of light at 225 s, or (F) 1 
minute pre-treatment with cessation of blue light at 225 s. for each experiment n=3 
(biological replicates), error is given as SEM. Fluxing was triggered by the addition of 
rapalog (1 μm) at 1 minute (red arrow).
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Figure 5.12 OptoCARFAST cells (V416T) yield low fraction of responding cells The 
fraction of cells responding, as measured by those cells with a median greater than the 
baseline, were observed under (A) continuous dark, (B) continuous light (with 1 minute 
pre-treatment), (C) light at 225 s, (D) light at 255 s, (E) a 30 s pulse of light at 225 s, or 
(F) 1 minute pre-treatment with cessation of blue light at 225 s. For each expreiment n=3 
(biological replicates), error is given as SEM. Fluxing was triggered by the addition of 
rapalog (1 μm) at 1 minute (red arrow).
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Figure 5.13 OptoCARSLOW cells (V416L) show light-controllable calcium fluxing 
The median calcium flux ratio above baseline was measured under (A) continuous dark, 
(B) continuous light (with 1 minute pre-treatment), (C) light at 225 s, (D) a 30 s pulse 
of light at 225 s, or (E) 1 minute pre-treatment with cessation of blue light at 225 s. for 
each expreiment n=3 (biological replicates), error is given as SEM. Fluxing was triggered 
by the addition of rapalog (1 μm)  at 1 minute (red arrow).
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Figure 5.14 OptoCARSLOW cells (V416L) show delayed return to signalling 
following blue light exposure TThe fraction of cells responding, as measure by those 
cells with a median greater than the baseline, were observed under (A) Continuou,s dark, 
(B) continuous light (with 1 minute pre-treatment), (C) light at 225 s, (D) a 30 s pulse 
of light at 225 s, or (E) 1 minute pre-treatment with cessation of blue light at 225 s. for 
each expreiment n=3, error is given as SEM. Fluxing was triggered by the addition of 
rapalog at 1 minute (red arrow).
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signal attenuation displayed by the slow-cycling variant, optoCARSLOW, could present a novel 
approach for looking at downstream activation events.     
 
5.3.4 OptoCARs recapitulate late T cell activation   
Engagement of the TCR leads to downstream T cell activation, proliferation, and T cell 
differentiation into different effector subsets. This process is reported to require sustained 
signalling over the course of hours to days (Au-Yeung BB et al. 2014; Miskov-Zivanov et al. 2013). 
On a seconds-to-minutes timescale the optoCARs were able to control receptor-induced calcium 
signalling. This process was reversible and repeatable with kinetics dependent on the photocycle 
kinetics of the LOV2 domain. Given that the duration of TCR stimulus is a key determinant of T 
cell fate I next sought to determine the effect of proximal signal modulation on downstream T-
cell activation. To do this, I looked at three separate readouts of T cell activation: upregulation of 
surface expression of the early activation marker, CD69 (Yamashita et al. 1993; Bartelt et al. 2009); 
upregulation of GFP expression under control of the NFAT promoter; and the release of the 
proliferation-inducing cytokine, IL-2 (Bartelt et al. 2009). To perform this assay I needed a means 
of providing long-term illumination to the cell cultures. In collaboration with the LMB Mechanical 
and Electronics Workshops, I modified a 3D-printable optogenetic ‘Light Plate Apparatus (LPA)’, 
details of which can be found in (Gerhardt et al. 2016). To prevent uneven illumination we 
developed a solid acrylic diffuser plate, which provided superior diffusive properties than the filter 
paper suggested by Gerhardt et al. (2016) (Appendix K). The modified LPA allows for modulation 
of light conditions on a well-by-well basis across a 24-well plate.     
 For complete T cell activation, antigen stimulation for a period of 24-48 hours has been 
reported, with longer periods of stimulation driving more rounds of T cell proliferation (Obst 
2015; Jenkins and Moon 2012). Although Jurkat T cells are a good model system, they do not 
respond to proliferative signals in the same way as host-derived peripheral T cells. I therefore 
focused my analysis on a 24-hour period of stimulation. Over this period I wanted to establish a 
baseline for the activation kinetics of CD69, NFAT-driven GFP, and IL-2 in the cell-cell conjugate 
assay. Unfortunately, it was found that the wildtype receptor was unsuitable for long-term 
activation assays. Pilot experiments looking at a single, 9-hour pulse of activation determined that 
there was a high degree of background activation (Appendix M). Cells triggered under continuous 
illumination were indistinguishable from cells triggered under continuous dark. Even at 100% 
LED intensity (~0.5 mW/cm2 on LPA) activation state was unaffected (Appendix M). Instead, I 
focused my efforts on the optoCARSLOW system. Data from the calcium flux assay suggested that 
Page 168
these cells would provide a lower level of background signalling than the other two variants (Figure 
5.13-14).  
 The optoCARs are both drug-inducible and light-controllable (Figure 5.1) and as such I 
tested two means of inactivating the optoCAR system, a chemical method and an optogenetic 
method. As blue light irradiation rapidly inactivated early signalling events (Figure 5.9-14) one 
might propose that blue light irradiation should terminate TCR induced downstream signalling on 
the assumption that continuous signalling from the TCR is required for the mediation of 
downstream events (Figure 5.15A). However, the effect of proximal signal termination on 
downstream signalling modules; such as Erk translocation, AP-1/NFAT transcription factor 
activation, and mRNA transcription and translation, remains somewhat unknown.  
To model the activation kinetics of the optoCAR system, conjugated cells were activated 
with heterodimerising drug and then inactivated by either blue-light irradiation (~0.2 mW/cm2) or 
homodimerising drug after a defined period of activation (Figure 5.15). The homodimerising drug 
has a higher affinity for the FKBP12 domain (Kd = 1.8 nM) than the heterodimerising drug, but 
does not generate a ternary complex with the FRB domain (Clackson et al. 1998). Thus, at low 
concentrations the homodimeriser outcompetes the heterodimeriser for FRB binding causing 
disengagement of the OptoCAR. This experiment was run over a 24-hour period (Figure 5.15). 
The time during which the cells are activated will herein be referred to as ‘Signal On’ (SON) and the 
time during which the cells are inactivated by either homodimeriser or light will be referred to as 
‘Signal Off’ (SOFF).  
It was found that drug treatment and light treatment were broadly comparable across the 
three output markers of T-cell activation. Following SON of 3 hours (SOFF = 21 hours) ~50% of 
the cells were positive for both CD69 (Figure 5.16A) and GFP (Figure 5.17A). The fraction of 
activated cells only slightly increased beyond this point. However the MFI of GFP (Figure 5.16B) 
and CD69 (Figure 5.17B) did not begin to plateau until SON = 6 hours (SOFF =18 hours). As the 
half-life of GFP is reported to be ~26 hours we would expect to see only limited signal decay over 
this time period (Corish and Tyler-Smith 1999).  These finding suggest that at least 3 hours of 
sustained signalling is needed to initiate gene expression and further sustained signalling is 
necessary for more robust gene expression. This finding suggests that even downstream TCR 
signalling events are under tight negative regulation. ELISA analysis of IL-2 cytokine expression 
confirmed this observation (Figure 5.18). Three hours of signalling was not enough to drive 
expression of IL-2¸ but by 6 hours IL-2 expression had begun to plateau (Figure 5.18). IL-2 is  
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Figure 5.15 Light inactivation and drug washout comparison (A) On the addition 
of rapalog (red line), after a short delay period the optoCAR systems initiate downstream 
signalling. Calcium flux experiments show that signalling is rapidly attenuated following 
blue light irradiation (cyan line). Periods where the receptor is active are referred to as SON 
(Signal on) and periods of blue light stimulation, where the receptor is disengaged are 
reffered to as SOFF (Signal off). (B) The receptor can also be inactivated on the addition of 
a homodimerising drug (dotted black line), which binds the Fv domain with higher affinity 
than the heterodimerising version, but does not engage the FRB domain, thus preventing 
signalling.
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Figure 5.16 OptoCAR-expressing cells upregulate NFAT-driven GFP expression 
following 3 hours of continuous signalling OptoCAR-expressing JNFAT cells were 
conjugated with Raji B cells and then triggered by the addition of rapalog (A/C). Signalling 
was inactivated after 0 hr, 0.5 hr, 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, or 24 hr, either by the addition 
of rapalog (B/B; black line) or by light (cyan line). All cells were harvest after a 24 hr 
period. Using a Matlab peak separation script the (A) fraction of activated cells was calcu-
lated and the (B) mean fluorescent intensity of the whole population was calcuated. MFI 
was normalised to the 0 hr activation and 24 hr activation samples. For each sample  
n=2.   
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Figure 5.17 OptoCAR-expressing cells upregulate CD69 expression following 3 
hours of continuous signalling OptoCAR-expressing JNFAT cells were conjugated with 
Raji B cells and then triggered by the addition of rapalog (A/C). Signalling was inactivated 
after 0 hr, 0.5 hr, 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, or 24 hr, either by the addition of rapalog (B/B; 
black line) or by light (cyan line). All cells were harvest after a 24 hr period. Using a Matlab 
peak separation script the (A) fraction of activated cells was calculated and the (B) mean 
fluorescent intensity of the whole population was calcuated. MFI was normalised to the 0 
hr activation and 24 hr activation samples. For each sample n=2. 
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Figure 5.18 IL-2 expression delayed relative to NFAT reporter GFP and CD69 
IL-2 expression in the spent media was assayed by ELISA. JNFAT cells expressing the 
optoCAR system were inactiviated at 0 hr, 0.5 hr, 1 hr, 3 hr, 6 hr, 9 hr, 12 hr, and 24 hr 
post-stimulation by rapalog (A/C). signalling was terminated either by drug washout with 
rapalog (B/B; black line) or light (cyan line). 
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known to be regulated by the NFAT transcription factor and thus this finding is consistent with 
the NFAT-reporter data (Chow et al. 1997). These findings are also in agreement with the 
observation that sustained TCR signalling is necessary to drive complete T cell activation 
(Rachmilewitz, Lanzavecchia, and J. 2002).  
 A gradual decrease in soluble IL-2 was observed in the light-treated cells (Figure 5.18). It 
was noted that within the LPA there was an increase in cell death, particularly in the innermost 
four wells (Appendix K). This was determined using ZombieAqua live-dead cells stain. This 
increase in cell death would likely affect the amount of cytokine detectable in the assay. Media in 
wells where cells had died was somewhat more yellow than wells where the majority of cells had 
lived thus it was determined that the LPA lid was so tight so as to block gas exchange. I have since 
obtained new lids for the glass-bottom 24-well plates.  
 
5.3.5 TCR signals sharply decay following withdrawal of input signals  
 The drug washout and light inactivation time course showed that 6 hours (SON = 6 hours) of 
continuous signalling was sufficient to drive robust CD69 upregulation and NFAT-driven GFP 
expression (Figure 5.16-17). With this value in mind, I next sought to interrogate TCR signal 
integration over time. It has been reported that rapid digitisation of the Ras signalling pathway and 
the accumulation of downstream signalling intermediates creates bistability within the system 
allowing T cells to integrate temporally discontinuous signals (Das et al. 2009; Faroudi et al. 2003). 
By fragmenting SON into discontinuous pulses, such that the total amount of signalling (STOTAL) 
always equalled 6 hours I hypothesised that it should be possible to determine the rate of signal 
decay downstream of the TCR. Although several signalling intermediates have been proposed, 
including IRF4 (Man et al. 2013; Huber and Lohoff 2014), Myc (Holst et al. 2008; Guy et al. 2013), 
and Fos (Faroudi et al. 2003; Locasale 2007), the precise nature of TCR signal integration remains 
to be fully described. By measuring the rate of signal decay over time I reasoned that it should be 
possible to build a temporal ‘roadmap’ of T cell activation events.  
 Shown in Figure 5.19 are three example pulse width modulation (PWM) experiments. A 
single 6 hour pulse of dark (SON), in which the system is active was used as the control (Figure 
5.19A). This 6 hour pulse of system activation was followed by an 18 hour pulse (18-ΣSOFF) of 
low-intensity blue light irradiation (~0.2 mW/cm2) to inactivate the signalling pathway, such that 
the total duration of the experiment was always 24 hours. To simplify these experimental 
conditions I refer to the pulses of dark, during which the signal is active, as SON and the pulse of 
light, during which the signal is interrupted, as SOFF. Both SON and SOFF can be adjusted, but the  
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Figure 5.19 Assaying signal integration through pulsed activity The calcium flux 
assays showed that signalling could be rapidly terminated by blue light, but that the 
JNFAT cells would return to signalling after a period of time defined by the photocycle 
kinetics of the LOV2 domain. The signalling time series assay determined that (A) 6 hours 
of continuous signalling was enough to drive GFP NFAT-reporter expression, CD69 upreg-
ulation, and secretion of IL-2. Periods of signalling (SON) where fragmented by pulses of 
blue light irradiation (SOFF) to assay the temporal integration of signals through the opto-
CAR. (B) The total amount of signaling was equal to 6 hours (STotal), with two periods of 
signaling (SON) of 3 hours each. The two pulses of SON are divided by a 3 hour pulse of blue 
light (SOFF). The remaining time until the cells were harvested (18-∑SOFF) was spent under 
blue light irradiation such that all samples were illuminated for a total of 18 hours. (C) 
Another example of a signal integration experiment. Here, SON equals 1 hour and SOFF 
equals 3 hours. STOTAL remains 6 hours. 
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total amount of time that the system is in the dark state (STOTAL) is always equivalent to 6 hours 
and the total amount of time that the system is in the light is always equivalent to 18 hours (ΣSOFF 
+ (18-ΣSOFF)), over the course of a 24 hour experiment (Figure 5.19B, C). In the example in 
Figure5.19B, SON is reduced to 3 hours and SOFF is also 3 hours. Thus, two 3 hour pulses of system 
activity are separated by a 3 hour pulse of system inactivity. If signalling through the TCR were 
cumulative, it would be expected that regardless of the duration of SON, STOTAL would always be 
equivalent. That is, NFAT reporter-driven GFP expression, IL-2 expression, or CD69 expression 
would be expected to be identical regardless of SON. The previous data show that <3 hours of 
continuous signalling is insufficient to drive gene expression (Figure 5.16-18) so it is unclear if 
short, discontinuous TCR signals can be summed toward a cumulative output response.   
 By pulsing TCR signalling with periods of inactivity, I was able to show that interruption 
of TCR input signals results in the rapid decay of downstream signalling (Figure 5.20-24). The data 
suggest that TCR signals are not additive, but are instead tightly negatively controlled. Shown in 
Figure 5.20 is an example of two different time course experiments, Figure 5.20A and Figure 5.20B 
represent the type of experiment shown in Figure 5.19C. Here, SON is 1 hour, thus STOTAL is divided 
into six, 1-hour pulses of activity. The topmost histogram is 6-hours of continuous dark and the 
bottommost is 24-hours of continuous light. Immediately above the bottom histogram is a single 
pulse SON control, which in this case is a single 1-hour pulse of darkness followed by 23 hours of 
light. Between the top and bottom two histograms are increasing pulses of SOFF, given in 
descending order, with the shortest SOFF increment at the top of the plot and the largest at the 
bottom. This data shows that increasing the period of inactivity (SOFF) between each pulse of 
signalling (SON) decreases the fraction of activated cells and the degree to which those cell are 
active. This seems to hold true for both GFP expression and CD69 expression (Figure 5.20A and 
Figure 5.20B, respectively). If SON is decreased to 30 minutes, this trend becomes more 
pronounced (Figure 5.20C, D). These plots are representative of just two values of SON and only a 
handful of values for SOFF. To build a more complete picture of signal integration in T cells I 
incremented SON from 5 minutes to 3 hours and SOFF from 10 seconds to 18 hours.  
 To visualise T cell activation across the spectrum of pulse width durations I used Matlab 
to perform peak separation between the positive and negative cells relative to a vehicle treated 
negative control. By calculating the area under the positive curve relative to the whole population 
I was able to determine the fraction of activated cells under each condition (Figure 5.21 & Figure 
5.23).  I looked at the degree to which cells became activated by measuring the mean fluorescent 
intensity (MFI) of the overall population, which was normalised to the single pulse control samples 
(Figure 5.22 & Figure 5.24). 
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Figure 5.20 TCR signalling is not additive Two example pulse width modulation 
experiments (A, B) SON equals 1 hour, STotal equals 6 hours. (C, D) SON equals 30 minutes, 
STotal equals 6 hours. The duration of SOFF is varied from well to well. Each histogram plot 
is drerived from a separate well of the LPA. (A) As the pulse of blue light between each 
pulse of signalling increases, both the fraction of GFP positive cells and the intensity of 
NFAT-driven GFP expression decreases. (B) CD69 upregulation also decreases as the light 
pulses between SON increases. (C) Each pulse of SON is reduced to 30 minutes. As the 
duration of the light pulses between SON pulses increased NFAT-driven gene expression 
decreases. (D) CD69 expression follows the same trend. 
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 As the duration of SON was increased, the fraction of cells positive for GFP gradually began 
to increase. This can be seen in the single pulse controls along the top row of the heat map (Figure 
5.21) and is consistent with the finding that <3hrs of continuous signalling is insufficient to drive 
GFP reporter expression. Interestingly, there was a negative correlation between the percentage 
of activated cells and the duration of SOFF. That is, as the duration of time between signal pulses 
increased, the fraction of activated cells decreased (Figure 5.21). This was particularly notable for 
samples where SON was below 90 minutes. Where SON was equal to, 90 minutes, 120 minutes, or 
180 minutes, incrementing SOFF did not greatly affect the fraction of activated cells. This finding 
suggests that T cells are able to integrate discontinuous signals into a cumulative output response. 
However, quantification of the mean fluorescent intensity (MFI) showed that although T cells 
were able to integrate discontinuous signals, the output response was not cumulative (Figure 
5.22A). By using the Matlab curve fitting function it was possible to measure the rate of exponential 
decay in TCR-derived signals. In doing this, it was found that increasing the duration of SOFF 
resulted in a drastic decrease in the MFI of the GFP reporter (Figure 5.22A). This was particularly 
true where SON was equal to 5 minutes. As the t1/2 of reversion of the LOV2 slow-cycling mutant 
is ~500 s (Table 5.1), the SOFF pulses were cycled more rapidly than the recovery of the LOV2 
domain and little signal was able to accumulate (Figure 21, Figure 22A, Appendix [Figure A]).    
 As the duration of SON was gradually increased from 5 minutes to 3 hours the rate of signal 
decay gradually decreased (Figure 22B, Appendix [Figure A]). This finding would be consistent 
with the hypothesis that continuous T cell signalling results in the accumulation of signalling 
intermediates. It would be expected that as the duration of TCR signalling were increased, there 
would be a proportional increase in signalling intermediate, allowing for an increased duration of 
signal memory between pulses.     
 Similar findings were observed when looking at CD69 upregulation (Figure 5.23-24). 
Following only 30 minutes of continuous signalling it was found that the majority of cells were 
positive for CD69 (Figure 5.23). This result is not surprising and reflects the fact T cells are primed 
for CD69 upregulation. CD69 is an early response gene and is rapidly transcribed with only low 
levels of signalling necessary to drive its expression (Yamashita et al., 1993). The ability of T cells 
to rapidly upregulate CD69 expression is apparent in the single pulse control data, where prior to 
samples <30 minutes show no CD69 expression, but 30 minutes of continuous activation is 
enough to drive CD69 expression (Figure 5.23, Top row). This trend is reflected across the heat 
map, as beyond 30 minutes (SON) the majority of cells were CD69 positive. This was invariant to 
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Figure 5.21 NFAT-driven GFP expression and SOFF duration are inversely 
correlated Using matlab peak separation, the fraction of activated cells in each well were 
calculated. The duration of each signal pulse (SON) is varied along the x-axis and the dura-
tion of each light pulse is varied along the y-axis (SOFF). The top row, outlined in red, 
represents a single continous pulse of signalling equivalent to the value given for SON 
along the x-axis. For each unit on the heat map n = 1<x<4 
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Figure 5.22 NFAT-driven GFP signal exhibits rapid decay (A) Mean fluorescent 
intensity of the population of cells in each well of the LPA was calculated and normalised 
to the 6 hour single pulse control and the SON single pulse control. Each point represents 
a single sample. Curves were generated using the Matlab exponential curve fitting func-
tion. Each curve is representative of a single SON value. The duration of the SOFF pulses are 
given along the x-axis. Each point is a single biological replicate. (B) The Matlab curve 
fitting function was used to calculated the rate constant for each SON curve. 
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Figure 5.23 CD69 is rapidly expressed on optoCAR stimulation Using matlab peak 
separation, the fraction of activated cells in each well were calculated. The duration of 
each signal pulse (SON) is varied along the x-axis and the duration of each light pulse is 
varied along the y-axis (SOFF). The top row, outlined in red, represents a single continous 
pulse of signalling equivalent to the value given for SON along the x-axis. For each unit on 
the heat map n = 2 or 3 (Biological replicates) 
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the duration of SOFF. Given the speed of CD69 upregulation and the long t1/2 of the receptor 
reversion rate, it is difficult to discern from this data if signals regulating CD69 expression are 
summative. 
 As with the NFAT reporter system, it was found that TCR signals governing CD69 
upregulation are tightly negatively controlled (Figure 5.24). Increasing the duration of SOFF caused 
a rapid decrease in CD69 expression. Once again this effect was most pronounced where SON was 
5 minutes (Figure 5.24A).  Interestingly, it was noted that increasing the duration of SON decreased 
the rate of signal decay (Figure 5.24B). Again, this finding is consistent with the hypothesis that 
the accumulation of short term signalling intermediates provides T cells with short-term ‘memory’ 
of their previous interactions (Locasale 2007; Faroudi et al. 2003). Increasing the duration of signal 
results in a corresponding increase in downstream signalling intermediates.       
 The data obtained from the 3 hour SON datasets should be interpreted with the caveat that 
as the duration of SOFF is increased the second 3 hour activation pulse is shifted closer to the end 
of the experiment (24 hours total). Transcription of mRNA and protein translation create an 
intrinsic time lag within the system, therefore it might be expected that the second pulse of 
activation would contribute somewhat less to the overall output response (GFP or CD69 
expression). This is mitigated by the fact that as SON is decreased as each individual pulse would 
now be expected to contribute less to the final output. Thus it is plausible that in the datasets 
where SON equals 90 minutes or 120 minutes, the MFI signal of GFP or CD69 could be more than 
the signal generated from two, 3-hour pulses of signalling. Indeed this does seem to be the case 
(Figure 22A, Figure 24A).   
  
5.4 Discussion  
5.4.1 A physiologically-relevant system for studying T cell activation  
Unlike other models of T cell activation, which rely on antibody stimulation or treatment with 
PMA to activate T cells, the optoCARs provide a system that closely recapitulates the endogenous 
TCR signalling pathway (Figure 5.1-5.2). As with previous studies we found that increasing the 
amount of ‘antigen’ (rapalog) did not affect the degree of activation (Au-Yeung BB et al. 2014), 
but rather the fraction of cells activated. However, in the long-term and short-term activation assay 
it was found that increasing drug concentration increased the amount of background activation.  
The calcium flux assays also confirmed that ITAM number affects the potency of the response. 
As our artificial receptors have only three ITAM signalling motifs, it was observed that the peak 
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amplitude of the calcium flux triggered through the optoCARs was lower than that seen in the 
cells triggered through SEE (Figure 5.6-5.7). As with clinically tested CARs, we might seek to 
address the potency of activation in the future by using a naturally dimerising receptor protein, 
such as CD28, for the foundation of the optoCAR. Nonetheless, the kinetics of the response 
including the delay in signalling and the fraction of activated cells remained comparable regardless 
of the receptor. This is in agreement with theoretical models of T cell activation (Mukhopadhyay 
et al. 2016). Ultimately, these findings show unprecedented temporal control over T cell signalling 
dynamics in a physiologically-relevant setting.   
 
5.4.2 A ‘temporal roadmap’ for T-cell activation  
 By using the optoCAR systems I have approached the T cell as a ‘black box’ system (Figure 
5.25). That is, this system allows for precise, tunable modulation of the input stimulus – light 
intensity/duration and rapalog concentration – and a set of quantifiable activation markers – 
CD69, NFAT-driven GFP expression, or IL-2 secretion. Without knowing anything more about 
T cell biology our data clearly shows that input signals along the TCR signalling axis are tightly 
regulated (Figure 5.25). Fortunately, extensive research into the basic biology of T cells allows us 
a framework in which to apply these findings. Contextually this finding makes sense. Conventional 
T cells play an important role in driving the overall immune response to infection, inappropriate 
activation of T cells can result in autoimmunity and severe inflammation. It is therefore in the best 
interest of an organism that relies on adaptive immunity to tightly regulate the activation of T cells.  
 The data presented in this chapter also highlight key features of T cell signal integration. 
Several studies have proposed the accumulation of unstable signalling intermediates in T-cell 
activation. One well-proven signalling intermediate involved in TCR-signal transduction is the 
accumulation of post-translational protein modifications. Engagement of the TCR results in 
phosphorylation of ITAM signalling motifs by the associated CD3 chains. These serve as docking 
sites for the kinase ZAP70, which phosphorylates other signalling molecules further downstream, 
including LAT and SLP76 (Smith-Garvin et al. 2009). These phosphorylated proteins represent 
early signalling intermediates in the T-cell activation process. Their accumulation is translated into 
downstream activation in a manner that is still incompletely resolved. The accumulation of post-
translational modifications provides very short-term memory of previous signals (Taylor et al. 
2017). Indeed, this is the foundation for the kinetic proofreading model of activation (Hopfield 
1974; McKeithan 1995). However, this phosphorylation is counteracted by phosphatases, such as 
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Figure 5.25 T cells as a black box system By controlling the signal inputs through the 
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underlying signalling mechanisms of the system
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CD45 and SHP-1/-2 that act to dampen TCR signalling (Schoenborn et al. 2011; Hui et al. 2017). 
This strong negative feedback mechanisms provides tight control over T-cell activation and is 
reflected in my results (Figure 5.21-24).  The data presented here show that early signals are very 
quickly cleared from the signalling network on the cessation of optoCAR stimulation. This is seen 
in the rapid decrease in calcium fluxing observed on blue light irradiation. Interestingly, this effect 
was at least partially dependent on the photocycle kinetics of the LOV2 domain, as the fast-cycling 
receptor was able to reinitiate signalling more quickly than the other two. This suggests that the 
phosphorylation modifications on CD3ζ last for at least a few seconds. This provides support for 
the kinetic proofreading with limited signalling model of activation, which allows the system to 
‘recall’ past engagements and rapidly reinitiate subsequent phosphorylation of the TCR (Lever et 
al. 2014). This effect is enhanced by TCR-pMHC interactions with a longer dwell time, which 
promotes TCR clustering (Taylor et al. 2017). 
 Further downstream the data support a different mechanism for signal integration. As the 
duration of the signalling pulse was increased I observed a corresponding decrease in the rate of 
signal decay (Figure 5.22, 5.24). This process occurred gradually as the duration of SON was 
increased. One possible explanation for this is the upregulation of immediate early gene (IEG) 
expression. IEGs are important in the cellular response to environmental stimuli and are expressed 
early during activation. The rapid expression of IEGs means that they do not rely on the 
upregulation of other transcription factors but instead rely on the existing cellular machinery 
(Abraham, Dragunow, and Tate 1991; Wilson et al. 2017). Indeed, Myc and Fos, two well-
characterised IEGs have been proposed as intermediates in the T cell activation process (Y. Wang 
et al. 2012; Macian 2005). Given that the switch in the rate of signal decay occurs around the time 
that these genes would be expressed, this presents a tantalising target for future analysis. Other 
optogenetic studies have identified IEGs as important integrators of signalling downstream of the 
platelet-derived growth factor receptor (Wilson et al. 2017). It will be interesting to see how these 
results compare in T cells as it has been suggested that the previous activation events that occur 
during T cell development shape the genetic and epigenetic landscape of future activation events 
(Locasale 2007; Ohkura et al. 2012). Taken together our findings can be used to piece together a 
‘temporal roadmap’ for T cell signalling. The optoCARs can be used to examine the temporal 
sequence of events leading to complete T cell activation as well as the broad mechanistic 
implications for these events.  
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5.4.3 Co-stimulatory/-inhibitory receptors in TCR signal transduction  
T cells express a number of different co-receptors, which act as both positive and negative 
regulators of T cell activation. Although the activities of these molecules in activating or inhibiting 
T cells are broadly understood, their mechanistic influence on signal integration remains poorly 
understood. We confirmed expression of the costimulatory receptor CD28 on the JNFAT cell 
line. A potential future line of enquiry would be the interrogation of the involvement of CD28 
mediated signalling in downstream activation. CD28 is reported to enhance activity of the 
Phosphoinositide 3-kinase (PI3K) signalling pathway (Garcon et al. 2007). Signalling along the 
PI3K axis has been shown to be involved in mediating TCR-induced signalling (Okkenhaug and 
Vanhaesebroeck 2003). In the absence of costimulatory signals T cells are directed toward anergy 
(Gimmi et al. 1993; Linterman et al. 2014). It might be expected that reducing CD28 signalling 
could sharpen the signal decay curve observed in NFAT-driven GFP and CD69 assays. Blocking 
αCD28 antibodies have been used clinically (Jang et al. 2008) and thus antibody blocking of the 
CD28 receptor interaction with its ligands, CD80 and CD86 on the surface of APCs, could prove 
useful in determining the involvement of this co- stimulatory receptor in TCR signalling. 
Alternatively, CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4), an inhibitory receptor 
expressed on the surface of T cells, has also been shown to interact with CD80 and CD86 (Greene 
et al. 1996). CTLA-4 has a higher affinity and avidity for CD80 and CD86 than CD28 and thus is 
able to outcompete CD28 for their binding even at low expression levels (McCoy and Gros 1999). 
Intracellularly CTLA-4 interacts with PP2A and SHP-2, which dephosphorylate the TCR signalling 
complex (Teft, Chau, and Madrenas 2009; Schneider and Rudd 2000). It would thus be expected 
that CTLA-4 would also increase the decay rate of TCR signalling. In enacting these experiments 
it is important to recognize that Jurkat T cells are reported to exhibit high basal levels of PI3K 
expression (Astoul et al. 2001). However, even with this in mind, many basic concepts in T cell 
biology were initially discovered in Jurkat cells and then confirmed in host-derived T cells (Bartelt 
et al. 2009). CD28 and CTLA-4 represent on two of the many co-receptors expressed on T cells, 
others have been well reviewed elsewhere (Chen and Flies 2013). Traditional genetic manipulation 
combined with our optoCAR system could yield new insights into the signal integration and 
translation of co-receptor-derived inputs. The fact that these sorts of experiments are possible is 
one of the key attributes of our cell-cell signalling system.  
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5.4.4 Conclusions  
 We have applied an engineering perspective to T cell biology by looking at the T cell as a 
black box system, but this terminology is not necessarily strictly applicable to the T cell. A truly 
black box system implies that the inner workings are unknown, but decades of research into the 
fundamental biology of T cells has provided us with a comprehensive understanding of the 
underlying signalling components. Our optogenetics approach into the interrogation of T cell 
signal integration has confirmed that proximal TCR signalling events are tightly negatively 
regulated and exhibit a rapid rate of signal decay. The results presented in this chapter outline the 
foundations for a precise temporal roadmap of TCR signalling events and their contribution to 
overall signal integration. Moving forward it will be important to further characterize the 
underlying biochemistry of the system and understand how manipulating the activation pathway 
affects T cell fate and function.  
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Chapter 6 – Structural features of  T cell-dependent bispecific 
antibody epitope affect T-cell activation and therapeutic 
potential  
The work presented herein was done in collaboration Ji Li*, Nicola J. Stagg*, Jennifer Johnston*, Sam Menzies, 
Danielle DiCara*, Vanessa Clark*, Maria Hrisopoulos*, Ryan Cook*, Dionysos Slaga*, Rin Nakamura*, Luke 
McCarty*, Siddharth Sukumaran*, Elizabeth Luis*, Zhenmao Ye*, Thomas D. Wu*, Tieko Sumiyoshi*, Dimitry 
Danilenko*, Genee Y. Lee*, Klara Totpal*, Diego Ellerman*, Isidro Hötzel*, John R. James, and Teemu Junttila*. 
This work is published in: “Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-
FcRH5/CD3 and is a Requirement for Myeloma Cell Killing”, Cancer Cell 31, 383-395, March 13 2017.  
*Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA   
6.1 Introduction  
6.1.1 Multiple Myeloma 
Multiple myeloma (MM) is one of the most common haematological malignancies (Siegel, Miller, 
and Jemal 2016). MM is characterised by the malignant outgrowth of plasma cells in the bone 
marrow and overproduction of monoclonal immunoglobulin protein (M protein), though this 
clinical feature varies within the patient population (Drayson et al. 2001; Kyle et al. 2003). Clinical 
manifestations include anaemia, renal failure, bone disease, and hypercalcaemia (Rajkumar et al. 
2014).  Current pharmacological treatment of MM relies on proteasome inhibitors, 
immunomodulatory drugs, monoclonal antibodies and Alkylating agents (Kyle and Rajkumar 
2009). Where patients are eligible, autologous haematopoietic stem cell transplantation is also used 
to treat MM. Unfortunately MM is still incurable and most patients treated for this malignancy will 
go on to relapse. Even with the most effect therapeutic regimes currently in use, median overall 
survival is only ~3 years (Kumar et al. 2017). As such, there is a need for new treatment options.      
 
6.1.2 FcRH5 as a clinical target  
One limiting factor in the development of cancer therapies is the availability of cancer-
specific biomarkers. Fc receptor homolog 5 (FcRH5) – also referred to as FcRL5, IRTA2 or 
CD307—is a surface-expressed protein found on B cells, including pre-B cells and plasma cells. 
There are 5 proteins in the FcRH family, each with Ig-like extracellular domains (Polson et al. 
2006). The genes expressing the FcRH family proteins are tightly clustered in the human 1q21 
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region amongst previously identified FcR genes (R. Davis et al. 2001). Genomic instability 
surrounding the FcRH5 locus frequently results in B cell malignancies with unbalanced 
translocations causing partial trisomy or tetrasomy of the IRTA1 and IRTA2 genes (Hatzivassiliou 
et al. 2001). As such, it was found that FcRH5 is expressed in MM as well as Burrkit’s Lymphoma 
and B-chronic lymphocytic leukaemia  (Polson et al. 2006; Miller et al. 2015), suggesting broad 
applicability as a biomarker for multiple B cell cancer subtypes.  
 
6.1.2 Immunotherapy and T cell-dependent bispecific antibodies 
Bispecific antibodies (bsAb) are a novel class of biopharmaceutical. There are currently around 50 
different bsAb formats available, but they can be broadly catagorised into two major groups: those 
containing an Fc region and those lacking an Fc region (Kontermann and Brinkmann 2015). 
Although the latter is generally smaller, the presence of an Fc region may be desirable in a 
pharmaceutical context because it allows for the mediation of further effector functions 
(Kontermann and Brinkmann 2015). Coloma & Morrison (1997) conceived of the idea of bsAbs 
twenty years ago, but it was not until recently that bsAbs have been applied in a clinical context. 
Importantly, bsAbs can be administered to patients “off-the-shelf” without the fear of latent 
reactivation. This is in contrast to chimeric antigen receptor T cell therapy, which requires genetic 
modification of patient T cells and may eventually result in latent reactivation (Chesi and Fonseca 
2017). 
 The first bsAb to receive market approval was catumaxomab (Removab®) (Linke, Klein, 
and Seimetz 2010). Catumaxomab is a trifunctional, bispecific antibody that combines anti-
epithelial cell adhesion molecule (EpCAM) with anti-CD3ε binding specificities. This bispecific 
reactivity allows for T cell activation toward tumour cells positive for EpCAM. The presence of 
the Fc region further serves to activate monocytes, macrophages, dendritic cells, and NK cells via 
Fcγ-receptor binding (Smith and Clatworthy 2014). Several other types of bispecific antibody are 
currently under development or are in clinical trials. These are well reviewed by Kontermann & 
Brinkmann (2015).  
 We tested the efficacy of bsAbs toward FcRH5-expressing MM cells. Our T cell-dependent 
bispecific antibody (TDB) combines anti-CD3ε binding specificity with specificity toward varying 
structural epitopes on FcRH5. CAR T cell therapies and bsAbs have previously been successfully 
tested against B cell leukaemias and lymphomas (Bargou et al. 2008; Sadelain, Brentjens, and 
Rivière 2013). Furthermore, clinical trials have shown that full-length TDBs represent an 
appropriate therapeutic format as they have a long serum half-life and low risk for forming anti-
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drug antibodies (Junttila et al. 2014; L. L. Sun et al. 2015). Despite these earlier findings, the 
molecular mechanism of T-cell activation by TDBs remains to be fully described.  
 
6.1.3 The kinetic segregation model of T-cell activation  
 The exact details of T-cell activation are still the focus of ongoing research, but it is well-
accepted that the process of TCR triggering is characterised by increased phosphorylation of the 
TCR complex and downstream signalling molecules, including ZAP70, LAT and SLP76 (Smith-
Garvin et al. 2009). The kinetic segregation model of T-cell activation states that phosphatases, 
such as CD45, are passively excluded from regions of close membrane proximity caused by the 
interaction of the TCR with pMHC, due to their large, rigid extracellular domains. This exclusion 
of phosphatases from the regions of tight membrane apposition allows Lck to unrestrictedly 
phosphorylate the ITAMs in the TCR complex, resulting in the recruitment of ZAP70 and a 
further bias toward downstream phosphorylation (James and Vale 2012). This exclusion of CD45 
is critical in the formation of a functional immune synapse (IS). The exclusion of proteins with 
large extracellular domains from regions where cell membranes are tightly juxtaposed appears to 
be a fundamental biophysical signalling mechanism (Schmid et al. 2016). 
 Previous studies of bsAbs have pointed toward the exclusion of CD45 from regions on 
the plasma membrane when the therapeutic is bound (Offner et al. 2006). It therefore follows that 
bsAbs may function to activate T cells in a manner analogous to the endogenous TCR-pMHC 
interaction.  We sought to confirm this hypothesis using a reductionist T cell system and a series 
of FcRH5-binding bsAbs.  
 
6.2 Materials & Methods  
6.2.1 TDB labelling  
For microscopy, TDBs were first dialysed into PBS, pH 7.2 and then labelled with Alexa Fluor 
647 using an antibody labelling kit (Thermo Fisher Scientific) according to the manufacturer’s 
protocol. Following labelling, a dye:protein ratio of ~4 was routinely achieved.   
  
6.2.2 Transient transfection  
To prepare HEK-T cells and FcRH5-expressing target cells for microscopy, cells were transiently 
transfected according to the protocol outlined in chapter 2, section 2.5.1. However, cells were 
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seeded into 6-well plates rather than MatTek imagining dishes. HEK293Ts were transiently 
transfected with 1 µg total of pHRSV-FcRH5-Ruby using 3 µl of GeneJuice reagent (Millipore). 
HEK T-cell expressing the 1G4 TCR (James and Vale 2012) were transiently transected with 
ZAP70-BFP, Lck, CD43:45-qGFP, and CBP/Csk to a total of 1.5 µg of DNA with 4.5 µl of 
GeneJuice. Ratio of DNA between constructs was 1:1:2:1.5, ZAP70:Lck:CD45:CBP/Csk.  
  
6.2.3 Confocal microscopy  
For confocal imaging, cells were trypsinised with 500 µl of 0.25% Trypsin, which was then 
inactivated with 1.5 ml of complete media. Cells were then mixed 1:1 in DBPS at high density with 
TDB antibody and conjugated at 37˚C for 30 minutes. Cells were gently resuspended by pipetting 
and transferred into imaging dishes with DMEMgfp (Clontech) to reduce photo-bleaching.  
 
6.2.4 Image Analysis  
Analysis of microscopy images was performed using Fiji (ImageJ). Channels were separated, 
background subtracted by 100 pixel rolling ball method, and images enhanced by exponential 
fitting. Pixel intensity for each channel was calculated to measure CD45 exclusion, FcRH5 
clustering, TDB clustering, and ZAP70 recruitment.    
 
6.3 Results  
6.3.1 TDBs activate T cells through the kinetic segregation of CD45  
During IS formation, the tight apposition of the T cell and APC, caused by the interaction of the 
TCR with pMHC and by integrin receptors, results in the exclusions of the phosphatase CD45 
from the cell-cell interface (Chang et al. 2016; S. Davis and van der Merwe 2006). In this kinetic 
segregation model of T cell activation CD45 is exclude from TCR-pMHC clusters because of its 
large, rigid extracellular domain (Figure 6.1) (James and Vale 2012; Schmid et al. 2016). Using 
HEK293T cells expressing the minimal machinery necessary for T cell activation, we were able to 
show that TDBs drive T cell activation through the exclusion of CD45 and clustering of the target 
molecule.      
 As has been discussed in previous chapters, early T cell activation is characterised by the 
phosphorylation of CD3 ITAMs by the Src family kinase, Lck. These phosphorylated ITAMs serve 
as a docking site for the SH2 domain of ZAP70 (Smith-Garvin et al. 2009). As ZAP70 is cytosolic 
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Figure 6.1 Anti-FcRH5/CD3 TDB conjugated cells mimic pMHC/TCR cell-cell 
junction (A) A schematic overview of the cell-cell interface with proteins represented 
approximately to scale. (B) representative image of TDB (1G7)-mediated conjugate 
between HEK293T cell expressing FcRH5-Ruby and HEK T cell. CD45 segregation and 
ZAP70 recruitment are clearly shown. (C) Schematic overview of TCR-pMHC interaction 
with proteins shown approximately to scale. (D) Conjugate is between pMHC-expressing 
Raji B cell and HEK T cell. Conjugate shows CD45 segregation from cell-cell interface and 
clustering of pMHC and ZAP70 recruitment. Cartoon schematics (A, C) were prepared by 
John James. Microscopy was performed and images prepared by Michael Harris (B,D).  
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in non-activated T cells, the recruitment of ZAP70 to the phosphorylated ITAMs can be used as 
a visual readout of T cell activation (Figure 6.1) (James and Vale 2012). We transiently expressed 
Lck, CBP/Csk, CD45 and Zap70 in HEK cells stably expressing the 1G4 TCR (HEK-T cells) 
(James and Vale 2012). HEK-T cells were conjugated with HEK293T cells transiently expressing 
FcRH5 in the presence of a TDB antibody with a membrane proximal binding epitope (Figure 
6.1A). This resulted in strong recruitment of ZAP70 to the cell-cell interface as well as clustering 
of the target molecule and exclusions of CD45 (Figure 6.1B). We found that this mimicked the 
synapse formation between HEK-T cells and Raji B cells expressing pMHC (Figure 6.1C, D).  
Close membrane apposition driven by the TCR-pMHC interaction resulted in the exclusion of 
CD45, clustering of pMHC at the membrane interface, and recruitment of ZAP70 to region of 
cell-cell contact (Figure 6.1D).  
 The formation of an immunological synapse between a CD8+ T cell and its target is 
essential for the directed secretion of cytolytic granules and target cell killing. To visualise the 
interface between the HEK-T cell and the target cell, a 3D, Z-stack image was taken of the TDB 
conjugated cells. This 3D confocal imaging was performed by Sam Menzies. As is consistent with 
the formation of an IS, these images show the formation of an IS-like structure with CD45 
excluded to the distal region of the contact area and FcRH5, and by extension the TCR, clustered 
within the centre (Figure 6.2A). Regions enriched for FcRH5 and CD45 were mutually exclusive. 
A line profile of the cell-cell interface confirmed the colocalisation of FcH5 with the TDB and 
exclusion of CD45 (Figure 6.2B). Taken together, these results indicate that TDBs drive T cell 
activation through the same molecular mechanism as the intrinsic TCR-pMHC interaction. Both 
mechanisms of triggering show increased exclusion of CD45 and target clustering at the cell-cell 
interface. Interestingly, the EpCAM-specific BiTE (Bi-specific T cell Engager) was also reported 
to drive the same exclusion of CD45 (Offner et al. 2006), indicating that this mechanisms may be 
intrinsic to bsAbs.  
 
6.3.2 Membrane proximity of TDB epitope enhances T-cell activation and target killing 
FcRH5 is a type I membrane protein with a large extracellular domain (Polson et al. 2006). It is 
known that the interaction of the TCR and pMHC brings the membranes of the T cell and the 
APC to within approximately 14 nm of each other (James and Vale 2012). The close apposition of 
the cell membranes is what drives the exclusion of CD45 (James and Vale 2012; Schmid et al. 
2016). To test the effect of epitope structural features on T-cell activation and tumour cell killing  
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Figure 6.2 FcRH5 clustering and CD45 exclusion at the cell-cell interface (A) 
An en face view of the cell-cell interface between a HEK T cell and a HEK expressing 
FcRH5-Ruby. (B) Line profile of the en face junction showing exclusion of CD45 (green) 
and concomitant clustering of FcRH5 (red) and TDB (blue). Microscopy (A) was 
performed by Sam Menzies and quantification (B) was performed by John James 
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Figure 6.3 Membrane-proximity of TDB FcRH5 epitope drives increased CD45 
segregation (A) Schematic overview of the TDB binding sites on FcRH5. (B) Repre-
sentative images of the TDB-mediated conjugates between HEK T cells and HEK293T 
cells expressing FcRH5. Conjugation was induced using the AF647-labelled TDB speci-
fied. (C) CD45 segregation and (D) FcRH5 clustering were measured by quantifying the 
intensity along the TDB labelled membrane section, relative to the total membrane. 
Cartoon schematic (A) was prepared by John James, Microscopy and quantification  
(B-D) was performed by Michael Harris. 
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we generated a series of TDBs with binding sites on FcRH5 increasingly proximal to the plasma 
membrane (Figure 6.3A).  
We generated and tested three different TDBs with epitopes at varying membrane 
proximities (Figure 6.3A). We found that target clustering and CD45 exclusion correlated with 
membrane proximity of the epitope (Figure 6.3B). TDB binding to the most membrane proximal 
Ig domain of FcRH5 (1G7), showed increased exclusion of CD45 when compared to TDBs 
targeting the central region (10A8) or the distal region (gD) of FcRH5 (Figure 6.3C). Conjugation 
with TDB-1G7 also resulted in increased clustering of FcRH5 at the cell-cell interface (Figure 
6.3D). The representative microscopy images in Figure 6.3 were taken by myself and the 
quantification of target clustering and CD45 exclusion (Figure 6.3C, D) was performed on data 
from image-sets created by myself (1G7-TDB and 10A8-TDB) and Sam Menzies (gD).  
 We next tested the efficiency of the TDB variants to induce T cell activation and target 
cell killing. CD8+ T cell were acquired from healthy donors and stimulated with the TDBs in the 
presence of FOX-NY cells expressing human FcRH5. This work was performed at Genetech in 
the lab of Teemu Junttila. It was found that 1G7-TDB triggered more robust T cell activation, as 
measure by SLP76 phosphorylation, than either the 10A8-TDB or the gD-TDB (Figure 6.4). 
Indeed, there was almost no observable phosphorylation of SLP76 in CD8+ T cells treated with 
gD-TDB (Figure 6.4). The inability of the gD-TDB to activate T cells was made obvious in a cell-
killing assay. Even high concentrations of the gD-TDB were unable to affect target cell killing 
(Figure 6.5). In contrast, CD8+ T cells treated with the 1G7-TDB demonstrated efficient target 
killing (Figure 6.5; EC50 = 0.5 nM). Finally, to confirm that these effects were driven by the location 
of the epitope we generated a truncated version of the FcRH5 protein in which the gD epitope 
was expressed directly above the 1G7 epitope (Figure 6.6A). It was found that in removing most 
of the extracellular domain, the efficiency of target cell killing was increased 25-fold (EC50 = 20 
pM) in CD8+ T cells stimulated with 1G7-TDB and that gD-TDB was now able to affect target 
cell killing (Figure 6.6B; EC50 = 0.19 nM).  
Of Note, the differences in binding affinity of the 1G7-TDB and the 10A8-TDB (12nM 
and 3 nM, respectively) do not account for their differences in ability to activate T cells (Figure 
6.4) (J. Li et al. 2017). Differences in expression of the truncated versus the non-truncated FcRH5 
constructs also do not account for the differences in killing (J. Li et al. 2017). These results indicate 
the structural characteristics of the TDB target epitope can alter the efficiency of T-cell activation 
and subsequent target cell killing.  
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Figure 6.4 Increased phosphorylation of downstream signalling proteins with 
membrane proximal epitope Periperal CD8+ T cells from healthy donors wite stimu-
lated with FoxNY cells expressing human FcRH5 and 1μg/ml TDB. SLP76 phosphoryla-
tion was measured by phospho-Western with total SLP76 as the input control. This 
experiment was performed in the lab of Teemu Junttila. 
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Figure 6.5 Membrane proximal epitope facilitates target cell killing FoxNY cells 
expressing human FcRH5 were killed by CD8+ T cells using either the 1G7-TDB (blue) 
or gD-TDB (red). 
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Figure 6.6 Truncation of FcRH5 improves CD8+ killing efficiency (A) The FcRH5 
construct was truncated such that the gD tag was immediately proximal to the 1G7-TDB 
binding epiptope. (B) CD8+-mediated target cell killing of FoxNY cells expressing the 
truncated FcRH5 variant. Target cell killing was induced using either 1G7-TDB (blue) or 
gD -TDB (red). All killing assays were performed in the lab of Teemu Junttila. 
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6.4 Discussion    
6.4.1 Epitope structural features affect therapeutic potential of bsAbs 
The results presented above indicate that along with serum half-life, complement fixation, 
antibody-dependent cellular cytotoxicity, binding affinity and stability, among other characteristics 
of bsAbs, the structural features of the target epitope should be considered in therapeutic design. 
We have shown that the membrane proximity of the bsAb target epitope strongly influences T-
cell activation. Epitopes proximal to the membrane showed enhanced capacity to activate T cells 
compared with membrane distal epitopes. To drive exclusion of CD45, the membrane of the T 
cell and the target cell must be tightly juxtaposed; a membrane proximal binding epitope facilitates 
this tight apposition. It was shown as well that optimal T-cell activation was driven by the bsAb 
target molecule itself. Truncation of FcRH5 resulted in target cell killing by 1G7-TDB at a 
considerably lower concentration than was required for the full length FcRH5 protein (Figure 6.6). 
This finding suggests that screens for future immunotherapeutic targets could rank the molecules 
based on their structural features, facilitating therapeutic design and efficiency.  
 
6.4.2 Combination Immunotherapy  
As discussed in chapter 5, T-cell activation is dependent on the integration of multiple signalling 
pathways. Co-receptors serve to both positively and negatively regulate T-cell activation. Two 
inhibitory receptors, commonly referred to as ‘checkpoint receptors’ are CTLA-4 and PD-1 
(Programmed Cell Death Protein-1) (Osada et al. 2015; McCoy and Gros 1999). Clinical trials have 
shown that blocking these receptor pathways can serve to enhance T-cell activation and tumour 
killing capacity (Callahan, Postow, and Wolchok 2015). It has been shown that myeloma cells 
upregulate the PD-1 binding partner, PD-L1 (programmed cell death protein ligand 1) (Gorgun et 
al. 2015), to circumvent killing by T cells. In this study it was shown that treatment of cynomolgus 
monkeys with the TDB resulted in an increase in PD-1 expression on CD8+ and CD4+ T cells 
(J. Li et al. 2017). T cells in which PD-1 was upregulated showed a reduced capacity for target cell 
killing, but antibody blockade of PD-L1 resulted in significantly improved target cell killing (J. Li 
et al. 2017). This finding lends support to the idea that TDBs can be used in combination with 
checkpoint inhibitors for improved treatment of MM patients, particularly in later disease stages.  
 
Page 201
6.4.3 Stratification of patient populations  
Genetic abnormalities of the 1q21 region, which contains the FcRH gene loci, are a common 
feature of B cell malignancies including MM (Polson et al. 2006). Duplications of the IRTA2 gene 
can result in the overexpression of FcRH5. This research suggest that MM cells overexpressing 
FcRH5 are exquisitely sensitive to TDB treatment (J. Li et al. 2017). There is a current lack of 
prognostic biomarkers for patients with MM. Genetic testing of the 1q21 locus for the 
identification of duplication or deletion events may serves as a useful prognostic indicator for the 
success of treatment with the FcRH5-TDB. In conclusion, these TDBs provide another weapon 
in the armament against a form of B cell malignancy that currently has limited treatment options.    
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Chapter 7 – Final Discussion  
7.1 Overview of Results  
In this thesis I present the development and application of several optogenetic and chemically-
controllable tools for the interrogation of T-cell activation events (Figure 3.2, 3.3, 3.9 & 5.1). I 
began this work by attempting to develop a set of LAT-based optogenetic switches for the analysis 
of microcluster formation. Although this work did provide novel insights into the understanding 
of early T cell signalling events, it was ultimately hampered by the intrinsic biological properties of 
the LOV2 domain. However, using the insights gained from this approach, I was able to reapply 
this LOV2 optogenetic technology toward the development of a set of optogenetic chimeric 
antigen receptors, ‘optoCARs’.  
Using both the LAT-based LOVTRAP system and the optoCARs I was able to show that 
early T-cell signalling events are under extremely tight negative regulation. On blue light irradiation 
of Jurkat T cells expressing either the LOVTRAP-LAT system or the optoCAR, I observed an 
almost immediate cessation of calcium signalling (Figure 4.16, 5.6-5.14). This results shows that 
early T cell activation is under tight negative regulation and that this effect is immediately 
transmitted through the TCR proximal signalling network within a matter of seconds. This feature 
of T cell signalling probably exists to set a sharp activation threshold between activating pMHC 
ligands and non-activating pMHC ligands. As the T cell must be able to distinguish between 
activatory and non-activatory signals with a high degree of selectivity and specificity (McKeithan 
1995; François et al. 2013), tight negative regulation of the TCR-proximal signalling components 
would serve to rapidly extinguish off-target activation. Although such a threshold has been 
proposed through modelling studies (François et al. 2013; Lever M et al. 2014), it has been difficult 
to experimentally show with the existing methods of T cell activation.  
 I have also used the optoCAR system to begin to interrogate the temporal integration of 
discontinuous TCR signals. It has been proposed that the accumulation of unstable signalling 
intermediates leads to a summative signalling outputs. This concept is well reviewed by Mayya and 
Dustin (2016). When viewed in the context of adaptive immune priming this hypothesis makes 
sense. T cell are reported to interact with multiple DCs on their transit through the secondary 
lymphoid organs (Qi, Kastenmüller, and Germain 2014). Although the data outlined above 
indicate that proximal signalling events are rapidly terminated on disengagement of the TCR, this 
finding does not negate the idea that more sustained interactions may lead to the development of 
downstream signal intermediates that provide the T cell with a form of ‘short-term’ memory of 
past signalling events. However, the time scale on which these intermediates accumulate and the 
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rate at which they decay remain almost completely unknown. To address this outstanding question 
I used the optoCAR system to fragment pulses of TCR-like signalling with pulses of system 
inactivity. In doing this I was able to determine that signals received through the optoCAR, and 
by extension the TCR, decay rapidly (Figure 5.21-24). Again, this finding suggests that TCR 
signalling is under tight negative regulation. However, it was observed that as the duration of each 
signalling pulse was increased, the rate of TCR signalling decay gradually decreased (Figure 5.22, 
5.23). This finding points to the accumulation of signalling intermediates. As the quantity of these 
intermediates increases, the longer the duration of short-term memory of past signalling events 
will be. 
 Finally, in this thesis I also define the mechanism of action of bispecific antibodies using a 
reductionist model of the T-cell signalling apparatus. Using HEK293T cells expressing the TCR 
(HEK T cells), CBP/Lck, CD45, and ZAP70 conjugated with cells expressing the Multiple 
Myeloma target FcRH5, I was able to show that αCD3/αFcRH5 bispecific antibodies activate T 
cells in a manner analogous to the endogenous TCR-pMHC interaction (Figure 6.1). That is, TDBs 
mediate the formation of a tight juxtaposition between the T cell and target cell membranes. This 
narrow cell-cell junction causes the exclusion of the phosphatase CD45 due to its large extracellular 
domain (Figure 6.3) (James and Vale 2012; Schmid et al. 2016). Interestingly, TDBs also mediate 
the clustering of the target molecule (J. Li et al. 2017). It was found as well that more membrane 
proximal epitopes drove this process more robustly, causing greater segregation of CD45 and 
increased target cluster and improved CD8+ T cell-mediated killing. This finding may have 
important implications for future therapeutic design both of antibody therapies and chimeric 
antigen receptors.    
 
7.2 Defining the limitations of the LOV2 optogenetic system         
The results presented in Chapter 4 highlight the current limitations of optogenetic tools. It was 
found that neither the LOVTRAP- nor the TULIPs-based LAT optogenetics tools were able to 
sustain downstream T cell signalling. Protein complexes are in a constant state of equilibrium 
between the associated state and the dissociated state. The propensity of these complexes to 
dissociate is measured as the dissociation constant (Kd). The effect of this intrinsic biochemical 
property was observed in both the TULIPs and the LOVTRAP system, but was more apparent 
during the Calcium flux assays with the TULIPs system. Both the constitutively active variant of 
the LOVpep system and a truncated version of the system where the PDZ binding sequence was 
fused directly to the TM domain of LAT showed identical calcium flux profiles, indicating that the 
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unsustained calcium flux was caused by an intrinsic property of the LOVpep-PDZ interaction. 
Indeed, experiments with the low affinity PDZ domain, which has a higher Kd, showed that 
calcium fluxing decreased more quickly in this version of the system than the high affinity 
(ePDZb1) version (Figure 4.22). Steric effects were ruled out by creating a fusion protein in which 
the high affinity PDZ domain was inserted between the TM domain and the signalling domain of 
LAT. Simply by anchoring the signalling domains at plasma membrane I was able to completely 
resolve the unsustained calcium fluxing phenotype.  
 As well as this, a high degree of background signalling was also detected in the LAT-based 
systems. This was determined to be due to the equilibrium state of the LOV2 domain itself, which 
oscillates between the active and inactive states. Blue light and darkness simply bias the equilibrium 
toward one state of the other, but regardless of the state of illumination a proportion of the protein 
will always exist in both states. Rational engineering and careful design of optogenetic systems in 
the future will likely help overcome this problem (Strickland et al. 2010; Yao, Rosen, and Gardner 
2008).  
 
7.3 Learning from past LOVs 
In developing the optoCARs, I implemented lessons from the LAT-based optogenetic systems. 
Namely, the addition of a CID domain to trigger the receptors. This second degree of control 
seemed to buffer the systems more against background binding of the Zdk domain to LOV2 and 
provided a cleaner ‘off’ state (Figure 5.6-5.14). This finding has important implications for the 
implementation of optogenetics systems. It may be that to overcome background binding in the 
‘off state’ a second degree of drug-inducible control may help reduce off-target effects.  
 
7.4 Future directions for the optoCAR system  
In Chapter 5, I show that the TCR signalling pathway is under tight negative control, but is still 
able to integrate temporally discontinuous signals. Das et al. (2009) showed that positive feedback 
in the Ras signalling pathway leads to hysteresis, which could provide a mechanism for short-term 
signalling memory. Although this may be true for more long term signals, the experiments 
presented in chapter 4 and 5 show that TCR signalling is under tight negative control and ceases 
almost immediately on interruption of proximal signalling events. The mechanistic implication for 
this remain to be fully described, though modelling studies have suggested the involvement of 
negative and positive feedback loops in regulating TCR signalling (Lever et al. 2016; Dushek et al. 
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2011; Honda et al. 2014; Altan-Bonnet and Germain 2005). To further characterise the mechanistic 
underpinnings of T cell activation if will be necessary to better characterise the dynamics of other 
signalling events. The optoCAR systems can be used to selectively ‘break’ the TCR signalling 
pathway to gain insight into the fundamental mechanisms of signalling.   
 Activation of the Ras pathway on TCR ligation, leads to phosphorylation and translocation 
of the canonical Erk protein. In unstimulated T cells Erk is present in the cytoplasm, but 
phosphorylation of Erk causes it to relocate to the nucleus. Once in the nucleus Erk alters the 
active state of early-acting transcription factors and initiates changes in gene transcription. It would 
be interesting to understand the dynamics of this process as the initiation of transcription and 
translation create an intrinsic lag in the signalling system (Mayya and Dustin 2016). Such a delay 
could create a degree of short-term memory. As with the calcium flux assay and the NFAT-GFP 
reporter, combining the optoCARs with fluorescent Erk reporters would allow us to visualise the 
effects of proximal signals on proteins much further down the signalling pathway. Others have 
used fluorescently tagged Erk constructs to visualise Erk dynamics in response to receptor 
activation (Fujioka et al. 2006), but by combining optogenetics with this system we can precisely 
measure the effects of signal modulation of Erk dynamics in real time.  
 For completeness, a fluorescently labelled Erk reporter, could be combined with a red-
fluorescent calcium indicator (Oheim et al. 2014) to observe both calcium signalling and Erk 
mobilisation. Both could be observed via confocal microscopy in conjunction with the LOV2 
optogenetic system. Assuming an appropriate panel of fluorescent markers were selected for the 
receptor components and Erk.  
 With regards to signal intermediates it would be interesting to begin to quantify the 
accumulation IEG products during the activation process and their rate of decay. Excitingly this 
approach was recently applied by Wilson et al. (2017) to investigate signal transmission along the 
Erk signalling axis. The authors investigated the expression dynamics of five IEG products: c-fos, 
btg2, rhob, klf2, and dusp4. These products were selected from a list of candidate genes 
upregulated following PDGF receptor stimulation (Wilson et al. 2017). Although this approach is 
more comprehensive, a number of candidates have been proposed to fulfil this role in T cell, 
including c-fos, IRF4, and BATF (Man et al. 2013; Nayar et al. 2014; Locasale 2007). Additionally, 
data mining the Gene Expression Omnibus (GEO) datasets may provide the transcription level 
data necessary to identify further candidate genes. Once a panel of candidates has been selected it 
should be possible to measure the accumulation and degradation of mRNA by qPCR and the 
protein by immunoblot. By comparing this data with the signal integration data presented in Figure 
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5.20-5.24, it should be possible to build a more complete picture of the mechanism by which T 
cells are able to decipher temporally encoded signals.  
 
7.5 Fine-scale adjustment of TCR signalling  
TCR signalling has been reported to occur digitally by a number of groups (Au-Yeung BB et al. 
2014; Kingeter et al. 2010; Das et al. 2009), but the presence of specific costimulatory of co-
inhibitory receptors is known to influence the ultimate state of T cell activation – this concept is 
well review by Chen & Flies (2013) . One important costimulatory receptor is CD28, which is 
expressed on the surface of T cells and interacts with both CD80 and CD86 expressed on the 
surface of CD86. CD28 is reported to interact intracellularly with PI3K. Antibody blockade of 
CD28 could yield insights into the nature costimulatory signals on T cell activation. Specifically, it 
would be interesting to measure the capacity for T cells integrate signals in the absence of these 
costimulatory signals. Would the rate of signal decay increase or remain the same? How are 
readouts of T cell activation changed including CD69, the NFAT-GFP reporter and IL-2 
production?  
 
7.6 Reapplying the optogenetic signalling approach to other immune receptors  
Finally, the optogenetic approach to signalling presented in this thesis could be useful in 
interrogating the signalling dynamics of other immune receptors. For example the BCR is also 
known to signal through a set of ITAMs on CD79. One could envision a reasonably easy 
substitution between the CD3ζ chain and CD79 for the interrogation of BCR signalling dynamics. 
Another interesting future target could be the FcRs, which function through the interplay of ITAM 
and ITIM motifs. Optogenetic tools provide a powerful mechanism for spatially restricting and 
precisely activating or inhibiting FcR signalling pathways. By redesigning the optoCAR system to 
function more like an FcR, it may be possible to investigate the mechanisms of signal integration 
along competing FcR signalling pathways. Such questions have remained difficult to address with 
the existing molecular toolkit, but optogenetics is opening up the field of molecular biology with 
a new set of tools that better reflect the dynamic nature of cell biology.  
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Appendix A  
Name  Sequence  Tm (˚C) Notes 
LATint'-SpeI_Fwd 5′- tagtagactagtccaggcagttacgacagcacatcctcag -3′ 65.7 CRISPR PAM Knockout  
IRES-NTOM20_Fwd 5′- cacgatgataatatggccacaaccatggtgggccgcaacagcgcg -3′ 70.0 Overlap extension IRES-NTOM 
NTOM20-IRES_Rev 5′- cgcgctgttgcggcccaccatggttgtggccatattatcatcgtg -3′ 55.0 Overlap extension IRES-NTOM 
NTOM20-IFP2_Fwd 5′- cgatccgaactttaaatctagagctcgggaccctcaacctttc -3′ 57.6 NTOM-tag IFP2 
IFP2-NTOM20_Rev 5′- gaaaggttgagggtcccgagctctagatttaaagttcggatcg -3′ 54.5 NTOM-tag IFP2 
LOV-IFP2_Rev 5′- gtagtagccaaggaaccacttccagaaccggcttctttcctctgcacctg -3′ 63.2 IFP2 – LOV2 fusion 
IFP2-LOV-Fwd 5′- caggtgcagaggaaagaagccggttctggaagtggttccttggctactac -3′ 59.8 IFP2 – LOV2 fusion 
NTOM20_Fwd 5′- atggtgggccgcaacagc -3′ 62.0 NTOM20 sequence cloning 
NTOM20_Rev 5′- tctagatttaaagttcggatcgctgcg -3′ 58.6 NTOM20 sequence cloning 
LATmut1_Fwd 5′- tagtcacgcgtgccaccatggaggaggccattttggtgccttgtgtcttggggctcctgctgctg -3′ 70.0 CRISPR gRNA mutation 
LATdblmut-LOV_fwd 5′- gccacagactgccaggcagtggaagtcctaggttggctactacacttg -3′ 70.6 LAT-TM cloning 
LATdblmut-LOV_Rev 5′- caagtgtagtagccaacctaggacttccACTgcctggcagtctgtggc -3′ 70.6 LAT-TM cloning 
IRES-LATmut_fwd 5′- cacgatgataatatggccacaaccatggaggaggccattttggtg -3′ 68.5 IRES LAT cloning 
IRES-Latmut_Rev 5′- caccaaaatggcctcctccatggttgtggccatattatcatcgtg -3′ 68.5 IRES LAT cloning 
Cherry 3'_Fwd-seq 5′- cccacaacgaggactacaccatcg -3′ 61.2 3′ sequencing primer 
IFP2-LOV_fwd2 5′- caggtgcagaggaaagaagccggctccggaagtcctaggttggctactac -3′ 61.2 IFP2 - LOV2 fusion 
LOV-IFP2_Rev2 5′- gtagtagccaacctaggacttccggagccggcttctttcctctgcacctg -3′ 64.2 IFP2 - LOV2 fusion 
IFP2stitch_fwd 5′- tccctcctctgtatctcggaggaccagaga -3′ 65.2 IFP2 overlap extension 
IFP2stitch_Rev 5′- tctctggtcctccgagatacagaggaggga -3′ 65.2 IFP2 overlap extension 
PDZ-Bgl_For 5′- tagtagagatctgatgccagaacttggatttagcatatcaggt -3′ 62.7 BglII site inserition 
FN3-Bam_Rev 5′- ctactaggatcccggtagttaatcgagattgggctagagtag -3′ 63.5 BamHI site insertion 
cpPDZ-Bam_Rev 5′- ctactaggatccgagtctttttcaaccctcactcgaatctcttgtt -3′ 64.8 BamHI site insertion 
AsiSI_LATtm_fwd 5′- tagtaggcgatcgccaccatggaggaggccattttggtgc -3′ 70.4 AsiSI site insertion 
LOVp_SpeI_Rev 5′- ctactaactagttcacacccaggtatccaccgc -3′ 63.3 SpeI site insertion LOVpep 
LOV2_SpeI_Rev 5′- ctactaactagttcaaagttcttttgccgcctcatc -3′ 60.7 SpeI insertion LOV2 
MluI_LAT(AGT)_fwd 5′- tagtagacgcgtgccaccatgggcagttacgacagcacatcctc -3′ 71.6 MluI insertion LAT 
Ruby-PDZ_fwd 5′- gtgggatggacgagctgtacaagggcagtggcatgccagaacttggatttagcatatcag -3′ 59.6 Ruby-PDZ fusion 
PDZ-Ruby_Rev 5′- ctgatatgctaaatccaagttctggcatgccactgcccttgtacagctcgtccatcccac -3′ 66.6 Ruby-PDZ fusion 
FN3-StopNotI_Rev 5′- ctactagcggccgctcaacggtagttaatcgagattgggctagag -3′ 68.4 FN3 Ruby fusion STOP 
Ruby-zdk_fwd 5′- gtgggatggacgagctgtacaagggcagtggcatggtggataacaaattcaataaagaaaag -3′ 53.4 ZDK – Ruby fusion 
Zdk-Ruby_rev 5′- cttttctttattgaatttgttatccaccatgccactgcccttgtacagctcgtccatcccac -3′ 66.6 ZDK – Ruby fusion 
zdk-StopNotI_rev 5′- ctactagcggccgctcattttggggcctgggcatcg -3′ 72.7 ZDK – Ruby fusion 
LAT-3'_seq 5′- gaactgcatcctggagcggctaag -3′ 61.7 LAT sequencing primer 
iRFP670-NoATG-Mul_For 5′- tagtagacgcgtgcgcgtaaggtcgatctcacc -3′ 67.5  
iRFP670-Bam_Rev 5′- ctactaggatcccgttggtggtgggcggcggtg -3′ 68.5  
cpPDZ-StopNot_Rev 5′- ctactagcggccgctcagtctttttcaaccctcactcgaatctcttgtt -3′ 63.0 for Ruby-cpPDZ stitch 
IRES-3'_seq_For 5′- ccacggggacgtggttttcc -3′ 61.0 
 
Forward sequencing primer for 3' 
end of IRES sequence 
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LOV-5'_seq_Rev 5′- actatcggacgcgaatataatggg -3′ 58.0 Reverse primer from 5' end of 
LOV  
P1_CRISPR_LAT_fwd 5′- cacagtcagctggacgcacactcagc -3′ 65.0 LAT CRISPR 
P2_CRISPR_LAT_Rev 5′- ctggcacccaaggtaggggacc -3′ 64.0 LAT CRISPR 
P3_CRISPR_LAT_fwd 5′- ctgccacctggtgcctacctgc -3′ 65.0 LAT CRISPR 
P4_CRISPR_LAT_Rev 5′- ggttcacgctcactcccacaccagg -3′ 66.0 LAT CRISPR 
P1_CRISPR_Mlu_fwd 5′- tagtagacgcgtgccacccacagtcagctggacgcacactcagc -3′ 73.9 LAT gDNA cloning 
P2_CRISPR_LAT_Not_Rev 5′- ctactagcggccgcctggcacccaaggtaggggacc -3′ 75.0 LAT gDNA cloning 
LATtm-pep_STOP_Not_Rev 5′- taggcggccgctcacacccaggtatcgatgctgcctctacttccactgcctggcagtctgtgg -3′ 69.4 LAT-TMpep cloning 
BglII_nMag_Fwd 5′- tagagatctggcggaagcggaggtagtggac -3′ 64.1 Magnets cloning 
BglII_FKBP_Fwd 5′- tagagatctggcggaagcggaggtagtggcgtccaagtcgaaaccattagtcc -3′ 61.4 CID cloning 
MluI_ATGpMag_Fwd 5′- tagacgcgtgccaccatgcacactctttacgcccctg -3′ 66.6 Magnets cloning 
MluI_ATG_FRB 5′- TAGacgcgtGCCACCATGatcctctggcatgagatgtggcatg -3′ 67.2 CID cloning 
FRB_Spe_Rev 5′- ctaactagtctttgagattcgtcggaacacatg -3′ 59.7 CID cloning 
pMag3X_Spe_Rev 5′- ctaactagtctcagtctcgcactgaaaccccatgc -3′ 63.3 Magnets cloning 
pMag_Spe_Rev 5′- ctaactagtttcggtttcgcactggaatcc -3′ 60.5 Magnets cloning 
Bam_FRB_Fwd 5′- tagggatccggaagtatcctctggcatgagatgtggcatg -3′ 63.0 CID cloning 
FRB-pep_Not_Rev 5′- ctagcggccgctcacacccaggtatcgcatgctgcctctacttccggagccctttgagattcgtcggaacac   -3′ 57.0 FRB spacer 
Bam_qGFP_Fwd 5′- tagggatccggaagtgtgagcaagggcgaggagctg -3′ 62.8 GFP spacer 
qGFP-pep_Not-Rev 5′- ctagcggccgctcacacccaggtatcGATGCTGCCTCTacttccggagcccttgtacagctcgtccatgccgag  -3′ 63.0 GFP spacer 
Spe_Ruby_fwd 5′- tagtagactagtgtgtctaagggcgaagagctgatc -3′ 59.1 Ruby for CRISPR vector 
CD6_CRISPR1_Fwd 5′- CACCGCTCCCGTTTGTCAGACGGAC -3′ N/A CRISPR oligo 
CD6_CRISPR1_Rev 5′- AAACGTCCGTCTGACAAACGGGAGC -3′ N/A CRISPR oligo 
CD6_CRISPR2_Fwd 5′- CACCGAGTGGCATTAGCTGCTACGC -3′ N/A CRISPR oligo 
CD6_CRISPR2_Rev 5′- AAACGCGTAGCAGCTAATGCCACTC -3′ N/A CRISPR oligo 
LATtm-PDZ_Fwd 5′- gccacagactgccaggatccggaagtccagaacttggatttagcatatcagg -3′ 58.0 LAT-PDZ fusion 
LATtm-PDZ_Rev 5′- cctgatatgctaaatccaagttctggacttccggatcctggcagtctgtggc -3′ 63.0 LAT-PDZ fusion 
LATint 5′- ttgaactggatgccccttggatac -3′ 60.0  
HA-Liker_Rev 5′- ccgtacgacgtaccagactacgcaGGCTCCGGGAGCGGAAGC -3′ 64.4 Overlap extension HA to the Zdk  
ZDK-Linker_fwd 5′- ggctccgggagcggaagcgtggataacaaattcaataaagaaaagacacg -3′ 55.6 Overlap extension HA to the Zdk  
LOV2_C450G_fwd 5′- gggaagaaacggcaggtttctacaagg -3′ 58.0 C/G mutation LOV2 
LOV2_C450G_Rev 5′- ccttgtagaaacctgccgtttcttccc -3′ 58.0 C/G mutation LOV2 
QC_C450G_Rev 5′- aaatttcttcacggctatattctgtcaactgc -3′ 58.0 QuikChange Q5 
LOV2_C450S_Fwd 5′- gggaagaaactccaggtttctacaagg -3′ 58.0 C/S mutation LOV2 
LOV2_C450S_Rev 5′- ccttgtagaaacctggagtttcttccc -3′ 58.0 C/S mutation LOV2 
AsiSI-NTOM_fwd 5′- tagtaggcgatcgccaccatggtgggccgcaacagc -3′ 62.0 AsiSI NTOM instert 
LATint_Mlu_Fwd 5′- tagtagacgcgtccaggcagttacgacagcacatcc -3′ 60.0 Mlu instert LATint 
NTOM-LAT_Fwd 5′- cgccgcagcgatccgaactttaaaggtagtccaggcagttacgacagcacatcctcag -3′ 63.0 NTOM-LATint fusion 
NTOM-LAT_Rev 5′- ctgaggatgtgctgtcgtaactgcctggactacctttaaagttcggatcgctgcggcg -3′ 63.0 NTOM-LATint fusion 
MluI-NTOM_fwd 5′- tagtagacgcgtgccaccatggtgggccgcaacagc -3′ 67.7  
Spe-NTOM_Rev 5′- tagtagactagttttaaagttcggatcgctgcggcg -3′ 65.0  
CRY2-Mlu_fwd 5′- Tagacgcgtgccaccatgaagatggacaaaaagactatagtttgg -3′ 59.0 CRY2 cloning 
CRY2PHR-Spe_Rev 5′- ctactaactagttgctgctccgatcatgatctgtgc -3′ 61.4 CRY2 cloning 
Page 231
CRY2FL-Spe_Rev 5′- ctactaactagttttgcaaccattttttcccaaacttgtag -3′ 57.3 CRY2 cloning 
CRY2(535)-Spe_Rev 5′- ctactaactagtaacagccgaaggtacttgttggtc -3′ 59.3 CRY2 cloning 
CRY2(515)-Spe_Rev 5′- ctactaactagtaatggtattagcccctaaggcctcg -3′ 60.0 CRY2 cloning 
CRY2(W349R)_Fwd 5′- ggaatgagagagcttcgggctaccggatgg -3′ 62.0 W/R overlap extension 
CRY2(W349R)_Rev 5′- ccatccggtagcccgaagctctctcattcc -3′ 62.0 W/R overlap extension 
CRY2(L348F)_Fwd 5′- ggaatgagagagttttgggctaccggatgg -3′ 62.0 L/F overlap extension 
CRY2(L348F)_Rev 5′- ccatccggtagcccaaaactctctcattcc -3′ 62.0 L/F overlap extension 
CRY2(G337E)_Fwd 5′- gacaaggcaggaccgagtatccgttggtggatg -3′ 68.0 G/E overlap extension 
CRY2(G337E)_Rev 5′- catccaccaacggatactcggtcctgccttgtc -3′ 68.0 G/E overlap extension 
CRY2-W734R_Fwd 5′- gaagtttcttctccttccagccaaatggggaatgaagtatttc -3′ 57.0 W/R overlap extension 
CRY2-W374R_Rev 5′- gaaatacttcattccccatttggctggaaggagaagaaacttc -3′ 57.0 W/R overlap extension 
CD6-3_fwd 5′- caccgttgcacttcacgcccggccg -3′ 68.0 CD6 cloning 
CD6-3_Rev 5′- aaaccggccgggcgtgaagtgcaac -3′ 68.0 CD6 cloning 
LATint-YtoF-Spe_Fwd 5′- tagtagactagtccaggcagtttcgacagcacatcctcag -3′ 65 LAT Y-to-F cloning 
CD6_SpeI_fwd 5′- tagtagactagtgccaccatgtggctcttcttcgggatcactgg -3′ 64.0 CD6 cloning 
CD6_MluI_fwd 5′- tagtagacgcgtgccaccatgtggctcttcttcgggatcactgg -3′ 64.0 CD6 cloning 
CD6_MluKO_Fwd 5′- ggtggagcacgcctgccgcagcg -3′ 65.0 CD6 MluI knockout 
CD6_MluKO_Rev 5′- cgctgcggcaggcgtgctccacc -3′ 63.0 CD6 MluI Knockout 
CD6_STOP-Not 5′- ctactagcggccgcctaggctgcgctgatgtcatcgtagtc -3′ 64.0 CD6 cloning 
CD6_Bam-STOP_Rev(DP) 5′- tcatcaggatccccggctgcgctgatgtcatcgtagtc -3′ 63.0 CD6 cloning 
CD6_AsiSI_Fwd 5′- tagtaggcgatcgcgccaccatgtggctcttcttcgggatcactgg -3′ 64.0 CD6 cloning  
Zeta_Ex1_1CRISPR_Fwd 5′- caccggtggaaggcgcttttcaccg -3′ N/A Zeta CRISPR gRNA oligo 
Zeta_Ex1_1CRISPR_Rev 5′- aaaccggtgaaaagcgccttccacC -3′ N/A Zeta CRISPR gRNA oligo 
Zeta_Ex1_2CRISPR_Fwd 5′- caccgtaatcggaactgtgcctgc -3′ N/A Zeta CRISPR gRNA oligo 
Zeta_Ex1_2CRISPR_Rev 5′- aaacgcaggcacagttgccgattac -3′ N/A Zeta CRISPR gRNA oligo 
Mlu_BFP_Fwd 5′- tagtagacgcgtgccaccatgagcgagctgattaaggagaacatgc -3′ 61.0 BFP into CRISPR construct 
BFP_BamSTOP_REV 5′- tcatcaggatccattaagcttgtgccccagtttgctaggg -3′ 65.0  
CD3zeta_gDNA_MluFwd 5′- acgcgtcaaaggccccacagtcctcc -3′ 59.0  
CD3zeta_gDNA_NotRev 5′- gcggccgcgaggagggaggatttgaagg -3′ 59.0  
Foxo_BamSTOP_Rev 5′- caccgtaatcggcaactgtgcctgc -3′ 70.0 Foxo1 reporter cloning 
Foxo_MluKO_fwd 5′- cgtcccgccgcaacgcctggggcaacc -3′ 72.0 Foxo1 MluI knockout 
Foxo_MluKO_Rev 5′- ggttgccccaggcgttgcggcgggacg -3′ 72.0 Foxo1 MluI knockout 
Foxo1_AsiSI_fwd 5′- tagtaggcgatcgccaccatggccgaggcgcctcaggtgg -3′ 71.0 Foxo1 cloning 
Foxo_IF_Fwd 5′- gagaattctcacgcggccaccatggccgaggcgcctcaggtggt -3′ 70.0 Foxo1 InFusion 
Foxo_IF_Rev 5′- ggcgaccggtggatcggatcccgggcccgc -3′ 70.0 Foxo1 InFusion 
FoxoGib_Fwd 5′- gctctcgagaattctcacgcgtatggccgaggcgcctcag -3′ 72.0 Foxo1 Gibson 
FoxoGib_Rev 5′- ccatggtggcgaccggtggatccgggcccgcggtaccgtcg -3′ 72.0 Foxo1 Gibson 
CD6_Gib_Fwd 5′- ggagctctcgagaattctcacgcgtatgtggctcttcttcggg -3′ 75.0 CD6 Gibson 
CD6_Gib_Rev 5′- caggtcgactctagagtcgcggccgctaggctgcgctgatgtc -3′ 75.0 CD6 Gibson 
Foxo-3'_seq 5′- tgccccacacctcgggtatgaacc -3′ 64.0 Foxo sequencing oligo 
1166-SFFV_5'seq 5′- cttctgttcgcgcgcttctgcttc -3′ 65.0 Sequencing from pHR promoter 
1167-WPRE_3'seq 5′- ccagaggttgattatcgataagc -3′ 65.0 Sequencing from WPRE sequence 
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Appendix B  
Construct Notes 
pHR-LATdblmut-Ruby CRISPR-proof LAT 
pHR-LATmut-Ruby gRNA site mutant LAT 
pHR-LAT(AGT)-Ruby LAT ser mutant 
pHR-LAT-Ruby Wildtype LAT 
pHR-LAT-TM-LOVpep LAT transmembrane LOVpep fusion Bam KO 
pHR-LAT-TM-LOVpep (No AGT) LAT transmembrane LOVpep fusion Bam site intact 
pHR-LAT-TM-LOV2 LAT transmembrane LOV2 fusion 
pHR-LATmutTM-LOV2 LAT transmembrane LOV2fusion Bam KO 
pHR-LATmutTM-LOV2 (No AGT) LAT transmembrane LOV2fusion BamHI site intact 
pHR-LAT-LOVpCA Constitutively active LOVpep 
pHR-LATmutTM-LOVpCA Constitutively active LOVpep CRISPR proof 
pHR-Zdk-LATint-Ruby Zdk-LAT fusion protein 
pHR-ePDZb1-LATint-Ruby High affinity PDZ LAT fusion protein 
pHR-ePDZb-LATint-Ruby Mid affinity fusion protein 
cpPDZ-LATint-Ruby Low affinity PDZ fusion protein 
pHR-ZDK-LATint-Ruby-IRES-LATtmLOV2 LOVTRAP IRES construct 
pHR-ePDZb1-LATint-Ruby-IRES-LATtmLOVpep High affinity TULIPs IRES construct 
pHR-ePDZb-LATint-Ruby-IRES-LAT-TM-LOVpep Mid affinity TULIPs IRES construct  
pHR-cpPDZ-LATint-Ruby-IRES-LAT-TM-LOVpep Low affinity TULIPs IRES construct  
pHR-ePDZb1-LATint-Ruby-IRES-LATtmLOVpCA Constitutively active IRES TULIPs construct 
pHR-ZDK-LAT(AGT)int-Ruby-IRES-LATtmLOV2 LOVTRAP IRES construct PAM KO 
pHR-ePDZb1-LAT(AGT)int-Ruby-IRES-LATtmLOVpep High affinity TULIPs IRES construct PAM KO 
pHR-ePDZb-LAT(AGT)int-Ruby-IRES-LAT-TM-LOVpep Mid affinity TULIPs IRES construct PAM KO 
pHR-cpPDZ-LAT(AGT)int-Ruby-IRES-LAT-TM-LOVpep Low affinity TULIPs IRES construct PAM KO  
pHR-ePDZb1-LAT(AGT)int-Ruby-IRES-LATtmLOVpCA Constitutively active IRES TULIPs construct PAM KO 
pHR-ZDK-LAT(AGT)int-Ruby-IRES-LATmutTMLOV2 LOVTRAP IRES construct CRISPR proof 
pHR-ePDZb1-LAT(AGT)int-Ruby-IRES-LATmutTMLOVpep High affinity TULIPs IRES construct CRISPR proof 
pHR-ePDZb-LAT(AGT)int-Ruby-IRES-LAT-mutTM-LOVpep Mid affinity TULIPs IRES construct CRISPR proof 
pHR-cpPDZ-LAT(AGT)int-Ruby-IRES-LAT-mutTM-LOVpep Low affinity TULIPs IRES construct CRISPR proof  
pHR-ePDZb1-LAT(AGT)int-Ruby-IRES-LATmutTmLOVpCA Constitutively active IRES TULIPs construct CRISPR proof 
pHCr[LAT1]-GFP LAT CRISPR construct 
pHCr[LAT1]-GFP LAT CRISPR construct 
pHR-mTagBFP BFP 
pHRSV-IFP2-Erk2 Mid Erk expression reporter 
pHR-IFP2-Erk2 High Erk expression reporter 
pHRI-IFP2-Erk2 Low Erk expression reporter 
pHR-Lck  
pHR-ICAM-1  
pHR-ZAP70-Ruby  
pHR-CD3 CD3 chains 
pHR-(1G4)-TCR 1G4 TCR subunits 
pHR-Zdk-LAT(AGT)int-ePDZb1-Ruby LOVTRAP-TULIPs fusion high affinity 
pHR-Zdk-LAT(AGT)int-ePDZb-Ruby LOVTRAP-TULIPs fusion mid affinity 
pHR-Zdk-LAT(AGT)int-cpPDZ-Ruby LOVTRAP-TULIPs fusion low affinity 
pHR-cpPDZ-LAT(AGT)int-Zdk-Ruby LOVTRAP-TULIPs fusion low affinity 
pHR-ePDZb-LAT(AGT)int-Zdk-Ruby LOVTRAP-TULIPs fusion mid affinity 
pHR-ePDZb1-LAT(AGT)int-Zdk-Ruby LOVTRAP-TULIPs fusion high affinity 
pHR-cpPDZ-LAT(AGT)int-Ruby-Zdk LOVTRAP-TULIPs fusion low affinity 
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pHR-ePDZb-LAT(AGT)int-Ruby-Zdk LOVTRAP-TULIPs fusion mid affinity 
pHR-ePDZb1-LAT(AGT)int-Ruby-Zdk LOVTRAP-TULIPs fusion high affinity 
pHR-LAT(AGT)-Zdk-Ruby  
pHR-LAT(AGT)-ePDZb1-Ruby  
pHR-Zdk-LAT(AGT)int-Ruby-cpPDZ LOVTRAP-TULIPs fusion low affinity 
pHR-Zdk-LAT(AGT)int-Ruby-ePDZb LOVTRAP-TULIPs fusion mid affinity 
pHR-Zdk-LAT(AGT)int-Ruby-ePDZb1 LOVTRAP-TULIPs fusion high affinity 
pHCM-CD43:45cyto-qGFP  
pHR-Junk-NTOM-LOV2F Intermediate NTOM cloning vector 
pHR-Junk-NTOM-LOVpF Intermediate NTOM cloning vector 
pHR-LATmutTM-LOV2-IRES-NTOM20-IFP2-LOVpF  
pHR-LATmutTM-LOV2-IRES-NTOM20-IFP2-LOVpep  
pHR-LATmutTM-LOVpep-IRES-NTOM20-iRFP670-LOV2  
pHR-LATmutTM-LOVpep-IRES-NTOM20-IFP2-LOV2  
pHR-LATmutTM-LOVpep-IRES-NTOM20-IRFP670-LOV2  
pHR-LATmutTM-LOVpF-IRES-NTOM20-IFP2-LOV2  
pHR-LATmutTM-LOV2-IRES-NTOM20-IRFP670-LOVpep  
pHR-LATmutTM-LOV2F-IRES-NTOM20-IFP2-LOVpF  
pHR-FcRH5-Ruby TDB target 
pHR-CaaX-IFP2 Membrane marker 
pHR-Clover Clover 
pHR-CD86tm-Fv Fv membrane tag 
pHR-LATmutTM-ePDZb1-LAT(AGT)-Ruby ePDZb1 LAT fusion protein 
pHR-pMagFast2-LAT(AGT)-Ruby Magnets LAT construct 
pHR-LATmutTM-nMagHigh1  Magnets LAT transmembrane constructs 
pHR-FRB-ZAP70-Citrine CID ZAP70 
pHR-CBP-P2A-Csk  
pHR-ePDZb1-LAT(AGT)-Ruby-IRES-LATmutTM-FRBpep  
pHR-ePDZb1-LAT(AGT)-Ruby-IRES-LATmutTM-pep Truncated TULIPs constructs 
pHR-LATmutTM-FKBP(Fv)  
pHR-LATmutTM-FRBpep  
pHR-IRES-LATmutTM-LOVpepCA  
pHR-IRES-LATmutTM-LOVpep  
pHR-IRES-LATmutTM-LOV2  
pHR-LATmutTM-qGFPpep  
pHR-FRB-LAT(AGT)-Ruby  
pHR-FRB-LAT(AGT)-Ruby-IRES-LATmutTM-FKBP CID LAT system 
pHR-pMagFast2-LAT(AGT)-Ruby-IRES-LATmutTM-nMagHigh1 Magnets LAT system 
pHCr[x] CRISPR 
pHCr[x]-Ruby CRISPR 
pHCr[x]-eGFP CRISPR 
pHCr[x]-mTagBFP CRISPR 
pHCr[CD6-1]-Ruby CD6 CRISPR 
pHCr[CD6-2]-Ruby CD6 CRISPR 
pHCr[CD6-1.1]-Ruby CD6 CRISPR 
pHCr[CD6-1.2]-Ruby CD6 CRISPR 
pHCr[CD6-2.1]-Ruby CD6 CRISPR 
pHCr[CD6-2.2]-Ruby CD6 CRISPR 
pHR-myrZDK-LAT(AGT)-Ruby Myristoylated ZDK 
pHR-LATmutTM-LOV(C450G) Photo-nonresponsive LOV2 domain 
pHR-HA-Zdk-LAT(AGT)-Ruby HA-tagged Zdk 
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pHR-LATmutTM-LOV2(V416T) Fast-cycling LOV2 
pHR-GFP-Erk2  
pHRI-myrZdk-LAT(AGT)-Ruby Low expression myrZdk construct 
pHR-Zdk-LAT(AGT)-Ruby-IRES-LATmutTM-LOV2(C450G)  
p8.91  
pMD2.G  
pHR-LATmutTM-LOV2(C450S)  
pHR-TCR G10 αβ-qGFP  
pHR-TCR 1G4 αβ-qGFP  
pHRI-LATdblmut-Ruby Low expression LAT construct 
pHRI-ePDZb1-LAT(AGT)-Ruby Low expression, high affinity PDZ construct 
pHRSV-Zdk-LAT(AGT)-Ruby Mid expression Zdk construct 
pHR ZAP70-BFP  
pHRSV-LATdblumut-Ruby Mid expression LAT vector 
pHRSV-ePDZb1-LAT(AGT)-Ruby Mid expression, high affinity construct 
pHR-ZAP70-qGFP (K369R)  
pHR-ZAP70-Ruby (K369R)  
pHCM-CD45(cyto)-qGFP  
pHR-ZAP70-BFP-K369R  
pHRI-ZDK-LAT(AGT)-Ruby Low expression Zdk construct 
pHR-mRuby2 RFP 
pHR-NTOM-IFP2-LOVpep  
pHR-NTOM-IFP2-LOV2  
pHR-NTOM-LOV2 pHR-NTOM-LAT-Ruby 
pHR-Cherry-CaaX Cherry membrane label 
pCRY2ΔNLS-FL-mCherry Full length CRY2 construct 
pCRY2PHR-Cherry CRY2PHR 
pCIBN-pmGFP CaaX GFP CIBN 
pHR-CIBN-pmGFP Same as above, but pHR vector 
pHR-CRY2PHR-LAT(AGT)-Ruby CRY2 LAT system 
pHR-CRY2PHR(L348F)-LAT(AGT)-Ruby Slow cycling 
pHR-CRY2PHR(W349R)-LAT(AGT)-Ruby Fast cycling 
pHR-CRY2(515)-LAT(AGT)-Ruby Truncated CRY2 
pHR-CRY2(535)-LAT(AGT)-Ruby Truncated CRY2 
pHR-CRY2ΔNLS)-LAT(AGT)-Ruby Full length CRY2 
pHR-CRY2PHR(W374A)-LAT(AGT)-Ruby Constitutive 
pHR-CRY2PHR(G337E)-LAT(AGT)-Ruby Dead CRY2 
pHR-CRY2(535;G337E)-LAT(AGT)-Ruby Dead, truncated CRY2 
pHR-CRY2(535;W374A)-LAT(AGT)-Ruby Constitutive, truncated CRY2 
pHu[LAT]R-TagBFP LAT siRNA 
pHu[LAT]R-mCherry LAT siRNA 
pHCr[CD6-1]-BFP CD6 CRISPR 
pHCr[CD6-1]-GFP CD6 CRISPR 
pHR-HAFv86-LOV2 OptoCAR transmembrane 
pHR-myrZDK-Zeta-Ruby OptoCAR signalling 
pBJneo CD6 
pHCr[CD6-3]-BFP CD6 CRISPR 
pHCr[CD6-3]-GFP CD6 CRISPR 
pHR-Zdk-LAT(YtoF)-Ruby Non-functional Zdk LAT fusion 
pHR-LAT (YtoF)-Ruby Non-functional full length LAT 
pHR-HAFv86-LOVpep TULIPs optoCAR 
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pHEFI-HAfv86-LOV2 Intron promoter OptoCAR 
pHEFI-HAfv86-LOV2(C450G) Intron promoter OptoCAR photo-nonresponsive 
pHRI-LATmutTM-LOV2 Low expression LAT transmembrane 
pHRSV-LATmutTM-LOV2 Mid expression LAT transmembrane 
pHR-LATmutTM-LOV2(I539E) Constitutively active LOV2 
pHR-LATmutTM-LOV2(V416L)  Slow cycling LOV2 
pHR-LATmutTM-LOVpep (C450G) Photo-nonresponsive LOVpep 
pHEFI-HAFv86-LOV2(I539E) Intron promoter OptoCAR constitutively active 
pHCr[ZetaEx1.1] CD3 zeta CRISPR  
pHCr[ZetaEx1.2] CD3 zeta CRISPR 
pHCr[ZetaEx1.1]-GFP CD3 zeta CRISPR  
pHCr[ZetaEx1.2]-GFP CD3 zeta CRISPR 
CIBN-CaaX Membrane-bound CIBN 
mCherry-CRY2-iSH2  
ePDZb1-Cherry-Caax  
pcDNA3.1 myc-p110a P110alpha subunit myc tag 
Zeta-LOV2 NO CRISPR CD3 transmembrane LOV2, CRISPR proof 
pHR-ZetaShort CD3 zeta transmembrane domain 
pHR-Zeta-LOV2  CD3zeta- LOV2 fusion 
pHR-Zeta-LOV2(V416L) CD3zeta- LOV2 fusion (slow) 
pHR-Zeta-LOV2(I539E) CD3zeta- LOV2 fusion (constitutively active) 
pHR-Zeta-LOV2(C450G) CD3zeta- LOV2 fusion (photo-nonresponsive) 
Foxo1-wt-EGFP  
Foxo1-mut-EGFP Does not translocate 
pHR-NFAT-GFP:iRFP  
pHRI-BFP-Erk2 Low expression Erk reporter  
pHRSV-BFP-Erk2 Mid expression Erk reporter 
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Appendix C  
The script below was written in BeanShell and run on MicroManager1.4. It was used to automate 
the confocal imaging process. Annotations are denoted in the script by “//”.  
 
//Place to save the image data 
String acqName = "FileName"; 
String saveDir = "FilePath"; 
 
//Number of frames to capture 
int numFramesPre = 5; 
int numFramesDuring = 20; 
int numFramesPost = 35; 
 
//Length of time to expose LED source 
int LEDExposure = 2; //seconds 
 
//Name of Channels to use for the imaging 
String[] channels = {"568Ex - 607Em", "640Ex - 708Em"}; 
Color[] colors = {Color.RED, Color.GREEN}; 
channelGroup = "BlueChannels"; 
//the channel strings 
 
//Exposure Times for each channel required (in ms) 
int[] exposures = {200, 200}; 
 
//Time between frames 
int FrameDelay=1000;  
 
//Whether to show the acquired data, and whether to save it or not 
boolean shouldShow = true; 
boolean shouldSave = true; 
 
 
//***DONT CHANGE BEYOND HERE!!!*** 
 
//Make new channelgroup with blue filter 
channelGroup = "BlueChannels"; 
if (mmc.isGroupDefined(channelGroup)){ 
 mmc.deleteConfigGroup(channelGroup);} 
mmc.defineConfigGroup(channelGroup); 
//Make the 568 Channel 
mmc.defineConfig(channelGroup,channels[0],"TICondenserCassette","State", "2"); //This moves condenser to 450nm 
mmc.defineConfig(channelGroup,channels[0],"RotrWheel","State", "3");  
mmc.defineConfig(channelGroup,channels[0],"Laser_568nm_TTL","State", "1"); //Laser 568nm On  
mmc.defineConfig(channelGroup,channels[0],"Laser_640nm_TTL","State", "0"); //Laser 640nm off 
//mmc.defineConfig(channelGroup,channels[0],"ESIOShutter","OnOff", "1");  
mmc.defineConfig(channelGroup,channels[0],"Core","AutoShutter", "0");  
mmc.defineConfig(channelGroup,channels[0],"Core","Shutter", "ALC");  
//Make the 640 Channel 
mmc.defineConfig(channelGroup,channels[1],"TICondenserCassette","State", "2"); //This moves condenser to 450nm 
mmc.defineConfig(channelGroup,channels[1],"RotrWheel","State", "5");  
mmc.defineConfig(channelGroup,channels[1],"Laser_640nm_TTL","State", "1"); //Laser 640nm On 
mmc.defineConfig(channelGroup,channels[1],"Laser_568nm_TTL","State", "0"); //Laser 568nm Off  
//mmc.defineConfig(channelGroup,channels[1],"ESIOShutter","OnOff", "1");  
mmc.defineConfig(channelGroup,channels[1],"Core","AutoShutter", "0");  
mmc.defineConfig(channelGroup,channels[1],"Core","Shutter", "ALC");  
 
 
//Number of times/positions/slices to repeat the assay on same position 
int numRepetitions=1; 
int numSlices = 1; 
int numPositions = 1; 
 
//stop any acquisitions and refresh 
gui.closeAllAcquisitions(); 
gui.refreshGUI(); 
 
//Create acquisition with defined values 
int numFrames=numFramesPre + numFramesDuring + numFramesPost; 
gui.openAcquisition(acqName, saveDir, numFrames, channels.length, numSlices, numPositions, shouldShow, shouldSave); 
 
//Set the data for the channels in the defined acquisition 
for (int i=0; i<colors.length; i++) 
   gui.setChannelColor(acqName, i, colors[i]); 
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for (int i=0; i<channels.length; i++) 
   gui.setChannelName(acqName, i, channels[i]); 
 
 
//Make sure LED light is off before starting 
mmc.setProperty("CoolLED_TTL", "State", "0"); 
 
gui.clearMessageWindow(); 
 
int i = 0; //Which channels to use  
mmc.setConfig(channelGroup, channels[i]); 
mmc.waitForConfig(channelGroup, channels[i]); 
 
//Start the loop for imaging 
start=System.currentTimeMillis(); //time from begin of acquisition 
 
for (int k=0; k< numRepetitions; k++){ 
 mmc.setExposure(exposures[i]); 
  for (int j=0; j<numFrames; j++) { 
    for (int i=0; i<channels.length; i++) { 
       mmc.setConfig(channelGroup, channels[i]); 
       mmc.waitForConfig(channelGroup, channels[i]); 
    
       //gui.snapAndAddImage(acqName, frame_number, channel_number, slice_number, 
position_number); 
      gui.message("About to snap image: Frame " + (j+1) + ", Channel " + (channels[i]) + " 
now"); 
      gui.snapAndAddImage(acqName, j, i, 0, 0); //Have removed variable for repititions and 
position as never likely to be used 
    } 
    //gui.sleep(2000); //Interval between frames 
    if (j==numFramesPre-1){         //counter j starts from 0, so have minus 1 from value 
     //Turn the light on and off using simple commands 
     mmc.setProperty("TICondenserCassette", "Label", "3-450nm"); 
     mmc.setProperty("CoolLED_TTL", "State", "1"); 
     gui.message("Turning blue light on now!"); 
     //gui.sleep(LEDExposure*1000); //Has to be in ms 
     //mmc.setProperty("CoolLED Shutter", "State", 0); 
    } 
    if (j==numFramesPre+numFramesDuring-1){ 
     mmc.setProperty("CoolLED_TTL", "State", "0"); //turn off the LED  
     gui.message("Turning blue light off now!"); 
    } 
    while ((System.currentTimeMillis() - start) < FrameDelay*(j+1)) {gui.sleep(1);}//time already in ms 
  } 
} 
 
//To end the acquisition 
mmc.setProperty("CoolLED_TTL", "State", "0"); 
mmc.deleteConfigGroup(channelGroup); 
gui.closeAcquisition(acqName); 
gui.refreshGUI(); 
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Appendix D 
The following script was used to interpret calcium flux data from the conjugate fluxing assay 
(Chapter 5). This script is written for use in Matlab. Annotations are denoted in green by “%” 
clearvars -except BigDataMedian BigDataFraction; 
clc; 
%First get the CSV files to import... 
[FileNames, PathName]=uigetfile({'*.csv'},'Select The CSV Files To Import...','MultiSelect', 
'on'); 
if isequal(FileNames,0), 
    clear; 
    return; 
else 
    FileNames = cellstr(FileNames); 
    NumFiles=length(FileNames); 
end 
%% Now get the default settings from user... 
clearvars -except FileNames PathName NumFiles BigDataMedian BigDataFraction 
  
qValues=doInputBox; %This opens dialog with all default values 
drawnow; 
  
% For 2500nM, time = 0:1:600, flux = 0:120 with 50 bins 
% For 500nM,  time = 0:1:600, flux = 0:180 with 75 bins 
  
%Now assign the user inputted values to variables: 
StartTime =     qValues.StartTime; 
EndTime =       qValues.EndTime; 
TimeWindow =    qValues.TimeWindow; 
MinFlux =       qValues.MinFlux; 
MaxFlux =       qValues.MaxFlux; 
NumHistSlices = qValues.NumHistSlices; 
IndoBG =        qValues.IndoBG; 
IndoLObg =      qValues.IndoLObg; 
IndoHIbg =      qValues.IndoHIbg; 
IndoLOcol =     qValues.IndoLOcol; 
IndoHIcol =     qValues.IndoHIcol; 
Timecol =       qValues.Timecol; 
PreDrugTime =   qValues.PreDrugTime; 
InjectionTime = qValues.InjectionTime; 
ThresholdVal =  qValues.ThresholdVal; 
ShowSurfPlots = qValues.ShowSurfPlots; 
ShowIndFits =   qValues.ShowIndFits; 
ShowMeanPlots = qValues.ShowMeanPlots; 
  
%% Retrieve data and derive parameters 
close all; 
for ii = 1:NumFiles, 
    ThisFile = regexprep(FileNames{ii},'\W','');                % Get rid of any characters 
that violate Matlab code 
    ThisFile = ['r' ThisFile(1:end-3)];                               % Remove the csv tag 
from end of filename 
    ThisFileFull=char(strcat(PathName,FileNames(ii)));          % Make complete FilePath 
    RawData.(ThisFile) =csvread(ThisFileFull,1);                % Import the selected file, 
removing header row 
end 
  
h1=fields(RawData);                                             % Get the names of files from 
RawData structure 
for ii = 1:length(h1), 
    ThisFile=char(h1(ii));                                      % The file to work on 
    DerivedData.(ThisFile)=(100*(RawData.(ThisFile)(:,IndoLOcol)-
IndoLObg)./(RawData.(ThisFile)(:,IndoHIcol)-IndoHIbg)) - IndoBG; %Calculation of Derived 
parameter in single column 
    TimeData.(ThisFile)=RawData.(ThisFile)(:,Timecol);          % Puts time data in separate 
stucture 
end 
  
NumTimeSlices=fix((EndTime-StartTime)/TimeWindow);              % Calculate appropriate bounds 
for time axis 
histedges=linspace(MinFlux,MaxFlux,NumHistSlices+1);            % Create bins for Indo-1 ratio 
timeedges=linspace(StartTime,EndTime,NumTimeSlices+1);          % Create bins for Time 
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for ii = 1:length(h1), 
    ThisFile=char(h1(ii));                                      % The file to work on 
    [~,~,TimeBins.(ThisFile)]=histcounts(TimeData.(ThisFile),timeedges);   % Parse time values 
into required bins 
    Data.(ThisFile)=zeros(NumHistSlices+1,NumTimeSlices+1);     % Create Data structure and 
add zero padding so surface displays all data 
    NormData.(ThisFile)=zeros(NumHistSlices+1,NumTimeSlices+1); % Create Normalised Data 
structure and add zero padding so surface displays all data 
     
    for i=1:NumTimeSlices, 
        [N,~] = histcounts(DerivedData.(ThisFile)(TimeBins.(ThisFile)==i),histedges);              
% Bin the Indo-1 data into 
        Data.(ThisFile)(1:NumHistSlices,i)=N'; 
        NormData.(ThisFile)(:,i)=100*(Data.(ThisFile)(:,i)/norm(Data.(ThisFile)(:,i))); 
        NormData.(ThisFile)(isnan(NormData.(ThisFile)))=0; 
         
        if timeedges(i) >= PreDrugTime && timeedges(i) < (PreDrugTime + InjectionTime), 
            NormData.(ThisFile)(:,i)=0; 
        end 
    end 
end 
  
  
  
%% Get Median Values above Threshold 
% User sets a defined value (could do by percentile?) and we use this to 
% index data so only values above it are used to determine median value. 
% Should be able to use the Derived data rather than histogram data 
  
h1=fields(DerivedData); 
  
fig1=figure; 
hold on; 
fig2=figure; 
hold on; 
  
for j=1:length(h1), 
    ThisFile=char(h1(j)); 
    ThisName=ThisFile; 
     
     
    AllFits.(ThisFile)=zeros(NumTimeSlices,6); 
    for i=1:NumTimeSlices, 
        TestY=NormData.(ThisFile)(:,i); 
        ThisFit=createFit(histedges',TestY,ThresholdVal); 
        ThisCoeffs=coeffvalues(ThisFit); 
        AllFits.(ThisFile)(i,:)=ThisCoeffs; 
        if timeedges(i) >= PreDrugTime && timeedges(i) < (PreDrugTime + InjectionTime), 
            AllFits.(ThisFile)(i,:)=NaN; 
        end 
    end 
     
    BGOffset=nanmean(AllFits.(ThisFile)(:,6)); 
    Threshold.(ThisFile)=smooth(AllFits.(ThisFile)(:,5),21) + BGOffset; 
    PreBins=round(PreDrugTime/TimeWindow); 
     
    for i=1:NumTimeSlices 
        ThisThreshold(i)=Threshold.(ThisFile)(i)+BGOffset; 
        ThisData=DerivedData.(ThisFile)(TimeBins.(ThisFile)==i); 
        ThisThreshData = ThisData(ThisData > ThisThreshold(i)); 
        MedianData.(ThisFile)(i)=median(ThisThreshData) - Threshold.(ThisFile)(i); % Correct 
for baseline drift 
        FractionData.(ThisFile)(i)=length(ThisThreshData)/length(ThisData); %%%% This is 
wrong, do count not sum!!!! 
        if timeedges(i) >= PreDrugTime && timeedges(i) < (PreDrugTime + InjectionTime), 
            MedianData.(ThisFile)(i)=NaN; 
            FractionData.(ThisFile)(i)=NaN; 
        end 
    end 
    % Remove background values 
    PreMedian=nanmean(MedianData.(ThisFile)(1:PreBins)); 
    PreFraction=nanmean(FractionData.(ThisFile)(1:PreBins)); 
     
    MedianDataCorr.(ThisFile)=MedianData.(ThisFile)-PreMedian; 
    FractionDataCorr.(ThisFile)=FractionData.(ThisFile)-PreFraction; 
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    disp([ThisFile]); drawnow; 
    figure(fig1); 
    plot(timeedges(2:end),MedianDataCorr.(ThisFile),'DisplayName', [ThisFile ' - Median' ]); 
    xlim([0 EndTime]); 
    set(gca,'XTick',0:30:510) 
    figure(fig2); 
    plot(timeedges(2:end),FractionDataCorr.(ThisFile),'DisplayName', [ThisFile ' - Median' ]); 
    xlim([0 EndTime]); 
    set(gca,'XTick',0:30:510) 
    %ylim([0 1]); 
end 
  
%% Show Surface Plots, if required 
ShowSurfPlots = true; 
if ShowSurfPlots == true, 
     
    %load('HeatColourMap.mat'); 
     
    h1=fields(DerivedData); 
    for ii = 1:length(h1), 
        ThisFile=char(h1(ii)); 
        figure; 
        %surf(timeedges,histedges,NormData.(ThisFile)); 
        imagesc(timeedges,histedges,NormData.(ThisFile)); 
        set(gca,'YDir','normal'); 
        title(ThisFile,'interpreter','none'); 
        %axis square; 
        xlim([0 EndTime]); 
        ylim([0 MaxFlux]); 
        %mycmap=HeatCMap; 
        %colormap(mycmap); 
        xlabel('Time (s)'); 
        ylabel('Indo-1 Ratio'); 
        set(gca,'YDir','normal') 
        set(gca,'XTick',0:30:510) 
        %caxis([0 25]); 
        view([0 90]); 
        hold on; 
        
plot3(timeedges(2:end),Threshold.(ThisFile),repmat(MaxFlux,1,NumTimeSlices),'LineWidth',1,'Col
or','k','LineStyle','--'); 
    end 
end 
  
  
  
  
%% Average Data plots 
h2=fields(MedianDataCorr); 
fig3=figure; 
hold on; 
fig4=figure; 
hold on; 
fig5=figure; 
hold on; 
  
  
sumMedian=0; 
sumFraction=0; 
sumSTDEV = 0; 
for i=1:length(h2), 
     
    tempMedian(i,:) = MedianDataCorr.(h2{i}); 
    tempFraction(i,:) = FractionDataCorr.(h2{i}); 
end 
 MedianDataCorr.Mean = mean(tempMedian()); 
 MedianDataCorr.STDEV = std(tempMedian()); 
 MedianDataCorr.SEM = std(tempMedian()) / sqrt(NumFiles); 
 FractionDataCorr.Mean = mean(tempFraction()); 
 FractionDataCorr.STDEV = std(tempFraction()); 
 FractionDataCorr.SEM = std(tempFraction()) / sqrt(NumFiles); 
  
figure(fig3); 
plot(timeedges(2:end),MedianDataCorr.Mean,'DisplayName', ['Median']); 
xlim([0 EndTime]); 
ylim([-5 20]); 
xlabel('Time (s)'); 
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ylabel('Indo-1 Ratio'); 
  
figure(fig4); 
plot(timeedges(2:end),FractionDataCorr.Mean,'DisplayName', ['Fraction']); 
xlim([0 EndTime]); 
ylim([0 1]); 
xlabel('Time (s)'); 
ylabel('Fraction Activated'); 
  
figure(fig5); 
plot3(timeedges(2:end),MedianDataCorr.Mean,FractionDataCorr.Mean,'DisplayName', h2{j}); 
xlim([0 EndTime]); 
zlim([0 1]); 
xlabel('Time (s)'); 
ylabel('Indo-1 Ratio'); 
axis square; grid on; 
view([-40 34]); 
drawnow; 
  
%% 
%Make some plots wiht shaded errors 
figure; 
shadedErrorBar(timeedges(2:end),MedianDataCorr.Mean,MedianDataCorr.STDEV); 
figure; 
smoothData = smooth(MedianDataCorr.Mean,3,'moving'); 
smoothErr=smooth(MedianDataCorr.SEM,3,'moving'); 
shadedErrorBar(timeedges(2:end),smoothData,smoothErr); 
figure; 
smoothData2 = smooth(FractionDataCorr.Mean,3,'moving'); 
smoothErr2=smooth(FractionDataCorr.SEM,3,'moving'); 
shadedErrorBar(timeedges(2:end),smoothData2,smoothErr2); 
  
%% Make BigData! 
%Change Condition... 
BigDataFraction.Nada=FractionDataCorr; 
BigDataMedian.Nada=MedianDataCorr;  
 
function [ answer ] = doInputBox() 
%UNTITLED2 Summary of this function goes here 
%   Detailed explanation goes here 
  
%Change the box size here 
BoxSize=50; 
  
Title = 'User Inputs for Ca Flux Analysis'; 
Prompt = {}; 
Formats = {}; 
DefAns = struct([]); 
  
Prompt(1,:) = {['Start Time'],['StartTime'],['s']}; 
Formats(1,1).required = 'on'; % StartTime 
Formats(1,1).type = 'edit'; 
Formats(1,1).format = 'integer'; 
Formats(1,1).unitsloc = 'rightmiddle'; 
Formats(1,1).size = BoxSize; % automatically assign the height 
DefAns(1).StartTime=0; 
  
Prompt(2,:) = {['End Time'],['EndTime'],['s']}; 
Formats(1,2).required = 'on'; % EndTime 
Formats(1,2).type = 'edit'; 
Formats(1,2).format = 'integer'; 
Formats(1,2).unitsloc = 'rightmiddle'; 
Formats(1,2).size = BoxSize; % automatically assign the height 
DefAns.EndTime=390; 
  
Prompt(3,:) = {['Time Window'],['TimeWindow'],['s']}; 
Formats(1,3).required = 'on'; % TimeWindow 
Formats(1,3).type = 'edit'; 
Formats(1,3).format = 'integer'; 
Formats(1,3).unitsloc = 'rightmiddle'; 
Formats(1,3).size = BoxSize; % automatically assign the height 
DefAns.TimeWindow=3; 
  
Prompt(4,:) = {['Min Flux'],['MinFlux'],['']}; 
Formats(2,1).required = 'on'; % MinFlux 
Formats(2,1).type = 'edit'; 
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Formats(2,1).format = 'integer'; 
Formats(2,1).size = BoxSize; % automatically assign the height 
DefAns.MinFlux=0; 
  
Prompt(5,:) = {['Max Flux'],['MaxFlux'],['']}; 
Formats(2,2).required = 'on'; % MaxFlux 
Formats(2,2).type = 'edit'; 
Formats(2,2).format = 'integer'; 
Formats(2,2).size = BoxSize; % automatically assign the height 
DefAns.MaxFlux=120; 
  
Prompt(6,:) = {['Flux Bins'],['NumHistSlices'],['']}; 
Formats(2,3).required = 'on'; % NumHistSlices 
Formats(2,3).type = 'edit'; 
Formats(2,3).format = 'integer'; 
Formats(2,3).size = BoxSize; % automatically assign the height 
DefAns.NumHistSlices=50; 
  
Prompt(7,:) = {['Column numbers for the required parameters'],[],[]}; 
Formats(3,2).type = 'text'; 
Formats(3,2).span = [1 2]; 
  
Prompt(8,:) = {['Indo1 (UV-405)'],['IndoLOcol'],['']}; 
Formats(4,1).required = 'on'; % IndoLOcol 
Formats(4,1).type = 'edit'; 
Formats(4,1).format = 'integer'; 
Formats(4,1).size = BoxSize; % automatically assign the height 
DefAns.IndoLOcol=1; 
  
Prompt(9,:) = {['Indo1 (UV-485)'],['IndoHIcol'],['']}; 
Formats(4,2).required = 'on'; % IndoLOcol 
Formats(4,2).type = 'edit'; 
Formats(4,2).format = 'integer'; 
Formats(4,2).size = BoxSize; % automatically assign the height 
DefAns.IndoHIcol=2; 
  
Prompt(10,:) = {['Time (ms)'],['Timecol'],['']}; 
Formats(4,3).required = 'on'; % IndoLOcol 
Formats(4,3).type = 'edit'; 
Formats(4,3).format = 'integer'; 
Formats(4,3).size = BoxSize; % automatically assign the height 
DefAns.Timecol=3; 
  
Prompt(11,:) = {['Background values for Indo-1 parameters'],[],[]}; 
Formats(5,2).type = 'text'; 
Formats(5,2).span = [1 2]; 
  
Prompt(12,:) = {['Indo1 (UV-405)'],['IndoLObg'],['']}; 
Formats(6,1).required = 'on'; % IndoLOcol 
Formats(6,1).type = 'edit'; 
Formats(6,1).format = 'integer'; 
Formats(6,1).size = BoxSize; % automatically assign the height 
DefAns.IndoLObg=0; 
  
Prompt(13,:) = {['Indo1 (UV-485)'],['IndoHIbg'],['']}; 
Formats(6,2).required = 'on'; % IndoLOcol 
Formats(6,2).type = 'edit'; 
Formats(6,2).format = 'integer'; 
Formats(6,2).size = BoxSize; % automatically assign the height 
DefAns.IndoHIbg=0; 
  
Prompt(14,:) = {['Indo-1 Ratio'],['IndoBG'],['']}; 
Formats(6,3).required = 'on'; % IndoLOcol 
Formats(6,3).type = 'edit'; 
Formats(6,3).format = 'integer'; 
Formats(6,3).size = BoxSize; % automatically assign the height 
DefAns.IndoBG=20; 
  
Prompt(15,:) = {['Other parameters to set'],[],[]}; 
Formats(7,2).type = 'text'; 
Formats(7,2).span = [1 2]; 
  
Prompt(16,:) = {['Time before stimulus'],['PreDrugTime'],['s']}; 
Formats(8,1).required = 'on'; % IndoLOcol 
Formats(8,1).type = 'edit'; 
Formats(8,1).format = 'integer'; 
Formats(8,1).unitsloc = 'rightmiddle'; 
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Formats(8,1).size = BoxSize; % automatically assign the height 
DefAns.PreDrugTime=60; 
  
Prompt(17,:) = {['Time needed for Injection'],['InjectionTime'],['s']}; 
Formats(8,2).required = 'on'; % IndoLOcol 
Formats(8,2).type = 'edit'; 
Formats(8,2).format = 'integer'; 
Formats(8,2).unitsloc = 'rightmiddle'; 
Formats(8,2).size = BoxSize; % automatically assign the height 
DefAns.InjectionTime=20; 
  
Prompt(18,:) = {['Indo-1 peak separation value'],['ThresholdVal'],['']}; 
Formats(8,3).required = 'on'; % IndoLOcol 
Formats(8,3).type = 'edit'; 
Formats(8,3).format = 'integer'; 
Formats(8,3).size = BoxSize; % automatically assign the height 
DefAns.ThresholdVal=30; 
  
Prompt(19,:) = {['Show Plots?'],[],[]}; 
Formats(9,2).type = 'text'; 
Formats(9,2).span = [1 2]; 
  
Prompt(20,:) = {['Surface Plots'],['ShowSurfPlots'],['']}; 
Formats(10,1).required = 'on'; % IndoLOcol 
Formats(10,1).type = 'check'; 
Formats(10,1).format = 'logical'; 
DefAns.ShowSurfPlots=false; 
  
Prompt(21,:) = {['Individual Fits'],['ShowIndFits'],['']}; 
Formats(10,2).required = 'on'; % IndoLOcol 
Formats(10,2).type = 'check'; 
Formats(10,2).format = 'logical'; 
DefAns.ShowIndFits=false; 
  
Prompt(22,:) = {['Mean Plot'],['ShowMeanPlots'],['']}; 
Formats(10,3).required = 'on'; % IndoLOcol 
Formats(10,3).type = 'check'; 
Formats(10,3).format = 'logical'; 
DefAns.ShowMeanPlots=true; 
  
Options.AlignControls = 'on'; 
  
  
answer = inputsdlg(Prompt,Title,Formats,DefAns,Options); 
  
end 
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Appendix E  
The following script was written in Matlab for the purpose of peak separation from the GFP 
reporter and CD69 data, Chapter 5. Annotations are denoted by “%” 
clear; 
clc; 
close all; 
%%Find background variance value from negative control 
%First get the CSV files for the background data 
[FileNames, PathName]=uigetfile({'*.csv'},'Select The CSV Files To Import...','MultiSelect', 
'on'); 
if isequal(FileNames,0), 
    clear; 
    return; 
else 
    FileNames = cellstr(FileNames); 
    NumFiles=length(FileNames); 
end 
  
clearvars -except FileNames PathName NumFiles 
  
% Retrieve data 
  
close all; 
for ii = 1:NumFiles, 
    ThisFile = regexprep(FileNames{ii},'\W','');                % Get rid of any characters 
that violate Matlab code 
    ThisFile = ThisFile(1:end-3);                               % Remove the csv tag from end 
of filename 
    ThisFileFull=char(strcat(PathName,FileNames(ii)));          % Make complete FilePath 
    RawData.(ThisFile) =csvread(ThisFileFull,1);                % Import the selected file, 
removing header row 
    tempData1 = RawData.(ThisFile)(:,1); 
    tempData1 = tempData1(tempData1>0); 
    tempData2 = RawData.(ThisFile)(:,2); 
    tempData2 = tempData2(tempData2>0); 
    %LogData.(ThisFile). = zeros(length(,2); 
    LogRawData.(ThisFile).GFP = log10(tempData1); 
    LogRawData.(ThisFile).R670 = log10(tempData2); 
end 
  
MinFlux=1; %Consider entering these values from the input box in the future. 
MaxFlux=100000; 
NumHistSlices=1000; 
  
histedges=linspace(log10(MinFlux),log10(MaxFlux),NumHistSlices+1); 
  
h1=fields(LogRawData); 
for ii = 1:length(h1), 
    ThisFile=char(h1(ii));                                      % The file to work on 
    BinData.(ThisFile).GFP=zeros(NumHistSlices+1,1);     % Create Data structure and add zero 
padding so surface displays all data 
    BinData.(ThisFile).R670=zeros(NumHistSlices+1,1);     % Create Data structure and add zero 
padding so surface displays all data 
    [N,~] = histcounts(LogRawData.(ThisFile).GFP,histedges);              % Bin the Indo-1 
data into 
    BinData.(ThisFile).GFP(1:NumHistSlices)=N'; 
    [N,~] = histcounts(LogRawData.(ThisFile).R670,histedges);              % Bin the Indo-1 
data into 
    BinData.(ThisFile).R670(1:NumHistSlices)=N'; 
end 
  
%% 
%Define background peak for both variables 
fig1=figure; 
hold on; 
fig2=figure; 
hold on; 
for j=1:length(h1), 
    ThisFile=char(h1(j)); 
    ThresholdGFP =2.5; 
    ThresholdR670 =2.25; 
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    %Define the background curve for GFP channel (NFAT reporter) 
    TestYGFP=BinData.(ThisFile).GFP; 
    %        ThisFit=createFit(histedges',TestYR670,ThresholdR670); 
    %        ThisFit=createFitNoThresh(histedges',TestYR670); 
    smoothDataGFP=smooth(TestYGFP,51); 
     
     
    figure(fig1); 
    plot(histedges',TestYGFP); 
    hold on; 
    plot(histedges',smoothDataGFP); 
    xlim([0 5]); 
     
    bgGFP=smoothDataGFP; 
     
    %Repeat and find the background curve for the R670 channel (CD69) 
    TestYR670=BinData.(ThisFile).R670; 
    %        ThisFit=createFit(histedges',TestYR670,ThresholdR670); 
    %        ThisFit=createFitNoThresh(histedges',TestYR670); 
    smoothDataR670=smooth(TestYR670,51); 
     
    figure(fig2); 
    plot(histedges',TestYR670); 
    hold on; 
    plot(histedges',smoothDataR670); 
    xlim([0 5]); 
     
    bgR670=smoothDataR670; 
    hold on; 
     
end 
% %% 
%can now use this proxy background peak to perform background subtraction 
%calculations. Replace this variable by using appropriate controls during 
%the FACS run. 
  
%% Now that you have defined the background values proceed to the rest of the data 
clearvars -except bgR670 bgGFP pBGR670 pBGGFP offsetR670 offsetGFP 
[FileNames, PathName]=uigetfile({'*.csv'},'Select The CSV Files To Import...','MultiSelect', 
'on'); 
if isequal(FileNames,0), 
    clear; 
    return; 
else 
    FileNames = cellstr(FileNames); 
    NumFiles=length(FileNames); 
end 
 
for ii = 1:NumFiles, 
    ThisFile = regexprep(FileNames{ii},'\W','');                % Get rid of any characters 
that violate Matlab code 
    ThisFile = ThisFile(1:end-3);                               % Remove the csv tag from end 
of filename 
    ThisFileFull=char(strcat(PathName,FileNames(ii)));          % Make complete FilePath 
    RawData.(ThisFile) =csvread(ThisFileFull,1);                % Import the selected file, 
removing header row 
    tempData1 = RawData.(ThisFile)(:,1); 
    tempData1 = tempData1(tempData1>0); 
    tempData2 = RawData.(ThisFile)(:,2); 
    tempData2 = tempData2(tempData2>0); 
    %LogData.(ThisFile). = zeros(length(,2); 
    LogRawData.(ThisFile).GFP = log10(tempData1); 
    LogRawData.(ThisFile).R670 = log10(tempData2); 
end 
  
MinFlux=1; 
MaxFlux=100000; 
NumHistSlices=1000; 
  
histedges=linspace(log10(MinFlux),log10(MaxFlux),NumHistSlices+1);            % Create bins 
for Indo-1 ratio 
  
h1=fields(LogRawData); 
for ii = 1:length(h1), 
    ThisFile=char(h1(ii));                                      % The file to work on 
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    BinData.(ThisFile).GFP=zeros(NumHistSlices+1,1);     % Create Data structure and add zero 
padding so surface displays all data 
    BinData.(ThisFile).R670=zeros(NumHistSlices+1,1);     % Create Data structure and add zero 
padding so surface displays all data 
    [N,~] = histcounts(LogRawData.(ThisFile).GFP,histedges);              % Bin the Indo-1 
data into 
    BinData.(ThisFile).GFP(1:NumHistSlices)=N'; 
    [N,~] = histcounts(LogRawData.(ThisFile).R670,histedges);              % Bin the Indo-1 
data into 
    BinData.(ThisFile).R670(1:NumHistSlices)=N'; 
end 
%% smooth and plot data 
h1=fields(LogRawData); 
fig3=figure; 
hold on; 
fig4=figure; 
hold on; 
for j=1:length(h1), 
    ThisFile=char(h1(j)); 
    ThresholdGFP =2.5; 
    ThresholdR670 =2.7; 
     
    TestYGFP=BinData.(ThisFile).GFP; 
    smoothData=smooth(TestYGFP, 51); 
    %        ThisFit=createFit(histedges',TestYGFP,ThresholdGFP); 
    %        ThisFit=createFitNoThresh(histedges',TestYGFP); 
    figure(fig3); 
    subplot(4,6,j); %should proably figure out a better way to layout theses figures  
    plot(histedges',TestYGFP); 
    hold on; 
    plot(histedges',smoothData) 
    xlim([0 5]); 
    allSmooth.(ThisFile).GFP=smoothData;%Think about making the smoothData bit an input 
variable that can be changed day to day. 
     
    TestYR670=BinData.(ThisFile).R670; 
    smoothData=smooth(TestYR670, 51); 
    %        ThisFit=createFit(histedges',TestYR670,ThresholdR670); 
    %        ThisFit=createFitNoThresh(histedges',TestYR670); 
    figure(fig4); 
    subplot(4,6,j); 
    plot(histedges',TestYR670); 
    hold on; 
    plot(histedges',smoothData); 
    xlim([0 5]); 
    allSmooth.(ThisFile).R670=smoothData; 
end 
%% 
%Calculate the background peak from your data and subtract the background 
%Need to make this into a loop for all of the data... 
h1=fields(LogRawData); 
fig5=figure; 
hold on; 
fig6=figure; 
hold on; 
  
%Calculate shift in amplitude between background and data background peak. 
%Plot background data against samples and show background subtracted data. 
for j=1:length(h1), 
    ThisFile=char(h1(j)); 
    smoothDataR670=allSmooth.(ThisFile).R670; 
     
    [bgR670max, bgR670idx] = max(bgR670); 
    bgR670xval = max(histedges(bgR670max == bgR670)); 
%     mask1 = (histedges < bgR670xval-(offsetR670/1000)); %This is if using proxy background  
    mask1 = (histedges < bgR670xval); 
    z0 = 5; 
    tol = 0.0001; 
    token=1; 
    prevSum = 1e6; 
    count = 0; 
    while token 
        newSum = (z0 * bgR670(mask1)) - smoothDataR670(mask1); 
        newSum = sum(sqrt((newSum).^2)); 
         
        if newSum > prevSum 
            token = 0; 
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        else 
            prevSum=newSum; 
            z0=z0-tol; 
        end 
         
        count = count + 1; 
         
    end 
    disp(z0); 
    disp(count); 
    figure(fig5); 
    subplot(4,6,j); 
    plot(histedges,smoothDataR670); 
    hold on 
    plot(histedges,bgR670); 
    plot(histedges,z0*bgR670); 
%     plot(histedges,pBGR670); 
%     plot(histedges,z0*pBGR670); 
    xlim([0 5]); 
    bgCorrR670=smoothDataR670-(z0*bgR670); 
%     bgCorrR6702=smoothDataR670-(z0*pBGR670); 
    plot(histedges,bgCorrR670); 
%     plot(histedges,bgCorrR6702'); 
    allCorr.(ThisFile).R670=bgCorrR670; 
%     allCorr2.(ThisFile).R670=bgCorrR6702; 
    allBgAdjusted.(ThisFile).R670=z0*bgR670; 
%     allBgAdjusted2.(ThisFile).R670=z0*pBGR670; 
end 
% z0=0:tol:5; 
% newSum = (z0 .* bgR670(mask1)) - smoothDataR670(mask1); 
% newSum = sum(sqrt((newSum).^2)); 
% plot(z0,newSum); 
  
%Repeat for GFP values 
for j=1:length(h1), 
    ThisFile=char(h1(j)); 
    smoothDataGFP=allSmooth.(ThisFile).GFP; 
     
    [bgGFPmax, bgGFPidx] = max(bgGFP); 
    bgGFPxval = max(histedges(bgGFPmax == bgGFP)); 
%     mask1 = (histedges < bgGFPxval-(offsetGFP/1000)); 
    mask1 = (histedges < bgGFPxval); 
    z0 = 5; 
    tol = 0.0001; 
    token=1; 
    prevSum = 1e6; 
    count = 0; 
    while token 
        newSum = (z0 * bgGFP(mask1)) - smoothDataGFP(mask1); 
        newSum = sum(sqrt((newSum).^2)); 
         
        if newSum > prevSum 
            token = 0; 
        else 
            prevSum=newSum; 
            z0=z0-tol; 
        end 
         
        count = count + 1; 
         
    end 
    disp(z0); 
    disp(count); 
    figure(fig6); 
    subplot(4,6,j); 
    plot(histedges,smoothDataGFP); 
    hold on; 
    plot(histedges,bgGFP); 
    plot(histedges,z0*bgGFP); 
%     plot(histedges,pBGGFP); 
%     plot(histedges,z0*pBGGFP); 
    xlim([0 5]); 
    bgCorrGFP=smoothDataGFP-(z0*bgGFP); %subtract actual background peak from data 
%     bgCorrGFP2=smoothDataGFP-(z0*pBGGFP);%subtract proxy background peak from data 
    plot(histedges,bgCorrGFP); 
%     plot(histedges,bgCorrGFP2); 
    allCorr.(ThisFile).GFP=bgCorrGFP; 
Page 248
%     allCorr2.(ThisFile).GFP=bgCorrGFP2; 
    allBgAdjusted.(ThisFile).GFP=z0*bgGFP; 
%     allBgAdjusted2.(ThisFile).GFP=z0*pBGGFP; 
end 
  
%Will need to create a data mask to specify the actual peak that we are 
%interested in. This can then be used to calculate the percentage of 
%activated cells. 
  
%This data will probably need to be adjusted to shift the peak left/right 
%% 
%Plot the postive peaks only. 
h1=fields(LogRawData); 
fig7=figure; 
hold on; 
fig8=figure; 
hold on; 
fig9=figure; 
hold on; 
fig10=figure; 
hold on; 
%calculate the area under the positive curve for R670 
mask5 = (histedges >= bgR670xval); 
mask6 = (histedges >= bgGFPxval); 
  
for j=1:length(h1), 
    ThisFile=char(h1(j)); 
     
    TempData=allCorr.(ThisFile).R670; %corrected to actual background 
%     TempData2=allCorr2.(ThisFile).R670; %corrected to proxy background 
    smoothData=allSmooth.(ThisFile).R670; 
    BgAdjData=allBgAdjusted.(ThisFile).R670; 
%     BgAdjData2=allBgAdjusted2.(ThisFile).R670; 
     
    figure(fig7); 
    subplot(4,6,j); 
    TempData(TempData<0)=0; %make all subzero values equivalent to zero.  
    plot(histedges,TempData); 
    hold on; 
     
        plot(histedges,smoothData); 
    %     plot(histedges,BgAdjData); 
    plot(histedges,BgAdjData); 
    plot(histedges(mask5),TempData(mask5)); 
%     plot(histedges(mask4),TempData(mask4)); 
    xlim([0 5]); 
     
    PosArea=trapz(histedges,TempData); 
    totalArea=trapz(histedges,smoothData); 
         OutputR670(j,1) = PosArea; 
         OutputR670(j,2) = totalArea; 
         OutputR670(j,3) = OutputR670(j,1)/OutputR670(j,2); 
    figure(fig9); 
    hold on 
        title('Background Adjusted Areas') 
        ylabel('Fraction of Cells Activated w/o Background') 
        bar(OutputR670(:,3)); 
        xlim([0 (length(FileNames)+0.5)]); 
        ylim([0 1]) 
end 
  
for j=1:length(h1), 
    ThisFile=char(h1(j)); 
     
    TempData=allCorr.(ThisFile).GFP; 
%     TempData2=allCorr2.(ThisFile).GFP; %corrected to proxy background 
    smoothData=allSmooth.(ThisFile).GFP; 
    BgAdjData=allBgAdjusted.(ThisFile).GFP; 
%     BgAdjData2=allBgAdjusted2.(ThisFile).GFP; 
    figure(fig8); 
    subplot(4,6,j); 
    hold on; 
    TempData(TempData<0)=0; 
    plot(histedges,TempData) 
    plot(histedges,smoothData); 
    hold on; 
    plot(histedges,BgAdjData); 
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    plot(histedges(mask6),TempData(mask6)); 
    xlim([0 5]); 
    
    PosArea=trapz(histedges(mask6),TempData(mask6)); 
    totalArea=trapz(histedges,smoothData); 
         OutputGFP(j,1) = PosArea; 
         OutputGFP(j,2) = totalArea; 
         OutputGFP(j,3) = OutputGFP(j,1)/OutputGFP(j,2); 
    figure(fig10) 
    hold on 
        title('Background Adjusted Areas') 
        ylabel('Fraction of Cells Activated w/o Background') 
        bar(OutputGFP(:,3)); 
        xlim([0 (length(FileNames)+0.5)]); 
        ylim([0 0.80]) 
end 
%%  
%Calculate median of activated cells  
mask5 = (histedges > bgR670xval); 
mask6 = (histedges > bgGFPxval);  
for j=1:length(h1), 
    ThisFile=char(h1(j)); 
     
    diffdata = allCorr.(ThisFile).R670; 
    diffdata(diffdata<0)=0; 
    sum1 = sum(histedges(mask5).*diffdata(mask5)'); %Mean calculations 
    sum2 = sum(diffdata(mask5)); %Mean calculations 
     
    medianR670 = bgR670xval + 0.001; 
    maskpre = mask5 & (histedges < medianR670); 
    maskpost = (histedges >= medianR670); 
    while trapz(histedges(maskpre),diffdata(maskpre)) < 
trapz(histedges(maskpost),diffdata(maskpost)) 
    medianR670 = medianR670 + 0.01; 
    maskpre = mask5 & (histedges < medianR670); 
    maskpost = (histedges >= medianR670); 
    end 
     
    OutputR670(j,4)=medianR670; 
    OutputR670(j,5)=sum1/sum2; 
end 
  
  
for j=1:length(h1), 
    ThisFile=char(h1(j)); 
     
    diffdata = allCorr.(ThisFile).GFP; 
    diffdata(diffdata<0)=0; 
        
    sum1 = sum(histedges(mask6).*diffdata(mask6)'); %Mean calculations 
    sum2 = sum(diffdata(mask6)); %Mean calculations 
     
    medianGFP = bgGFPxval + 0.001; 
    maskpre = mask6 & (histedges < medianR670); 
%     maskpre = (histedges < medianGFP); 
    maskpost = histedges >= medianGFP; 
    while trapz(histedges(maskpre),diffdata(maskpre)) < 
trapz(histedges(maskpost),diffdata(maskpost)) 
    medianGFP = medianGFP + 0.01; 
    maskpre = (histedges < medianR670) & mask6; 
%     maskpre = (histedges < medianGFP); 
    maskpost = (histedges > medianGFP); 
    end 
     
    OutputGFP(j,4)=medianGFP; 
    OutputGFP(j,5)=sum1/sum2; 
end 
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Appendix F (A) HEK293T cells expressing full-length LAT-Ruby (B) Jurkat E6.1 Cells 
expressing full-length LAT-Ruby (C) J-LKO cells expressing full-length LAT-Ruby 
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Appendix G Single cell cloning of the Jurkat LAT CRISPR cell lines provided us with a 
range of different clones. Shown above are the representative flux profiles relative to the 
Jurkat parental cell line. 
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Appendix H Prior to intracellular FACS, I used immunoblotting to interrogate LAT expres-
sion. Shown above is the J-LKO cell line transduced with the IRES versions of the TULIPs 
and LOVTRAP constructs. ZAP70 was used as the input control. HEK293T cells were used 
as an expression control for LAT. 
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Appendix I Over the course of weeks I observed a drop in TCR expression in the J-LKO 
cell line.
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Appendix J To perform real time modulation of calcium signalling we developed a FACS 
light box. This box can be used to modulate th light conditions for a single FACS tube 
while running samples on a flow cytometer 
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Appendix K (A) Schematic overview of the LPA (B) Image of LPA with labelled compo-
nents (C) Calibrated LED intensity calulations. (D) Prior to upgrading the LPA lid we 
consistently observed a large degree of cell death in some wells of the LPA. This is a 
representative heat map of cell viability.  
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Appendix L OptoCARSLOW expression was observed to decrease slight over a period of 
weeks. Here, receptor expression immediately after thawing (magenta) and after 5 weeks 
of use (cyan)
OptoCARslow (BV425)
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Appendix M I initially tried long term LPA stimulations with the wildtype optoCAR 
system. IT was found that blue light irradiation equivalent to the slow-cycling experi-
ment was not sufficient to terminate NFAT-GFP expression or CD69 upregulation. Even 
when the LED intensity was increased to maximum on the LPA there was still no drop in 
GFP expression or CD69 upregulation. 
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Appendix N Using the OptoCARSLOW system I titrated the concentration of (A/C) heterodi-
merizer required to inactive The majority of cells over a 9 hour period of stimulation. As 
the concentration of drug was increased the fraction of responding cells increased as did 
the population mean fluorescent intensity (MFI) (A) The fraction of GFP positive cells (B) 
The MFI of the whole population of reporter cells for GFP (C) The fraction of cells positive 
for CD69 (D) The MFI of the reporter cell population for CD69. 
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IFP2-CaaX
Appendix O The Zdk-LATint-Ruby and ePDZb1-LATint-Ruby show cytoplasmic 
localisation in the absence of their LOV2 binding partners (A) HEK293T cells were 
transfected with pHR-ePDZb1-LATint-Ruby and pHR-IFP2-CaaX. In the absence of the 
LOVpep domain, the LATint-Ruby construct is localised to the cytoplasm. (B) HEK293T 
cells were transfected with pHR-Zdk-LATint-Ruby and pHR-IFP2-CaaX. In the absence of 
the LOV2 domain, the LATint-Ruby construct shows cytoplasmic localisation. Images are 
representative of n=2 (biological replicates). 
MergeFP2-C aXLATint
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